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Abstract 
 
In Chapter 1, I introduce ischaemic stroke, thrombolytic therapy, 
thrombolysis trials and then discuss the rationale for exclusion criteria in 
stroke thrombolysis guidelines.   
 
In Chapter 2, I describe methods for examining outcomes in patients that are 
currently recommended for exclusions from receiving alteplase for acute 
ischaemic stroke.     
 
In Chapter 3, I examine Virtual International Stroke Trials Archive (VISTA) 
data to test whether current European recommendation suggesting exclusion 
of elderly patients (older than 80 years) from thrombolysis for acute 
ischaemic stroke is justified. Employing non-randomised controlled 
comparison of outcomes, I show better outcomes amongst all patients (P < 
0.0001; OR, 1.39; 95% CI, 1.26 to 1.54), young patients (P < 0.0001; OR, 1.42; 
95% CI, 1.26 to 1.59) and the elderly patients (P = 0.002; OR, 1.34; 95% CI, 
1.05 to 1.70). Odds Ratios are consistent across all age deciles > 30 years. 
Outcomes assessed by National Institutes of Health Scale (NIHSS) score and 
dichotomised modified Rankin Scale score are consistently similar.  
 
In Chapter 4, I compare thrombolysed patients in Safe Implementation of 
Thrombolysis in Stroke International Stroke Thrombolysis Register (SITS-ISTR) 
with VISTA non-thrombolysed patients ("comparators" or "controls") and test 
exactly similar question as in Chapter 3.  Distribution of scores on modified 
Rankin scale are better amongst all thrombolysis patients than controls (odds 
ratio 1.6, 95% confidence interval 1.5 to 1.7; Cochran-Mantel-Haenszel 
P<0.001). Association occurs independently amongst patients aged ≤80 (0R 
1.6, 95%CI1.5 to 1.7; P<0.001; n=25,789) and in those aged >80 (OR 1.4, 95% 
CI 1.3 to 1.6; P<0.001; n=3439). Odds ratios are consistent across all 10 year 
age ranges above 30, and benefit is significant from age 41 to 90; 
dichotomised outcomes (score on modified Rankin scale 0-1 v 2-6; 0-2 v 3-6; 
and 6 (death) versus rest) are consistent with the results of ordinal analysis. 
These findings are consistent with results from VISTA reported in Chapter 3. 
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Age alone should not be a criterion for excluding patients from receiving 
thrombolytic therapy. 
 
In Chapter 5, I employ VISTA data to examine whether patients having 
diabetes and previous stroke have improved outcomes from use of alteplase 
in acute ischaemic stroke. Employing a non-randomised controlled 
comparison, I show that the functional outcomes are better for thrombolysed 
patients versus nonthrombolysed comparators amongst non-diabetic (P < 
0.0001; OR 1.4 [95% CI 1.3-1.6]) and diabetic (P = 0.1; OR 1.3 [95% CI1.05-
1.6]) patients. Similarly, outcomes are better for thrombolysed versus 
nonthrombolysed patients who have not had a prior stroke (P < 0.0001; OR 
1.4 [95% CI1.2-1.6]) and those who have (P = 0.02; OR 1.3 [95% CI1.04-1.6]). 
There is no interaction of diabetes and prior stroke with treatment (P = 0.8). 
Neurological outcomes (NIHSS) are consistent with functional outcomes 
(mRS).  
 
In Chapter 6, I undertake a non-randomised controlled comparison of SITS-
ISTR data with VISTA controls and examine whether patients having diabetes 
and previous stroke have improved outcomes from use of alteplase in acute 
ischaemic stroke. I show that adjusted mRS outcomes are better for 
thrombolysed versus non-thrombolysed comparators amongst patients with 
diabetes mellitus (OR 1.45[95% CI1.30-1.62], N=5354), previous stroke (OR 
1.55[95% CI1.40-1.72], N=4986), or concomitant diabetes mellitus and 
previous stroke (OR 1.23 [95% CI 0.996-1.52], P=0.05, N=1136), all CMH 
p<0.0001. These are comparable to outcomes between thrombolysed and 
non-thrombolysed comparators amongst patients suffering neither diabetes 
mellitus nor previous stroke: OR=1.53(95%CI 1.42-1.63), p<0.0001, N=19339. 
There are no interaction between diabetes mellitus and previous stroke with 
alteplase treatment (t-PA*DM*PS, p=0.5). Present data supports results 
obtained from the analyses of VISTA data in chapter 5. There is no statistical 
evidence to recommend exclusion of patients with diabetes and previous 
stroke from receiving alteplase.  
 
In Chapter 7, I examine VISTA data to test whether exclusion of patients 
having a mild or severe stroke at baseline would be justified. Stratifying 
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baseline stroke severity for quintiles of NIHSS scores, I observe that there are 
significant associations of use of alteplase with improved outcomes for 
baseline NIHSS levels from 5 to 24 (p<0.05). This association lose significance 
for baseline NIHSS categories 1 to 4 (P = 0.8; OR, 1.1; 95% CI, 0.3-4.4; N = 
8/161) or ≥ 25 (P = 0.08; OR, 1.1; 95% CI, 0.7-1.9; N = 64/179) when sample 
sizes are small and confidence interval wide. These findings fail to provide 
robust evidence to support the use of alteplase in the mild or severe stroke 
patients, though potential for benefit appears likely. 
 
In Chapter 8, I present a meta-analysis of trials that investigated mismatch 
criteria for patients’ selection to examine whether present evidence supports 
delayed thrombolysis amongst patients selected according to mismatch 
criteria. I collate outcome data for patients who were enrolled after 3 hours 
of stroke onset in thrombolysis trials and had mismatch on pre-treatment 
imaging. I compare favourable outcome, reperfusion and/or recanalisation, 
mortality, and symptomatic intracerebral haemorrhage between the 
thrombolysed and non-thrombolysed groups of patients and the probability of 
a favourable outcome among patients with successful reperfusion and clinical 
findings for 3 to 6 versus 6 to 9 hours from post stroke onset. I identify 
articles describing the DIAS, DIAS II, DEDAS, DEFUSE, and EPITHET trials, 
giving a total of 502 mismatch patients thrombolysed beyond 3 hours. The 
combined adjusted odds ratios (a-ORs) for favourable outcomes are greater 
for patients who had successful reperfusion (a-OR=5.2; 95% CI, 3 to 9; I2=0%). 
Favourable clinical outcomes are not significantly improved by thrombolysis 
(a-OR=1.3; 95% CI, 0.8 to 2.0; I2=20.9%). Odds for reperfusion/recanalisation 
are increased amongst patients who received thrombolytic therapy (a-
OR=3.0; 95% CI, 1.6 to 5.8; I2=25.7%). The combined data show a significant 
increase in mortality after thrombolysis (a-OR=2.4; 95% CI, 1.2 to 4.9; I2=0%), 
but this is not confirmed when I exclude data from desmoteplase doses that 
are abandoned in clinical development (a-OR=1.6; 95% CI, 0.7 to 3.7; I2=0%). 
Symptomatic intracerebral haemorrhage is significantly increased after 
thrombolysis (a-OR=6.5; 95% CI, 1.2 to 35.4; I2=0%) but not significant after 
exclusion of abandoned doses of desmoteplase (a-OR=5.4; 95% CI, 0.9 to 31.8; 
I2=0%). Delayed thrombolysis amongst patients selected according to 
mismatch imaging is associated with increased reperfusion/recanalisation. 
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Recanalisation/reperfusion is associated with improved outcomes. However, 
delayed thrombolysis in mismatch patients was not confirmed to improve 
clinical outcome, although a useful clinical benefit remains possible. 
Thrombolysis carries a significant risk of symptomatic intracerebral 
haemorrhage and possibly increased mortality. Criteria to diagnose mismatch 
are still evolving. Validation of the mismatch selection paradigm is required 
with a phase III trial. Pending these results, delayed treatment, even 
according to mismatch selection, cannot be recommended as part of routine 
care. 
 
In Chapter 9, I summarise the findings of my research, discuss its impact on 
the research community, and discuss weaknesses inherent in registry data 
and limitation of statistical methods. Then, I elaborate the future directions I 
may take to further research on the theme of this thesis.  
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Chapter 1 
Introduction 
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1 Introduction 
1.1 Background 
Stroke is defined as a ‘rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function with symptoms lasting 24 hours or longer or 
leading to death, with no apparent cause other than vascular origin’.1 It is 
classified into ischaemic stroke and haemorrhagic stroke. Ischaemic stroke 
occurs after reduction in cerebral blood flow leading to loss of neuronal 
functions.2  Symptoms correspond to the vascular territory involved. If hypo-
perfusion persists, the involved tissue gradually undergoes infarction. 
Haemorrhagic stroke occurs due to rupture of a blood vessel in brain 
parenchyma.3 
Stroke is the third leading cause of death.4 Survivors lead a life that is 
characterised by physical dependence and suffering due to several 
neurological symptoms (like cognitive decline, dementia, depression or 
seizures).5-7 Every year approximately 15 million people suffer from stroke. Of 
these, about 5 million die and another 5 million are left with residual 
disability.8 Costs involved in providing curative, preventive and rehabilitative 
measures to these patients are significant.9,10 The United States of America 
spends about 17 billion dollars a year in caring for these patients.11,12  For 
example, in 2000, Medicare for Stroke hospitalisations cost $7.04 billion, the 
average being $15,818 per person.11 Europe is subject to suffer similar major 
costs.13,14 Developing (emerging) economies are no less affected. Here, stroke 
incidence is 7-10 times greater than the developed countries.15 Urgent 
measures to control the stroke epidemic are needed.16-18,19-22  
A patient who presents with an acute onset of ischaemic stroke is offered a 
therapy called thrombolytic therapy. At present, alteplase is the only 
thrombolytic agent that is licensed for use in ischaemic stroke.23 As per 
guidelines, this drug should be given only to a selected group of patients.23,24  
Table 1.1 shows that there are differences in the wordings of 
contraindications for alteplase use across different jurisdictions.25 
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Figure  1-1Loss of Disability Adjusted Life Years (above) and mortality rate (below) 
attributed to stroke within European Union (above)  
 
 
Source: www.who.int (Permissions obtained from World Health Organization Press  
WHP  (Permissions Management and Reprint Rights) 20 Avenue Appia,  Office 4152  
CH-1211 Genève 27,  Switzerland; ID number 82115)13,14 
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Table  1-1  Contraindications to the use of alteplase in acute ischaemic stroke in European Union, United States and Canada 
 
List of contraindications 
European License for t-
PA use in Stroke23 
United States  
Guidelines26 Canadian Guidelines27 
If Brain imaging shows  intracranial 
haemorrhage 
Contraindicated Contraindicated Contraindicated 
Age group <18 years or >80 years of age Contraindicated   
If onset of symptoms occurred >4.5  
hours1 
Contraindicated Contraindicated Contraindicated 
Severe stroke (e.g. NIHSS >25) Contraindicated   
If patient has a minor deficit or 
symptoms rapidly improving 
Contraindicated Contraindicated Contraindicated 
If heparin was given  ≤48 hours ago and  
patient has an elevated APTT 
Contraindicated Contraindicated Contraindicated 
                                               
1
   Use of rtPA in the time period of 3 to 4.5 hours after stroke has received a Class I Recommendation, Level of Evidence B by the American Heart Association. In these patients, 
exclusion criteria include (a) those that are  employed for treatment in 0-3 hours and (b) those incorporated within ECASS III trial: age > 80 years, patients receiving anticoagulant with 
an INR of >1.7 baseline NIHSS >25 or presence of diabetes mellitus and previous stroke28. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP, Jr. Expansion of the time window for 
treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 
2009;40:2945-8. 
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List of contraindications 
European License for t-
PA use in Stroke23 
United States  
Guidelines26 Canadian Guidelines27 
If platelet count ≤100 000/mm3 Contraindicated Contraindicated Contraindicated 
If patient is  receiving oral 
anticoagulants 
Contraindicated and if  INR >1.7, then 
contraindicated 
and if INR >1.7,then 
contraindicated 
If a severe stroke is demonstrated by 
brain imaging 
Contraindicated Contraindicated in case of  
>1/3 cerebral hemisphere 
Contraindicated in case 
of >1/3 MCA territory 
If seizure occurred  at stroke onset Contraindicated Contraindicated Contraindicated 
If patient has a manifest or recent 
severe or dangerous bleeding 
Contraindicated If it occured in prior 21 
days, then alteplase is 
contraindicated 
If it occured in prior 21 
days, then alteplase is 
contraindicated 
If there is a history of intracranial 
haemorrhage 
Contraindicated Contraindicated Contraindicated 
If there is a suspected subarachnoid 
haemorrhage 
Contraindicated Contraindicated Contraindicated 
Prior stroke within the last 3 months Contraindicated Contraindicated Contraindicated 
Bacterial endocarditis Contraindicated   
Myocardial infarction in the past 3 
months 
 Contraindicated Contraindicated 
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List of contraindications 
European License for t-
PA use in Stroke23 
United States  
Guidelines26 Canadian Guidelines27 
Pericarditis Contraindicated  If post myocardial, then 
t-PA is contraindicated 
If patient has a history of recent 
puncture of a non-compressible blood 
vessel 
Contraindicated If in past 7 days, then t-PA 
is contraindicated 
If in past 7 days, then t-
PA is contraindicated. 
If patient underwent a major surgery If in past 3 months, t-PA 
is contraindicated 
If in past 14 days, then t-
PA is contraindicated 
If in past 14 days, t-PA 
is contraindicated. 
If patient’s systolic blood pressure >185 
or diastolic >110 mm Hg or if there is a 
need of aggressive management to 
reduce blood pressure to these limits 
t-PA is contraindicated t-PA  is contraindicated t-PA is contraindicated 
Prior stroke and concomitant diabetes Contraindicated   
Intracranial neoplasm, arteriovenous 
malformation, or aneurysm 
Any history of CNS 
damage, then t-PA is 
contraindicated 
t-PA is contraindicated t-PA is contraindicated 
If patient suffered a significant trauma 
in past 3 months 
contraindicated If head trauma, t-PA is 
contraindicated 
If head trauma, t-PA is 
contraindicated 
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List of contraindications 
European License for t-
PA use in Stroke23 
United States  
Guidelines26 Canadian Guidelines27 
Acute pancreatitis Contraindicated   
Blood glucose levels (mmol/L) Contraindicated if levels 
are <2.7 or >22.2 
Contraindicated if levels 
are <2.7 
Contraindicated if 
levels are <3 or >22 
Ulcerative gastrointestinal disease 
during the last 3 months, oesophageal 
varices, arterial-aneurysm, 
arterial/venous malformations 
Contraindicated   
History of Obstetrical delivery Contraindicated   
Neoplasm with increased bleeding risk Contraindicated   
Severe liver disease, including hepatic 
failure, cirrhosis, portal hypertension 
(oesophageal varices) and active 
hepatitis 
Contraindicated   
Recent (<10 days) traumatic external 
heart massage 
Contraindicated   
Other illness that could limit 
effectiveness or increase risk of 
  Contraindicated 
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List of contraindications 
European License for t-
PA use in Stroke23 
United States  
Guidelines26 Canadian Guidelines27 
bleeding in the judgment of the 
physician 
 
Adapted from Jacques De Keyser, Zuzana Gdovinová, Maarten Uyttenboogaart, Patrick C. Vroomen, Gert Jan Luijckx Intravenous Alteplase for Stroke: Beyond the 
Guidelines and in Particular Clinical Situations, Stroke 2007 38(9):2612-2618 (Permissions obtained from Wolters Kluwer Health, License Number 2783781278803)25
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1.2 Pathophysiology of Ischaemic Stroke 
Ischaemic stroke occurs following occlusion of vessel(s) that supply blood to 
brain tissue. Clots destined to occlude the cerebral blood vessel originate either 
in circulation and then reach the brain vessels, e.g., from an artery or heart in 
case of artery-to-artery embolism or cardio-embolism respectively, or develop 
locally (like an atheroma) and reduce the distal cerebral blood flow (e.g., 
following arterial stenosis due to the occlusion of arteries or the arterioles).3   
Occlusion of the brain vessels results in an abrupt reduction of cerebral 
perfusion which then results a mismatch of the brain’s requirement of oxygen 
and the amount that is actually available.29  
Normal rate of blood flow in grey matter is 0.8 ml/g/minute. Brain functions are 
preserved as long as blood flows at a rate above 0.25 ml/g/minute. When it falls 
below 0.15 ml/g/minute, neurons enter a phase of irreversible morphological 
change leading to their death.29,30 As a result, at stroke onset, there is often an 
ischaemic core (that is irreversibly damaged) which is surrounded by an area of 
hypo-perfused brain parenchyma (“penumbra”; that is not yet infarcted). The 
penumbra is an ischaemic tissue that is functionally impaired and is likely to 
undergo an infarction if it is not salvaged before a certain duration by using 
reperfusion or/and other strategies. If it is not salvaged, penumbra undergoes 
progressive recruitment into an infarct core. In a time-dependent manner, it 
expands and approximates the maximal volume that was originally at risk.29,30 
Penumbra may derive some blood supply from surrounding collateral circulation, 
such as the Circle of Willis, ophthalmic artery or the leptomeningeal arteries. 
However, because these patients differ in the amount of possible collateral 
circulation, a similar degree/type of occlusion of brain vessels leads to a 
variable amount of ischaemic insult. Penumbra is present in most patients until 3 
hours of stroke onset, and then, the proportion of patients with penumbra 
diminishes to about 40% by 23 hours.31 
Cerebral ischaemia also results in a time-dependent cascade of events at 
molecular level leading to cell death.32  
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1.3 Preclinical studies on thrombolytic therapy for acute 
ischaemic stroke 
Meyer et al showed successful thrombolysis in embolic stroke models of cats and 
monkeys. 33  They used intravenous or intra-arterial bovine or human plasmin for 
thrombolysis. 33 Here, the thrombolysis was not associated with excess 
haemorrhagic infarctions.33  
 
Del Zoppo studied neurological outcomes (defined by a neurological function 
measured quantitatively by employing a neurologic scale, computerised 
tomography based estimation of cerebral infarction volume and carotid 
angiography) after the intracarotid administration of urokinase in baboons that 
suffered stroke in the right corpus striatum. 34 In these models, stroke was 
induced by compression of the right middle cerebral artery (just before the 
branching of the lenticulostriate arteries) lasting 3 hours. Also, six animals were 
employed as concurrent untreated controls. 34 The controls underwent occlusion 
of middle cerebral artery but did not receive the urokinase infusion. 34The study 
demonstrated improved neurologic outcomes and reduction in infarction volume 
amongst those baboons that received urokinase compared to those that did 
not.34 The study was significant because it showed that “thrombolytic therapy 
given within 3 hours of experimental thrombotic occlusion may salvage 
neurologic function and reduce cerebral infarction volume without CT scan 
detectable intracranial bleeding.” 34 
 
Zivin et al studied neurological outcomes in embolic stroke models of rabbits 
that were first injected with numerous small clots in their carotids and then 
given tissue plasminogen activator. 35  Use of tissue plasminogen activator was 
associated with significant improvement in neurological outcomes. 35   Further, it 
was also shown that the concentrations used in in-vitro lysis of clots were similar 
to those that were anticipated in vivo situations. 35   No haemorrhages related to 
the use of the drug were seen. 35   In summary, the study showed that the tissue 
plasminogen activator could be used early after the stroke onset.35   
Nishant Kumar Mishra, 2011  Chapter 1, 28 
 
 
Experiments indicated that the use of thrombolytic therapy was associated with 
excess haemorrhages if thrombolysis was given in delayed time after the stroke 
onset; and the rates were lower if it was given within 3.5 hours.36,37 But, Lyden 
et al showed that there were no differences in the rates of cerebral 
haemorrhage if rabbits were thrombolysed with alteplase at 10 minutes, 8 hours 
or 24 hours.38 Therefore, they concluded that “tPA treatment successfully causes 
thrombolysis of cerebral emboli without causing an increase in the incidence of 
cerebral haemorrhage in rabbits”. 38 Later, Lyden et al also showed that the 
streptokinase (and not the t-PA) was associated with significantly higher rates 
(and also size) of ICH. 39  Sundt et al showed that ischaemia could be tolerated 
for 3 hours, and maybe longer and vascular occlusion did not immediately lead 
to death of all neurons fed by the supplying artery. 40 Similarly, Harvey et al 
showed that in case of monkeys, it takes about 50 minutes for ischaemia to last 
so that it leads to the infarction of the entirely affected parenchyma.41 
 
These preclinical experiments indicated that the use of thrombolytic therapy 
was an option to treat ischaemic stroke patients, and that the treatment should 
be offered as soon as possible after the onset of cerebral ischaemia. Therefore, 
when Brott et al42 undertook to pursue a dose finding study for t-PA in humans, 
they decided to treat patients as soon as possible. 
  
1.4 Thrombolytic therapy in acute ischaemic stroke 
From the previous discussion, it is apparent that recruitment of ischaemic 
penumbra into the core of cerebral ischaemia progresses in a time-dependent 
manner.29,32,40,41 If this progression is to be halted, a logical treatment would be 
to achieve rapid reperfusion of ischaemic tissue before it gets fully infarcted. By 
achieving this, one expects to see better outcomes in these patients.  
1.5 Thrombolytic agents  
Thrombolytic agents include recombinant tissue plasminogen activator (rt-PA), 
desmoteplase, urokinase, anisoylated plasminogen streptokinase activator 
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complex, staphylokinase, streptokinase, recombinant pro-Urokinase and 
tenecteplase.43  
Amongst these, only rt-PA, also referred to as alteplase, activase or actilyse, is 
licensed for use in acute ischaemic stroke.23  
Some physicians also use desmoteplase, urokinase or alteplase in an extended 
time window based on their local experience or in the settings of clinical trial.44-
47 Streptokinase was investigated in the past and the trials had to be 
prematurely terminated because the drug was associated with excess 
complications.48-50 To date, alteplase is the only thrombolytic agent that has a 
proven efficacy in patients suffering acute ischaemic stroke; desmoteplase has 
potential, and is being investigated in delayed time windows. 
1.5.1 Tissue Plasminogen Activator (t-PA) 
Tissue Plasminogen Activator (t-PA) is an endogenous fibrin specific serine 
protease that releases plasmin from plasminogen by lysing arginine-valine 
bond.51 In addition to a thrombolytic effect, t-PA also has various pleiotropic 
effects: excitotoxicity,52,53 proteolysis of extracellular matrix ( contributes in  
neuronal migration, e.g. by neurite and axonal extension),54-57 long term 
potentiation (enhanced memory formation),58-61 vasoactive effect (vasodilation 
at lower concentrations of t-PA and vice versa),62, 63 and enhanced expression of 
metalloproteinases (like MMP-9).64-71   
Before stroke physicians began to use it, alteplase was already in use for the 
treatment of acute myocardial infarction (AMI). A clot can occlude the coronary 
arteries and lead to AMI. Thrombolytic agents are used in these patients to 
recanalise the occluded blood vessels.. Patients that suffer AMI are treated with 
either a 3-hour infusion regimen72-75 or an accelerated regimen.76-78   In the 
former regimen, a dose of 100mg (6-10% of dose administered bolus, followed by 
50-54% as infusion over one hour and then 20% over each succeeding hour) is 
given to the patients (Dose is 1.25 mg/kg if the patients weight is less than 65 
kg).72-75 In case of the latter regimen, dose is 100mg for those weighing more 
than 67 kg (15mg intra venous bolus, then 50mg in half an hour infusion and then 
35mg over the next hour).76-78 For those who weigh less than 67 kg, the dose 
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used is 15mg bolus, then 0.75 mg/kg in half an hour infusion and finally 0.5 
mg/kg during next one hour.77,78  In case of AMI, aim of the thrombolytic therapy 
is to achieve recanalisation of the coronaries and salvage the ischaemic cardiac 
parenchyma. This leads to improved outcomes.23 
Hoping for a similar phenomenon to occur in ischaemic stroke patients and 
guided by findings from animal models (see section 1.5) NINDS investigators 
initiated dose finding studies  for t-PA in ischaemic stroke patients (NINDS pilot 
study part 1 and part 2).79 In part 1 of the study, 74 patients were investigated 
within 90 minutes of symptoms onset after the administration of alteplase in 
doses ranging from 0.35 mg/kg (maximum dose of 25 mg) to 1.08 mg/kg. Here, 
none of the 58 patients treated with a dose </= 0.85 mg/kg developed cerebral 
haematoma.42 In part 2 of study, patients were treated between 90 minutes and 
180 minutes of symptoms onset with alteplase at a dose of 0.6 mg/kg (maximum 
dose: 60 mg, N=8), 0.85 mg/kg (maximum dose: 90 mg, N=6) or 0.95 mg/kg 
(maximum dose: 90 mg, N=6). Here, the risk of cerebral haematoma was 17% for 
patients receiving a dose >/=0.85 mg/kg.80   
1.5.2 Urokinase (u-PA) 
Urokinase is a trypsin-like enzyme that is produced in the kidney and excreted in 
human urine. It acts as a plasminogen activator (Molecular Weight 54000). 81-84  
Several investigators have examined outcomes from its use in ischaemic stroke 
patients either in a non-randomised design or by comparing outcomes with the 
use of other thrombolytic agents,44,47,85-92 or in a randomised controlled trials 
design.93-98 
 
In a double blind study design, Abe et al (1981) randomised patients that 
suffered from presumed thrombotic strokes within 2 weeks. Those that suffered 
presumed embolic stroke or severe stroke were excluded. Patients received 
urokinase at the dose 60000 units/day for 7 days (n=57) or received a placebo 
(n=56). Outcomes were measured at 4 weeks after the start of treatment and 
included measurement of global improvement rating and safety assessment. 
Patients underwent a CT scan at baseline and a repeat CT examination if they 
suffered neurological worsening. Clinical improvement occurred in 70.4% 
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thrombolysed patients compared to 56% non-thrombolysed patients. 
Haemorrhages did not occur in both arms.99  
Atarashi et al (1985) examined outcomes in patients that had a presumed 
diagnosis of cerebral arterial thrombosis of 5 days. 94  Patients received 
urokinase (n=191, two groups comprising high dose urokinase 240 000 u/day IV 
for 7 days and low dose urokinase 60 000 u/day for 7 days) or placebo (n=94) in a 
double blind design. 94  Where possible, the patients also underwent an 
angiography. 94  Those that suffered a presumed embolic stroke or a severe 
neurological deficit were excluded from enrolment. Outcome measures included 
clinical improvement described as per a final global improvement rating (done at 
4 weeks after the treatment was begun) and safety (defined by absence of any 
side effects). 94  Thrombolysis was offered in a 120 hours’ time window. Rates of 
clinical improvement were similar in both arms: 45% in the thrombolysis group 
and 43.6% in placebo group. Rates of haemorrhage were 1% and 1.1% the two 
arms respectively.94  
Australasian Urokinase Stroke Study (AUST) was a multicentre randomised 
controlled trial that investigated outcomes from the use of intra-arterial 
urokinase in patients suffering posterior circulation stroke.95 Patients were 
either given urokinase (in increments of 105 IU to a maximum dose of 106 IU) 
within 24 hours of symptoms onset or entered into the control arm. 20 patients 
were screened, 16 randomised, 8 received urokinase. Primary outcome at 6 
months (defined by combined morbidity (Barthel Index and Rankin Score)) 
occurred in 7/8 of the patients that received only anticoagulation and 4/8 of the 
patients that also received urokinase(OR 0.14, 95%CI 0.02-1.43).95 Odds for 
disability free survival were 1.33 (95% CI 0.07-26.62). Outcome data are shown 
in figure 1.2.95 
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Figure  1-2 Figure showing outcomes in patients enrolled in AUST trial that 
randomised patients with urokinase and anticoagulants (heparin and 
warfarin) or only the anticoagulants  
 
(Source: Modified from Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey 
GJ, Stewart-Wynne EG, Rosen D, McNeil JJ, Bladin CF, Chambers BR, Herkes GK, 
Young D, Donnan GA. Results of a multicentre, randomised controlled trial of intra-
arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. 
Cerebrovasc Dis. 2005; 20(1):12-7; Permissions for use obtained from S. Karger AG, 
Basel) 95 
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Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) 
selected 114 patients (intra-arterial urokinase N=57 or placebo N=57) with 
symptoms of ischaemic stroke for last 6 hours and a demonstrable occlusion of 
middle cerebral artery (M1/M2) on CT angiography.97 The study had to be 
stopped when tissue plasminogen activator received approval for use in 
ischaemic stroke in Japan. Non-significantly higher rates of favourable outcomes 
(m-RS 0-2) were observed on day 90 in the group that received thrombolytic 
therapy compared to the placebo arm (49.1% vs. 38.6%, p=0.3). Secondary 
outcome defined by m-RS 0-1 on day 90 was achieved by 42.1% and 22.8% of the 
patients in the respective treatment arms (p=0.045). Neurological improvement 
(NIHSS 0-1 at day 90) occurred more frequently after the use of urokinase 
(p=0.02). The study reported mortality rates of 5.3% and 3.5% in thrombolysis 
and control arm (p=1.000). Rates of intracerebral haemorrhage at 24 hours of 
treatment occurred in 9% and 2% of the patients (p=0.2).97 
1.5.3 Prolyse  
Prolyse (nasaruplase), a glycosylated 411-amino acid single chain molecule (r-
proUK), is a precursor of urokinase. In the presence of fibrin associated plasmin, 
it gets activated into double chain urokinase (UK) on the surface of a thrombus. 
Heparin enhances the thrombolytic effect of urokinase, either by the release of 
tPA from the endothelium or by neutralisation of thrombin. Urokinase is an 
endogenous plasminogen activator (t1/2= 9 to 12 minutes).
100-103 
Prolyse was investigated in two intra-arterial thrombolysis trials called Prolyse in 
acute cerebral thromboembolism (PROACT) I and II in a 6 hour time window.104,105 
The drug was administered intra-arterially in the proximal 1/3rd (or close to the 
proximal tip) of the clot in the middle cerebral artery (MCA 1 or MCA 2).  Prolyse 
was used at a dose of 6 mg in PROACT I and 9 mg in PROACT II; low dose iv 
heparin was given to all patients for four hours at the start of angiography in 
both PROACT I and PROACT II. PROACT I, a phase II randomised study, showed 
recanalisation efficacy (2P=0.02) and the safety (SICH rates, 2P=0.6) from the 
use of intra-arterial thrombolysis in a 6 hour time window.104  Later, PROACT II 
study showed significantly better functional outcomes in thrombolysed patients 
compared to the controls (90 day m-RS 0-2 was achieved by 40% of the patients 
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in treatment arm compared to 25% in the control arm, p=0.04; N=180, patients 
randomised in  proportions of 2:1 between treatment and control arms). Rates of 
recanalisation were 66% vs. 18%, p<0.05 and SICH within 24 hours 10% vs. 2%, 
p=0.06 between the two groups respectively. Despite showing an improvement in 
functional outcomes, the therapy failed to obtain approval from regulatory 
authorities.105  
 
1.5.4 Desmoteplase 
Desmoteplase is a novel plasminogen activator that is derived from saliva of 
Desmodus rotundus.  It differs from alteplase in that it lacks the 2nd kringle site 
in its molecular structure; does not need to be cleaved by plasmin and is active 
in its single chain form. It has reduced neurotoxicity and limited passage through 
the blood-brain-barrier. DSMA has a theoretical advantage over rt-PA as it is 
almost non-functional if fibrin is absent.106-108 Investigators have been examining 
its efficacy and safety for use in acute ischaemic stroke patients in a delayed 
time window.108  
Desmoteplase in Acute Ischaemic Stroke (DIAS) was a placebo controlled double 
blind dose finding phase II study which enrolled patients (baseline stroke severity 
on  NIHSS 4-20) for thrombolysis in 3 to 9 hours’ time window (Total patients: 
104 patients). After treating 47 patients with a fixed dose regimen (25 mg, 
37.5mg or 50 mg) of desmoteplase or placebo (part 1), dosing pattern were 
modified because there occurred excessive symptomatic intracerebral 
haemorrhages (26.7%). Investigators switched over to part II of the study in 
which a lower weight adjusted dose of 62.5 microgram/kg, 90 microgram/kg and 
125 microgram/kg were used. In the part II of the study, rates of symptomatic 
intracerebral haemorrhages were 2.2%; no SICH occurred in the placebo arm. 
Reperfusion rates were 71.4% in patients treated with 125microgram/kg 
compared to 19.2% in the placebo arm. Favourable 90% clinical outcome 
occurred in 60% of patients treated with 125 microgram/kg of desmoteplase, 
13.3% patients with a dose of 62.5microgram/kg of desmoteplase and 22.2% of 
placebo treated patients. The study showed a strong correlation of early 
reperfusion with improved clinical outcomes (P=0.0028).109 
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Dose Escalation of Desmoteplase for Acute Ischaemic Stroke (DEDAS) study was 
another placebo-controlled double blind dose escalation phase II randomised 
study. It employed weight adjusted doses similar to DIAS and treated patients in 
a 3 to 9 hour time window. In this study, 8 patients received placebo and 29 
received desmoteplase (90 microgram/kg: n=14). No symptomatic intracerebral 
haemorrhage occurred. Rate of reperfusion was 37.5% in the placebo arm, 18.2% 
in the desmoteplase arm that used a dose of 90microgram/kg and 53.3% in 
desmoteplase arm that used a dose of 125 microgram/kg arm. 25% of the 
placebo arm patients, 28.6% of 90 microgram/kg arm patients and 60% of 125 
microgram/kg desmoteplase had good clinical outcomes on day 90.110 
Desmoteplase at doses of 90 and 125 microgram per kg was shown to be 
associated with a strong dose-response relationship in a phase II design. 109,110 
Between 2005 and 2007, Hacke et al randomised 193 patients in a dose ranging 
double blind placebo controlled trial in which patients that suffered acute stroke 
were selected based on presence of tissue at risk visible on either CT or MRI.111 
123 patients entered the desmoteplase arm (n=57 for dose 90 microgram/kg and 
n= 66 microgram/kg) and 63 received placebo.111 Median NIHSS at baseline was 
6(IQR 6-14) and only 30% patients had a visible occlusion at baseline brain 
imaging.111 In the three groups of patients that received desmoteplase at dose of 
90microgram/kg, 120 microgram/kg or placebo, the respective clinical response 
rates on day 90 (defined by composite NIHSS improvement of 8 or more points, 
or NIHSS of 0 or 1, m-RS of 0-2 points, Barthel Index  75-100) were 47%,36% and 
46%; change in lesion volume between baseline and day 30 were 14%,10.8% and -
10%; rates of symptomatic intracerebral haemorrhage were 3.5%,4.5% and0%; 
and mortality rates were 5%,21% and 6%. The study failed to show benefit.111 
Dose finding studies allow investigators to select a dose for further investigation 
in randomised controlled settings. 
1.5.5  Tenecteplase 
Tenecteplase is a mutant form of plasminogen activator which is characterised 
by delayed clearance, longer half-life, greater fibrin selectivity, greater 
resistance to plasminogen activator inhibitor and greater ability to lyse a 
thrombus compared to alteplase. This drug appears to be safe for use in acute 
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ischaemic stroke.112-114 Chapman et al undertook to compare thrombolysis from 
use of wild t-PA and tenecteplase. 114 They used a model of New Zealand White 
rabbits who suffered ischaemic stroke due to injection of radio labelled blood 
clots. 114 t-PA was administered to 57 animals, tenecteplase to 70 animals (43 
received a dose of 0.6mg/kg, the rest received a dose of 1.5 mg/kg) and 37 
animals were used as controls. The study found recanalisation rates that were 
similar between the animals that received tenecteplase or alteplase.114 The 
study concluded: “while tPA increases haemorrhage rate, the haemorrhage 
associated with TNK treatment is not statistically different compared with 
controls or the tPA group.”114 
In a pilot dose escalation study, Haley et al showed that tenecteplase at a dose 
of 0.1-0.4 mg/kg could safely be used in the acute ischaemic stroke patients: 
there occurred no symptomatic intracranial haemorrhages in these dose 
ranges.115 A phase IIb/III trial of tenecteplase had to be prematurely 
terminated.116 The study involved an “adaptive, sequential dose selection 
procedure that used major neurological improvement at 24 hours balanced by 
risk (Symptomatic Intra-cerebral Haemorrhage)” and allowed investigators to 
exclude the dose of 0.4mg/kg as inferior, but because the trial did not finish, an 
optimal dose between the other doses (0.1 and 0.25mg/kg) could not be 
identified. 116 Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- 
(ATTEST) trial is a pilot phase study that would compare outcomes between 
patients who would receive tenecteplase (dose: 0.25mg/kg; maximal dose 25mg) 
or alteplase (dose: 0.9 mg/kg administered as 10% bolus and then 90% of the 
dose as IV infusion over 1 hour; maximum dose 90 mg) in a prospective, 
randomised, blinded outcome evaluation clinical trial design.117  
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1.6 Clinical trials to evaluate therapy for acute ischaemic 
stroke 
The invention of CT technology led to better stroke trials: physicians could 
select those patients for thrombolytic therapy who did not have intracerebral 
haemorrhage on CT brain. 
In 1992, del Zoppo and colleagues, examined outcomes in ischaemic stroke 
patients who received alteplase in an 8 hours’ time window for cerebral artery 
occlusion. The study reported 40% rate of recanalisation, 9.6% symptomatic 
intracerebral haemorrhages and 12.5% mortality (N=139).118 Later, Brott and 
Haley showed that dose < 0.95 mg/kg was safe for use in these patients.42,80   
Mori et al showed that use of thrombolytic therapy was associated with excess 
recanalisation rates.119 Finally a “bridging trial”, in a randomised double blind 
controlled design (n=27, 20 treated in 90 minutes and 7 in 91-180 minutes; dose 
used 0.85 mg/kg) indicated the efficacy of alteplase in improving outcomes at 24 
hours. The study highlighted the need of a larger RCT.120 
1.7 Randomised controlled trials for alteplase use in 
acute ischaemic stroke 
1.7.1 European Australasian Collaborative Acute Stroke Study 
(ECASS) I 
In ECASS I trial, patients were treated with a dose of 1.1 mg/kg in a 0-6 hours’ 
time window. The target Population (TP) excluded protocol violators (17.4% of 
patients). This study failed to show a significant difference in primary endpoints 
(Barthel Index and m-RS on day 90) in Intention-to-Treat (ITT) analysis, but 
showed significant improvement in outcomes in per-protocol analysis (P=0.035), 
analyses of secondary end points (a combination of Barthel index and Rankin 
scale) (P<0.001, in both ITT and TP analyses), and also analyses of neurological 
outcomes (P=0.03, TP analyses only). The rate of recovery was significant until 7 
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days for all patients and until a month for the target population. Hospital stays 
were shortened in the alteplase arm and the mortality and ICH rates were 
similar in both arms.121 Investigators concluded: “intravenous thrombolysis in 
acute ischemic stroke is effective in improving some functional measures and 
neurologic outcome in a defined subgroup of stroke patients with moderate to 
severe neurologic deficit and without extended infarct signs on the initial CT 
scan.” 121 
1.7.2 National Institutes of Neurological Diseases (NINDS) study 
The NINDS study (291 patients in part 1, 333 in part 2) was the first randomised 
controlled trial that showed safety and efficacy from use of alteplase in acute 
ischaemic stroke patients (dose:0.9 mg/kg, maximal dose of 90, time window: 
within3 hours of symptoms onset)  
Part I of the study defined early treatment response as improvement in NIHSS 
scores by > /= 4 or a complete recovery at 24 hours. 24 Whereas analysis of early 
treatment response failed to show a statistically significant improvement, a 
subsequent post-hoc analysis noted improvement on median NIHSS scores at 24 
hours (8 vs. 12, p<0.02).  Global outcome scores improved in patients that 
received active treatment in part 2 (OR 1.795% CI: 1.2-2.6).   The study reported 
an 11-13% absolute increase in excellent outcomes and a non-significant 
reduction in mortality (17% vs. 21%, p=0.30). The rates of symptomatic 
haemorrhage were significantly greater in the treatment arm compared to 
placebo (6.4% vs. 0.6%, p<0.001).122  It was the first study to demonstrate 
efficacy and safety of alteplase in a 3 hour window that led to its FDA approval 
for use in acute ischaemic stroke.123 
1.7.3 European Australasian Collaborative Acute Stroke Study 
(ECASS) II 
ECASS II examined outcomes in ischaemic stroke patients and used a dose of 0.9 
mg/kg within 6 hours of symptoms onset. Though it failed to confirm a 
statistically significant benefit (p=0.2, n=800) when data were examined for 
patients that achieved a Rankin score of 0-1, in a post-hoc analysis better 
outcomes were observed when data were examined for patients that achieved 
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functional outcomes defined by m-RS = 0-2 (54.3% vs. 46%, p=0.02). Rates of 
symptomatic haemorrhages were 8.8% in thrombolysed patients and 3.4% in the 
non-thrombolysed group.124  
1.7.4 Streptokinase Trials  
Three streptokinase trials, the Multicentre Acute Stroke Trial in Europe (MAST-E, 
1996), the Multicentre Acute Stroke Trial in Italy (MAST-I, 1995) and the 
Australian Streptokinase Study (ASK,1996) were all terminated prematurely 
because of complications.48-50  
The MAST-E study showed greater mortality (p=0.06) and a trend towards 
reduced disability (and also a shorter stay in a rehabilitation centre/nursing 
home) if the patient received streptokinase.49  
The MAST-I study failed to show benefit in any of its treatment compared to 
placebo arms. Symptomatic haemorrhages were more common in the 
streptokinase arm.48  
The ASK study was characterised by higher mortality, worse clinical outcome and 
increased ICH rates. Analyses of patients who received streptokinase therapy 
within 3 hours of symptoms onset (N=70) with patients who were treated beyond 
3 hours (N= 270) showed that the former group had better outcomes.50,125 
1.7.5 Alteplase Thrombolysis for Acute Noninterventional 
Therapy In Ischaemic Stroke Study (ATLANTIS)  
The ATLANTIS study started recruiting patients in August 1991 and had originally 
aimed to enroll patients within 6 hours of the onset of symptoms’.  In December 
1993, the time window was modified to 0 to 5 hours of symptom onset. After the 
publication of NINDS trial, the time window was narrowed down to treatment 
within 3 hours. Owing to these changes, the ATLANTIS trial was reported in two 
parts: part A (patients enrolled until December 1993, N=142) and part B.126-128  
 
85% of patients in part A of the ATLANTIS trial received alteplase beyond three 
hours of symptoms’ onset.128 There was a significant increase in proportion of 
patients that achieved 4 points improvement in NIHSS scale at 24 hours (40% vs. 
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21% patients, P=0.02). There was a significant increase in proportion of SICH by 
tenth day of stroke (11% vs. 0%, P<0.01) and mortality by three months (23% vs. 
7%, P<0.01).127,128 The outcomes in 61 patients treated within 3 hours of 
symptom onset were similar to the NINDS trial showing a 35% absolute increase 
in favorable outcomes.126 
 
The part B of the study found no significant difference in the excellent 
neurologic outcome (defined by NIHSS of 0 or 1 at day 90), between the 
treatment and control arm (34% vs. 32%, P=0.65, N= 613).127 
1.7.6 European Australasian Collaborative Acute Stroke Study 
(ECASS) III  
ECASS III was the second positive t-PA trial that showed efficacy of t-PA in the 3-
4.5 hour time window (52.4% vs. 45.2%; OR 1.34, 95% CI 1.02-1.76, P=0.04, 
N=821).129 The trial was mandated by EMEA in order for the drug to receive the 
license within the European Union.23 Though there occurred excess ICH (27% vs. 
17.6%, p=0.001) in the alteplase arm, the proportion of patients that suffered 
symptomatic ICH was smaller (2.4% vs. 0.2%, P=0.008). Mortality rates were 
similar between the alteplase and the placebo group (7.7% vs. 8.4%, P=0.68).129 
1.8 Findings from pooled data analyses and meta-
analyses of t-PA trials  
1.8.1 First pooled analyses of t-PA stroke trials   
Pooled analyses of data from ECASS, NINDS, ATLANTIS (N=2775) showed an 
inverse relationship between the time since symptom onset and improved 
outcomes: OR=28 (95% CI 18—45) for 0—90 minutes, 16 (11—22) for 91—180 
minutes, 14 (11—19) for 181—270 minutes, and 12 (09—15) for 271—360 
minutes(P=0.005)). The hazard ratios for time windows 0-90, 91-180,181-270 
were 1.0, and for time window 271-360, 145 (95% Confidence Interval 102—
207).  The risk of cerebral haemorrhage had a significant association with the 
use of t-PA (5.9% vs. 1.1 %, p<00001). Whereas the time since symptom onset 
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was not associated with occurrence of cerebral haematoma, use of alteplase 
(p<0.0001) and age (p<0.0001) were. 130  
1.8.2 Second pooled analyses of alteplase trials  
A recent pooled analysis of t-PA trials (2010) by Lees et al reconfirms the 
efficacy of t-PA in 4.5 hours of symptoms onset.131 
1.8.3 Cochrane review meta-analyses   
The Cochrane group reports a meta-analysis of clinical trial data by examining 
the safety and efficacy of thrombolytic therapy in acute ischaemic stroke 
patients. These meta-analyses are just not limited to alteplase trials (that 
constitute 55% of its data), but also include trials that investigated 
streptokinase, urokinase, desmoteplase and pro-urokinase (N= 26 trials, 7152 
patients). About 0.5% of these patients are older than 80 years of age. Odds for 
death or dependency (m-RS 3-6) in patients thrombolysed in 3-6 hours after 
stroke onset are 0.8, 95% CI 0.73-0.90. In a 6 hour window, t-pa therapy is 
associated with significant odds of 3.5 for symptomatic haemorrhage; for 
mortality, these are OR 1.31, P<0.05. In a 3 hour time window, there occurred a 
significant reduction in the rates of death or dependency with odds of 0.7; for 
death, OR=1.13, 95%CI 0.86-1.48. Odds for all-cause mortality within 10 days 
were 1.8 for all patients (95%CI 1.4-2.2, N=4423); for those who got t-PA, 
OR=1.2, 95% CI 0.9-1.7, N=2500.92  
1.9 Observational data on use of alteplase 
After the NINDS trials were reported, many physicians were still not convinced. 
They argued that the study was conducted in specialised stroke centres and 
therefore data were not generalisable to other settings.132-134 Hence, there was 
felt a need to examine outcomes in community hospitals. I report a summary of 
various observational studies that examined t-PA for acute ischaemic stroke. 
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1.9.1 Houston community experience 
Chiu et al reported outcomes in 30 patients treated with alteplase between 
December 1995 and December 1996 (dose of 0.9mg/kg):  rate of symptomatic 
intracerebral haemorrhage: 7%; rate of fatal ICH: 3%; 37% patients recovered to 
full independence (Barthel Index 95-100) and 30% with m-RS 0-1. The rate of 
mortality on day 90 was 20%.135 
1.9.2 Cologne community experience 
Grond et al described their experience from Cologne (n=100): door to needle 
time: 48 minutes;  stroke onset to arrival time: 78 minutes;  day 90 Barthel 
Index of 95-100 achieved by 53% patients;  40%  achieved a m-RS  of 0-1,  NIHSS 
score of 0-1: 42%; symptomatic ICH rate of  5%; and  mortality rate of 12%.136 
1.9.3 Oregon community experience 
 33 patients received alteplase. The result indicated that t-PA-use was “feasible 
and efficacious”: mortality rates=18.2%; 36.4% patients achieved m-RS of 0-1 at 
3 months. 137 
1.9.4 Cleveland community experience 
By employing a chart review of 3948 patients enrolled in 29 different hospitals in 
Cleveland, Ohio, between1997-1998, Katzen et al aimed to estimate rates at 
which t-PA was used in the community. 138  This study highlighted that many 
patients were not getting t-PA because the time window of t- 3 hours was too 
short: only 17% of the patients could be hospitalised within the 3 hour time limit 
and only 1.8% finally received alteplase. NIHSS was recorded in 405 of patients, 
median 12. This study highlighted that t-PA was associated with excess poor 
outcomes: symptomatic haemorrhages in 15.7% of the patients (a rate that was 
2.5 times that of the NINDS study). A large proportion of patients (50%) had 
deviated from the t-PA guidelines. The deviations included use of antithrombotic 
agents within 24 hours of alteplase use (in 37.1% of patients; heparin in 16 
patients, aspirin in 7 patients, their combination in 2 patients and ticlopidine in 
1 patient), thrombolysis beyond 3 hours (even those treated within 3 hours 5 
minutes were considered eligible, N=4 in these extra 5 minutes; 12.9% treated 
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between 3 hours 10 minutes and 6 hours 13 minutes) and raised blood pressure.  
Excess deaths occurred if they received alteplase compared to those who did not 
receive alteplase (15.7% vs. 5.1%, p<0.01). These findings differ from 
experiences of other groups: STARS (discussed in subsequent section) reported   
rates of symptomatic haemorrhage = 3%, which were 5 times lower than what 
Cleveland experienced. Excess adverse events in Cleveland were attributed to 
practices that deviated from t-PA guidelines. The Cleveland study differed from 
others: these were retrospective chart reviews; patients were identified based 
on the ICD system; data were collected on a 6 monthly basis; nurses would look 
for cases after these had already occurred (case ascertainment bias); a 
population that was different in characteristics compared to other centres that 
reported earlier (19.4% valvular heart disease in Cleveland cohort compared to 
only 8.3% in NINDS) and importantly deviations from guidelines. 138 
A subsequent paper from the Cleveland group described patients that were 
admitted to their Clinical Health System between 2000 and 2001. This time 
investigators practiced performance monitoring, frequently reviewed data, 
provided round-the-clock access to the stroke team by introducing a stroke 
pager and raising the education level regarding stroke management. Now, 18.8% 
of the patients reached hospitals within 3 hours; the rate of symptomatic ICH 
was 6.4%; and protocol violations occurred in 19% of the patients. 139 
These two studies from Cleveland highlighted that there was a need to educate 
participants in “chain of delivery” and strictly follow the t-PA guidelines. 138,139 
1.9.5 Standard Treatment with Alteplase to Reverse Stroke 
(STARS)  
STARS was an American study that aimed to examine outcomes in ischaemic 
stroke patients that received alteplase between February 1997 and December 
1998 (N: 389 patients, centre participation: 24 academic and 33 community 
centres). Median onset to treatment time was 2 hours 44 minutes; and, baseline 
NIHSS score 13. On day 30, mortality rates were 13%; Rankin score 0-1 35%, 
Rankin score 0-2 43%; rate of symptomatic haemorrhage 3.3% (N=13) and 
mortality attributed to symptomatic haemorrhage N= 7. STARS showed that t-PA 
could be safely administered in university and community settings. 122,129,140    
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1.9.6 Vancouver Experience 
Chapman et al report outcomes in 46 patients who were given t-PA in a 3 hour 
time window and based on NINDS protocol. Here, SICH rates were 2.2 % (at 36 
hours); outcomes at 13 months were mortality 22%, 43% reaching a m-RS of 0-1 
and 48% a Barthel Index of 95-100. 141 
1.9.7 Calgary Experience 
Over half of the patients in Calgary data suffered ischaemic stroke (1168/2165; 
duration: 1996 to 1999). Delay in patients’ arrival accounted for 73% of the 
patients’ exclusion. Only 84 of the 314 patients received alteplase despite 
presenting within t-PA time window; overall, only 4.7% patients received 
alteplase. Outcomes of thrombolysed patients on day 90 were comparable to 
randomised data: 54% of reached m-RS of 0-2 and 7.1% patients developed 
Symptomatic ICH. Reasons why some patients were excluded despite presenting 
within 3 hours include: presence of mild stroke (13.1%) or rapidly improving 
stroke (18.2%) at baseline; delay in referral (8.9%); and, patient suffered other 
illnesses that would have adversely affected outcomes (8.3%).  It should be 
noted that, about 32% of those patients who suffered a mild or rapidly improving 
stroke were still dependent upon discharge or had died while they were still in 
the hospital. The Calgary experience highlights that mild or rapidly improving 
stroke patients do not always have a spontaneous resolution of symptoms or 
better outcomes. 142 In chapter 7, I examine this question. 
1.9.8 Berlin Experience 
Koennecke reported data collected over two years during which 75 patients 
(9.4%) received alteplase. 2.7% suffered cerebral haemorrhages. 40% achieved 
m-RS of 0-1, 32% a m-RS of 2-3 and 13% a m-RS of 4-5; 15% of the patients died. 
The investigators highlighted that performance improved with time, and 
gradually more and more patients could be enrolled). 143 
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1.9.9 Houston Experience 
Grotta et al reported improvement in neurological outcomes of 269 patients that 
received alteplase (baseline NIHSS 14.4+/- 6.1 to 7+/-7 at discharge) between 
January 1996 -June 2000. SICH rates were 4.5 %.144 
1.9.10 Canadian Activase for Stroke Effectiveness Study 
The Canadian group examined 1099 patients who received t-PA during February 
1999 to June 2001.  Stroke severity was NIHSS=15.   46% patients achieved m-RS 
of 0-2 on day 90 and the rate of ICH was 4.6%. Baseline Stroke severity, baseline 
ASPECT scores, age, atrial fibrillation and baseline blood sugar levels predicted 
outcomes in this population. Raised blood pressure and hyperglycaemia at 
baseline were predictors of ICH occurrence. This study suggested that IV rt-PA 
could safely be used in Canada.145 
1.9.11 The Safe Implementation of Thrombolysis in Stroke 
studies 
Following the NINDS trial, alteplase was approved in the USA (in 1996) and 
Canada (in 1999) for use in acute ischaemic stroke.123 But, European drug 
authorities were hesitant to permit its use in the European Union.23 Alteplase 
was finally approved for use in ischaemic stroke patients in 2002 subject to the 
fulfilment of two conditions by the study sponsor (i.e. Boehringer Ingelheim): (a) 
to conduct a pan-European observational study with strict monitoring of 
outcomes in patients receiving t-PA and (b) to conduct a randomised controlled 
trial evaluating outcomes beyond 3 hours of symptoms onset.23 In order to fulfil 
the first requirement, the Safe Implementation of Thrombolysis in Stroke 
Monitoring Study (SITS-MOST) a study was conducted, and for the second 
requirement, the ECASS III.129,146  
The primary aim of the Safe Implementation of Thrombolysis in Stroke 
Monitoring Study (SITS-MOST) was to assess the safety and efficacy of alteplase 
in patients treated within the European Union, Iceland and Norway in a 3 hour 
time window. The study enrolled 6483 patients between 25 December, 2002 and 
30 April, 2006 from 285 centres spread across 14 member states. The study 
employed some monitoring procedures for data collection. For example, national 
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co-ordinators and professional monitors in collaboration with the study sponsor, 
Boehringer Ingelheim, source verified sample source data. 146 The study reported 
that “a minimum of 10% of patients recruited in SITS-MOST were monitored and 
in UK  source data verification was done by independent clinical staff under the 
direction of the UK national coordinators who also checked for the completeness 
of registrations at all sites.” 146 About half of the centres that participated had 
little prior experience with thrombolysis. The baseline characteristics were 
similar between the SITS-MOST patients and the randomised trials. At 24 hours, 
the SICH rate was 1.7% per SITS-MOST definition. On day 7, 7.3% patients 
suffered SICH per Cochran definition (8.6% in randomised trials). Mortality by 90 
days was 11.3% compared to 17.3% as observed in the randomised trials. Thus, 
the SITS-MOST study showed that the alteplase could be safely administered 
within three hours of symptom onset.146 
The Safe Implementation of Treatments in Stroke (SITS) group compared the 
outcomes in patients treated in the 3-4.5 hour time window (n=664) with 
patients treated in the <3 hours’ time window (n=11 865) (enrolled between 
December 25, 2002 and November 15, 2007) employing data that were recorded 
in the prospective International Stroke Thrombolysis Registry (ISTR). 147   
Outcomes did not differ significantly between the two groups: the rates of 
symptomatic intracerebral haemorrhage within 24 h (haemorrhage type 2 
associated with National Institutes of Health Stroke Scale [NIHSS] ≥4 points 
deterioration) were 22% versus 16%, p=024; mortality at 3 months: 127% 
versus 122%, p=072 and adjusted p=0053); and independence (modified Rankin 
Score 0-2) at 3 months 580% versus 563%, p=042 and adjusted p=018. 147 The 
findings offered some data to show that alteplase could safely be given in a 3-
4.5 hour time window after ischaemic stroke. 147 Later the ECASS III trial showed 
that use of alteplase was indeed associated with improved outcomes when 
patients were treated in a 3-4.5 hour time window. 129 
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1.10 Brain Imaging 
1.10.1 Introduction 
 
The invention of Computed Tomography (CT) technology was a major 
technological advance in the field of clinical medicine. It led to the award of a 
Nobel prize to Dr Hounsfield.148 With a CT scan, a physician could now exclude 
an intracranial haemorrhage and the stroke mimics. It is a widely available 
imaging modality that is used by stroke physicians to image stroke patients.  
 
Brain MRI is considered better because it provides the physicians with some 
additional information. For example, s/he can see the hyper acute ischaemic 
changes on the Diffusion Weighted Imaging (DWI) sequences, haemorrhages on 
Gradient Echo (GRE) sequences and predict the timing of stroke onset based on 
Fluid Attenuated Inversion Recovery (FLAIR) sequences (DWI-FLAIR 
mismatch).149,150   
 
Perfusion brain imaging gives information about the haemo-dynamic changes 
that occur after cerebral ischaemia (e.g. cerebral blood flow, volume and other 
perfusion parameters). CT Angiography (CTA) or MR Angiography (MRA) give the 
visual details of brain vessels (e.g. the occlusions). Physicians aim to achieve 
recanalisation/reperfusion, and therefore on being able to see a vessel occlusion 
on CTA or MRA, physicians can implement an appropriate recanalisation strategy 
for treatment of these patients.151 For example, patients having occlusion of 
“Carotid-T” occlusion of middle cerebral arteries are known to respond poorly to 
iv t-PA and these patients may be considered as candidates for intra-arterial or 
mechanical thrombolysis by some physicians.152 
 
  
1.10.2 Ischaemic Penumbra  
 
That an ischaemic penumbra develops after a cerebral vessel occlusion was 
known to stroke neuroscientists long before t-PA therapy was introduced as a 
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treatment of acute ischaemic stroke.29,30,153,154 When a cerebral artery occludes 
the core of ischaemic lesion suffers irreversible injury and surrounding tissue is 
functionally silent because of hypo-perfusion. If the hypo-perfusion persists, the 
central core enlarges and gradually the whole of hypo perfused brain 
parenchyma undergoes infarction. However, if the perfusion is restored early 
enough, a large portion of surrounding hypo-perfused tissue can be prevented 
from undergoing infarction.29  
 
The rate at which penumbra recruits into the infarct core differs between 
individuals, for it is a dynamic process, and depends upon vasomotor response to 
ischaemia and collateral circulation that are specific to an individual and differ 
between individuals.29  From the statistical analyses of randomised t-PA trials 
data, we know that the odds for improved outcomes are significantly >1 only 
until 4.5 hours after onset of the symptoms.131 The patients that were treated in 
the 4.5-6 hour time window had odds of (for better outcomes) 1.22 but here the 
confidence intervals were wide, i.e., 0.92 to 1.61.131  Current interest is, 
therefore, in the identification of those patients who may still have salvageable 
parenchyma despite delayed presentation. In the confidence interval for OR in 
the time interval 4.5-6 hours suggests that while some patients might benefit 
from t-PA, others would suffer excess harm.131 There is a potential to select 
patients despite delay in their arrival based on presence of penumbra.46 
 
 
1.10.3 Multimodal Stroke Imaging  
 
Multimodal stroke imaging aims to provide information about the extent of 
salvageable brain tissue, site of vessel occlusion, state of the collaterals. It also 
helps exclude cerebral haemorrhage or a stroke mimic.155-162 
 
Multimodal MRI protocol takes < ½ hour and includes sequences like T2-
Weighted, Fluid Attenuated Inversion Recovery (FLAIR), T2*- and diffusion 
weighted imaging (DWI) along with the perfusion weighted imaging (PWI) and MR 
angiography.  
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Standard T1-, T2-weighted, and FLAIR sequences are sensitive to vasogenic 
oedema. After the stroke onset, these take hours to develop. T2-weighted 
images or FLAIR images provide information about tissue characteristics that 
help the physician to exclude stroke mimics. Diffusion weighted imaging is 
sensitive to regions of ischaemia and develops within minutes of symptoms 
onset. Hence, it allows detection of ischaemic areas soon after the stroke onset. 
This is because DWI reflects signal changes that occur due to relative restriction 
of intracellular protons resulting from the failure of ATP dependent Na+/K+ 
pumps. These pumps pump the intracellular water out of the cells. While ADC 
values return to normal within days of ischaemia, hyper intensity on DWI may 
persist for weeks.163,164  
 
Immediate visualisation of an ischaemic stroke lesion is an advantage of DWI 
imaging over CT imaging. However, a study based on analyses of DEFUSE trial 
data indicated that the DWI lesions might be reversible (referred to as 
“Reversible Acute Diffusion Lesion Already Reperfused (RADAR)”)165 Recently, 
however, an analysis of DEFUSE and EPITHET data (n=119) indicated that a 
clinically relevant diffusion lesion reversal (DLR) is uncommon.166,167 The findings 
from the former study describing RADAR were attributed to errors in co-
registration of images and/or infarct atrophy. 166,167  
 
DWI is a useful tool and shows up hyper-acute ischaemic lesions as hyper intense 
signals on MR scans. Clinically, there are scenarios when a patient with a prior 
stroke presents with a recurrent stroke with symptoms suggesting a new infarct 
in the same territory. It is also likely that these patients may not have a new 
stroke but seizure activity from the scar of a previous lesion or symptoms due to 
deranged metabolic parameters or underlying infections. In order to decide 
whether new symptoms are due to a previous event or from a fresh infarct, the 
physician may want to use DWI sequence of MRI that can help confirm a fresh 
ischaemic lesion by the presence of bright hyper-intense signals. Also, DWI shows 
up smaller lesions that are very subtle on CT scans (e.g. lesions in posterior 
fossa). 
 
Gradient Recalled Echo (GRE) sequences and other T2*W images are equal in 
sensitivity compared to CT images when detecting an acute ICH. T2*W images 
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also pick up signals from deposits of hemosiderin, thus allowing identification of 
patients that suffer vasculopathies and are prone to spontaneous bleeding.168 
 
Further, there appears to be a potential for FLAIR images in wake-up stroke: 
FLAIR negative DWI positive MRI may indicate a time window of less than 3 (or 
4.5 hours) from symptoms onset (specificity 0.93, positive predictive value: 
0.94; but, sensitivity 0.48 and negative predictive value 0.43).149,169  
 
Also, Fluid-attenuated inversion recovery (FLAIR) is the most sensitive MRI pulse 
sequence for detecting subarachnoid haemorrhage and shows the lesion as high 
signal intensity.170,171 MRI can also identify a cerebral venous sinus thrombosis. 
Acute thrombus contain deoxyhemoglobin which is visible on T2*W imaging as 
linear or dot shaped low signal areas of magnetic susceptibility in a blood vessel 
lumen.172-174   
 
In addition, 3-D Time-of Flight (TOF) MRA imaging informs the state of vascular 
flow: when a saturation pulse is applied repeatedly, stationary protons in an 
excited plane get saturated while the flowing blood protons do not. Vascular 
contrasts are preferred because they have a relative independence from the 
flow dynamics and substantially reduce artefacts.175 MRA also allows visualisation 
of vascular occlusion or a stenosis. 
 
MR perfusion imaging refers to various techniques that allow non-invasive 
measurement of tissue perfusion and give haemodynamic data like tissue blood 
volume, blood flow and mean transit time. This technique involves serial 
measurement of signal changes that occur in surrounding tissue when a contrast 
bolus passes through its capillaries.29,176 Data so obtained are then transformed 
into relative tissue-concentration time course data. The haemodynamic 
parameters are measured based on a model that expresses the manner in which 
tracer passes through (or gets distributed within) the tissue. Variables that 
influence these parameters are the method of infusion (bolus vs. constant) and 
the pharmacokinetics of the contrast agent used for imaging (diffusibility of the 
agent, volume of distribution and half-life to reach equilibrium). The exogenous 
tracer method works on an assumption that the tracer stays restricted within the 
intravascular compartment (i.e. no diffusion into the extracellular space).  The 
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endogenous tracer method works on an assumption that the tracer diffuses 
freely between the intravascular and extravascular compartment.177,178  
 
In the case of ischaemic stroke patients, the exogenous tracer method based 
Dynamic state MR perfusion technique is used. When a bolus of paramagnetic 
tracer passes through a capillary network, there occur rapid alterations of the 
local magnetic field of surrounding brain tissue. These signal changes are 
measured by ultrafast imaging techniques like Echo Planar Imaging MRI.178,179 
Signal-time course data so obtained are then transformed into  relative tissue-
concentration time course data which then lead to the calculation of 
haemodynamic parameters like Mean Transit Time (MTT, average time taken by 
the contrast to pass through capillaries), cerebral blood volume (CBV; blood 
volume per unit of brain), relative cerebral blood flow (CBF; blood flow per unit 
brain mass per minute), time-to-peak (TTP; time to peak of the contrast agent 
in the vessel) and T-max (Time to peak of residue function). Because of the 
rapid passage of the bolus through the capillaries, a good temporal resolution 
can be achieved. 177,178 Because CBF, CBV and MTT depend on variables like bolus 
injection (dose, rate of injection, paramagnetic property of contrast) or patient 
characteristics (total body vascular volume and cardiac output)) that have intra- 
and inter-individual variability, semi-quantitative (relative) values obtained by 
using an internal reference point (like normal grey or white matter) are 
preferred.177,178 The Cerebral Blood Volume is calculated by measuring the area 
under curve of the tracer concentration time graph. 144,145 Calculation of 
cerebral blood flow requires extensive processing of imaging data and includes 
steps like deconvolution of arterial input function. 144,145 Cerebral Blood Flow 
then equals cerebral blood volume divided by mean transit time. The arterial 
input function varies between the voxels. Because most methods assume them 
to be a constant, there are chances of committing an error (e.g. when the 
middle cerebral artery is diseased on one side).177,180   
 
The concept of Diffusion Perfusion mismatch was recently tested in a few studies 
but failed to show success in achieving the primary end points.111,181 
Investigators attributed the failure to trial design, e.g., in DIAS II mild strokes 
were recorded. Whereas these studies defined mismatch as a ratio of 1.2 
between the perfusion volume and diffusion weighted lesion, analyses of DEFUSE 
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trials data later suggested that an optimal ratio should have been 2.6.182 There is 
a potential to select patients in a 3-6 hour  time window based on MR diffusion 
perfusion mismatch criteria: in DEFUSE there was a significant association 
between a successful recanalisation and reduction in infarct growth in patients 
with mismatch (OR 5.4, P=0.04).183  
 
Contraindications to the use of MR based imaging include patients having 
pacemakers, metallic implants, electronic devices or obesity. Some patients may 
also need sedation for agitation or claustrophobia.   
 
Further, thanks to the efforts of regulatory authorities that led to better clinical 
practices (e.g. screening patients and not using gadolinium when GFR is below 
30ml/minute per 1.73 metre square) and likely new treatment(s), the incidence 
of nephrogenic systemic fibrosis have substantially reduced (≈0).184-186   
 
Multimodal CT imaging includes non-contrast CT, a perfusion CT and a CT 
angiography. These take about ten minutes.  
 
Non contrast CT is used to exclude haemorrhages and other stroke mimics. It is 
widely available and can be done rapidly. Non contrast CT scan can identify 
some early ischaemic changes like hyper dense vessels, insular ribbon sign, loss 
of clarity of the lentiform nucleus or loss of grey white matter differentiation; 
but these are subtle in the first 3 hours of stroke onset (sensitivity is only 25% 
compared to DWI).187 Non-contrast CT provides structural information and no 
physiologic information; and hypo-attenuation is highly specific to infarction.  
 
CT angiography provides detailed information on vessel characteristics like the 
site of occlusion and may confirm recanalisation after the drug use. In addition, 
it can be used to assess flow in collateral blood vessels.188  
 
In the CT perfusion studies, it is the entry and washout of iodinated contrast 
agent that is studied; and the signal density of contrast, while in its transit 
through the capillaries, is analysed for image interpretation. CT contrast agent 
and CT tissue density have a linear relationship and therefore it is simpler to 
calculate the quantitative brain perfusion data. Conventional CT scanners are 
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unable to image the whole brain as they scan a 2-4 cm section of brain 
parenchyma in each contrast bolus administered; but better newer CT scanners 
allow greater brain coverage.188 
 
Dynamic perfusion CT involves measurement of brain haemo-dynamics by 
employing first pass tracer methodology.189 The method involves a continuous 
cine scanning lasting about 45 seconds (scan rate: 1 image per second). The 
patient is injected with ≈ 50 cc of 350 mg/dL iodinated contrast material 
intravenously. 190 Because low kilovolts (about 90 kilovolt peaks) or milli amperes 
(about 150mA) protocols are used, patients are not exposed to excessive 
radiation.190 Whereas an unenhanced CT brain results in radiation exposure of 
2.5 mSv, perfusion CT leads to an exposure of 1.6-2.0 mSv.149 Unless the 
contrasts are used in patients suffering renal failure or diabetes mellitus, the 
use of contrast is considered safe.191  
 
In 2009, it was discovered that more than 200 patients had received a radiation 
overdose in Cedars Sinai Medical Centre, Los Angeles California over a period of 
1.5 years. 186 192 Subsequent investigation by the United States Federal Drug 
Agency led to the identification of a total of 385 patients from six hospitals that 
had been exposed to radiation overdose.192 193 The investigations failed to 
identify violations of the laws or regulations; and noticed that when the scanners 
were used according to the specifications given by the manufacturer, 
overexposure to radiation did not occur.193 This incidence had occurred because 
of an error in the computer tomography console, and the overexposure was 
discovered when a patient reported suffering hair loss after receiving a CT 
scan.186 192 The levels of radiation were 8 times higher than the permissible 
limits.186 192 40% of the patients suffered alopecia because of these exposures. 192 
To prevent recurrence of similar incidents , CT quality assurance programs are 
needed.186 US-FDA had recommended that “(a) imaging facilities assess whether 
patients who underwent CT perfusion scans received excess radiation; (b) 
imaging facilities review their radiation dosing protocols for all CT perfusion 
studies to ensure that the correct dosing is planned for each study; (c) imaging 
facilities implement quality control procedures to ensure that dosing protocols 
are followed every time and the planned amount of radiation is administered; 
(d) radiologic technologists check the CT scanner display panel before 
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performing a study to make sure the amount of radiation to be delivered is at 
the appropriate level for the individual patient;(e)if more than one study is 
performed on a patient during one imaging session, practitioners should adjust 
the dose of radiation so it is appropriate for each study.”192 Wintermark and Lev, 
in an editorial, highlight that “while unnecessary radiation exposure should be 
avoided, a medically needed CT scan obtained with appropriate acquisition 
parameter has benefits that outweigh the radiation risks.”186 
 
Helical CT scanners, operating in cine mode are employed to obtain perfusion CT 
data. Multi-slice CT scanners are better because these allow for greater tissue 
coverage in each of the acquisitions.189 Automatic injectors are used; rate of 
contrast injection: 3-4 cc/second; Catheter size employed >/=22 gauge.189,194,195  
 
Post-processing software used to process CT perfusion data (time taken: about 5 
minutes) employ methods like rate of upslope estimation of cerebral blood flow 
(when the infusion rates are above about 6 cc per second) or deconvolution 
analysis (when the infusion rates are 4-5 cc per second); the latter provides 
quantitatively accurate rates.196   
 
CBF, CBV, MTT are read on the computer console allowing a physician appreciate 
visually the image at the same time as quantitatively analyse the region of 
interest. MTT are prolonged in areas where brain perfusion is reduced; and are 
sensitive to haemodynamic changes in the brain. Under perfusion they can be 
examined by comparing the CBV, CBF and MTT between the brain regions that 
are abnormal to their mirror images in the control area. Areas with prolonged 
MTT and increased CBV are considered to be the “tissue at risk”. Areas with 
reduced CBV with prolonged MTT correspond to an infarct core.197  
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Table  1-2  Acquisition and Post processing Parameters recommended for CT and MR perfusion 
 
Acquisition Parameter    Suggested by Roadmap for CT    Suggested by Roadmap for MR 
Type of sequence      Not applicable      Single-shot gradient echo EPI 
Duration       2-phase acquisition     90–120 s 
Temporal resolution     1000 ms      </=1500–2000 ms 
Other technical details     Peak kilo voltage 80kvp, current 100mAs  Echo time 1.5T (35–45 ms);  
3T (25–30 ms), flip angle  
 1.5T (60–90°); 3T (60°) 
 
Magnet strength      N/A        1.5 or 3.0T 
Anatomic Coverage      20 mm (minimum) coverage per bolus   >/=12 slices 
Slice thickness      5–10 mm       5 mm 
Field of view        about 24cm      about 24cm 
Avoidance of lenses     above orbits       Not Applicable 
Basal ganglia coverage     Yes       Not Applicable 
Slice orientation stated     Yes        Yes 
Contrast type      N/A        Gadolinium use stated 
Contrast volume      35–50 mL      Not Applicable 
Contrast concentration     350–370 mg/ml     Not Applicable 
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Injection delay      N/A        10s 
Injection rate      4–6 mL/s       4–6 mL/s 
Saline chaser described     Yes        Yes 
Power injector used     Yes        Yes 
Cannula gauge      18–20G       18–20G 
Side of injection      Right       Right 
Antecubital vein used     Yes        Yes 
Post processing parameter    CT perfusion     MR perfusion 
Use of deconvolution     Yes       Yes 
Arterial input function selection lateralisation  Yes       Yes    
Arterial input function selection artery   Yes       Yes 
Venous output function site    Yes       N/A 
 
[Source: Dani KA, Thomas RG, Chappell FM, Shuler K, Muir KW, Wardlaw JM. Systematic Review of Perfusion Imaging With Computed 
Tomography and Magnetic Resonance in Acute Ischaemic Stroke: Heterogeneity of Acquisition and Post processing Parameters: A 
Translational Medicine Research Collaboration Multicentre Acute Stroke Imaging Study. Stroke, 2011, e-pub 
doi:10.1161/STROKEAHA.111.629923. Permissions obtained from Wolters Kluwer Health, License Number 2783781063122.]198 
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Multimodal brain imaging has potential for use in selecting patients for 
thrombolytic therapies. At the moment, however, there is a need for 
standardising the image processing methods.198,199 
 
 
1.11 Adverse events after use of thrombolytic therapy 
Thrombolytic therapy is associated with adverse events like intracerebral 
haemorrhage, systemic bleeding or allergic reactions (like orolingual oedema, 
laryngeal oedema, anaphylaxis, or rash). 
Intracerebral Haemorrhage is the most feared complication of thrombolytic 
therapy. Its rate of occurrence is examined as an outcome measure (for safety) 
in clinical trials of thrombolytic therapy. Symptomatic intracerebral 
haemorrhage (SICH) has various definitions. The NINDS definition of SICH  is any 
haemorrhage that is associated with any neurological deterioration.122 The 
ECASS II definition of SICH is any haemorrhage with neurological deterioration, 
as indicated by an NIHSS score of 4 or more than the value at baseline or the 
lowest value within 7 days, or any haemorrhage leading to death.124 In the ECASS 
III protocol, symptomatic intracranial haemorrhage was defined as “any 
apparently extravascular blood in the brain or within the cranium that was 
associated with clinical deterioration, as defined by an increase of 4 points or 
more in the score on the NIHSS, or that led to death and that was identified as 
the predominant cause of the neurologic deterioration”.129 Hence, this definition 
is a modification of ECASS definitions in which it is further specified that the 
haemorrhage has to be identified as the predominant cause of the neurologic 
deterioration.129 As per SITS-MOST criteria, the symptomatic intracerebral 
haemorrhage (SICH) is defined as a local or remote parenchymal haemorrhage 
type 2 on the 22 to 36 hour post imaging scan, combined with a neurological 
deterioration of 4 or more points compared with baseline NIHSS or the lowest 
NIHSS value between baseline and 24 hours.146 Haemorrhagic infarction type 1 
refers to small petechiae along the margins of the infarct. Haemorrhagic 
infarction type 2 refers to confluent petechiae within the infracted area, but 
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without space-occupying effect. Parenchymal haematoma types 1 are the 
haematoma that occupy ≤30% of the infarcted area with some slight space 
occupying effect. Parenchymal haematoma type 2 refers to dense haematoma 
occupying larger than 30% of the infarcted territory and occupies substantial 
space, or as any haemorrhagic lesion outside the infarcted area.  
Orolingual oedema or the oedema of throat and mouth may occur from the use 
of intravenous t-PA.200-202 Hill et al report 9 cases of orolingual angioedema in a 
series of consecutively enrolled 176 patients. The severity was reported as 
“mild, transient and contra lateral to the ischaemic hemisphere”.200 The authors 
reported a significantly increased risk of orolingual oedema with the use of 
angiotensin converting enzyme inhibitors (Relative Risk 13.6, 95% CI 3.0-62.7).200  
1.12 Exclusion of patients from receiving alteplase 
Investigators that design randomised controlled trials want to pick up the 
positive “signals” of treatment effect and not let the “noise” (effect of a 
heterogeneous study population that trials enrol) dilute it. In order to achieve 
this, the trialists a priori decide to exclude certain subgroups of the patient 
population that according to them would add to the “noise”. Hence, when t-PA 
trials were designed, certain subgroups of patients were excluded from getting 
t-PA. Investigators assumed that these patients were more likely to suffer poor 
outcomes (e.g. baseline severity >25 on NIHSS scale) or would get better any 
way (e.g. mild strokes). As a result, when the trials turned positive, those 
patients that were recommended for exclusion were not given approval in the 
drug license. This is because of lack of randomised data and not because the 
trial had shown poor outcomes in those patients.( See Table 1-3) 
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Table  1-3 Table showing various exclusion criteria that were incorporated in the t-PA trials  
 
Exclusion criteria NINDS122 ATLANTIS-A* 126-128 ECASS III129 EPITHET181 
Intracranial haemorrhage  Yes Yes Yes Yes 
Unknown time since 
symptoms onset 
Yes Yes Yes Yes 
Rapidly improving symptoms 
or only minor before start of 
infusion 
Yes Yes; minor stroke< 4 
points on NIHSS 
Yes Minor stroke 
defined as m-RS 
<5; rapidly 
improving stroke 
Seizure at stroke onset Yes Yes, if known active 
seizure disorder; or first 
seizure within the 6 
hours immediately 
before administration 
of study drug 
Yes Yes 
Stroke or serious head 
trauma within previous 3 
months  
Yes Head trauma in last 90 
days; stroke in past 6 
weeks 
Yes Yes 
Combination of diabetes and No No Yes No 
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previous stroke 
Platelet < 100000/ml Yes  Yes Yes 
Systolic BP>185 and Diastolic 
BP>110. 
Yes, if aggressive 
blood pressure 
treatment was 
needed. 
Yes; or if requiring 
aggressive treatment to 
bring down the BP to 
normal. 
Yes, and if 
aggressive 
treatment was 
needed. 
Yes, if aggressive 
treatment was 
needed. 
Blood glucose level  Yes, if <50  and > 400 
mg/dl 
Yes, if <50 or >400 
mg/dl 
Yes if <40 or > 400 
mg/dl 
Yes if <40 or > 400 
mg/dl 
Symptoms suggestive of SAH 
even if CT is normal 
Yes Yes Yes Yes 
Anticoagulant treatment Yes, if received 
heparin in previous 
48 hours and had an 
elevated PTT;PT>15 
seconds 
 Yes Yes, if received 
heparin in 
previous 48 hours 
and had an 
elevated 
PTT;PT>15 
seconds 
Major surgery or severe 
trauma in previous 3 months 
Surgery within 14 
days. 
Surgery in last 30 days; 
or a biopsy of a 
parenchymal organ; or 
Yes Surgery in last 14 
days 
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trauma with internal 
injuries or ulcerative 
wounds; 
Gastrointestinal or Urinary 
Tract Haemorrhage 
Yes, if within 
previous 21 days 
  Yes, if within last 
21 days. 
Arterial puncture on non-
compressible site 
Yes, if within 
previous 7 days 
  Yes, within 
previous 7 days 
Other medical disorders 
associated with increased 
risk of bleeding 
 Hereditary or acquired 
haemorrhagic diathesis 
(raised 
APTT,PT;Coagulation 
factor deficiency; oral 
anticoagulant therapy 
with raised PT) 
Yes  
Others  Coma, severe 
obtundation, fixed eye 
deviation or complete 
hemiplegia; previous 
intracranial 
haemorrhage, 
Age <18 or > 80 
years 
If patient presents 
before 3 hours or 
after 6 hours; age 
below 18; non  
contrast CT scan 
showing 
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neoplasm, 
arteriovenous 
malformation or 
aneurysm; presumed 
septic embolus, 
pericarditis, presence 
of vascular thrombus or 
aneurysm related to 
AMI; other serious 
advanced  terminal 
illness; any other 
condition that 
investigator felt would 
cause  significant harm 
to patients if the drug 
was given; if patient 
was participating in any 
other trial; CT Brain 
showing high density 
lesions suggesting 
haemorrhage and 
major early 
ischaemic 
changes; inability 
to undergo MRI; 
history of ICH; if 
confounding 
neurological 
illnesses present 
like dementia or if 
patient suffered a 
life threatening 
illness. 
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haemorrhage, 
significant mass effect  
showing midline shift or 
SAH; pregnancy, 
lactation or parturition 
within last month. 
 
*ATLANTIS B had similar exclusion criteria. In addition it considered the presence of parenchymal hypo density, loss of grey/white matter distinction, 
and/or effacement of cerebral sulci in 33% of the middle cerebral artery territory as exclusion criteria; these were based on data from ECASS trial.161 
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It is more than 15 years since the first positive t-PA trial, NINDS trial (two parts, 
published together), was reported.24   So far only the time criteria of drug 
licensing has been examined in a randomised trial design in which the findings 
suggested that the time window could be extended until 4.5 hours of symptoms 
onset.129  Many of the original exclusions continue to persist in routine clinical 
practice and prevent a significant proportion of patients from getting 
thrombolysis therapy.  
Large proportions were excluded from the NINDS trial. 17367 patients were 
originally screened. Then, investigators had excluded 8708 (51.6%) patients 
because of delayed presentation, 10% (N=1749) due to rapidly improving 
symptoms, 7.8% (N=1306) due to intracranial haemorrhage, 6.6% patients 
(N=1106) due to minor symptoms, 6.1% (N=1021) because of age <18 or >80 
years, 2.9% (N=490) due to serious illnesses, 2.3% (N=391) due to seizure at 
stroke onset, 2.2% (N=373) because they were not stroke, 1.3% (N=219) because 
of a recent stroke, 1.2% (N=210) due to prior use of oral anticoagulant and 1% 
(N=169) due to previous subarachnoid haemorrhage.  Only 3.5 % of the screened 
patients were finally enrolled to the NINDS trial.122,123   
David Tong and colleagues reported Simplified Management of Acute Stroke 
Using Revised Treatment criteria (SMART) for thrombolytic therapy. In the 
absence of these criteria, a large proportion of patients would be excluded from 
getting t-PA (as shown in figure 1-2). According to SMART recommendations all 
ischaemic stroke patients are considered for use of thrombolytic therapy despite 
presence of common exclusions (see figure 1-2).203,204  
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Figure  1-3 Figure shows frequency of common 
relative contraindications to the use of 
alteplase in acute ischaemic stroke.  
 
 
 
 
 
 
 
 
 
Source: http://www.westernstroke.org/files/4_ExtendingTimeWindow_Tong.pdf (permissions obtained from Dr D Tong)203,204   
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Because the various non-evidence-based (i.e. randomised data are lacking) 
exclusions are suggested by drug licensing agencies, many physicians strictly 
follow them. As a result, large proportions of patients who have ischaemic 
stroke and present within the therapeutic time window fail to receive 
thrombolytic therapy. In this thesis, I revisit the rationale behind these 
exclusions and then examine outcomes in those who are recommended for 
exclusion from getting t-PA.  For this, I asked various t-PA trialists about the 
deliberations that took place during the period that preceded these trials (at the 
design phase), and got some information from NINDS investigator, Prof James 
Grotta.  I mention them here. 
t-PA was selected for use in the NINDS trial at a dose of 0.9mg/kg based on two 
underpowered studies.42,80 These studies had suggested that there were 
increased risks with the use of higher doses. Regarding exclusion criteria, there 
were no numerical cut-offs prescribed for baseline severity in the NINDS trial. 
Regarding a query about exclusions based on blood sugar levels, I was informed 
that these were based on consensus in the group: it was decided to exclude 
patients whose blood sugar levels were low enough to cause stroke-like 
symptoms or high enough to lead to neurological problems. Regarding 
appropriate cut-offs for platelet count or prothrombin time at baseline, a 
consensus was built based on the practices by cardiologists for myocardial 
infarctions. The purpose of exclusions was that the investigators wished to 
reduce risks, i.e., chance of bleeding, in most cases. Exceptions to this were the 
situations like seizures, rapid improvement of symptoms and high or low 
glucose level which were included to eliminate the stroke mimics. Rapidly 
improving or minor symptoms were excluded because investigators wished to 
exclude the TIAs. The source of many of the exclusions in the NINDS trial was 
from the exclusions prescribed for patients having myocardial infarctions e.g., 
patients having prior stroke or serious head trauma within preceding 3 months 
and major surgery in previous 14 days, gastrointestinal haemorrhage or urinary 
tract haemorrhage within the previous 21 days, arterial puncture at a non-
compressible site within prior 7 days or platelet counts below 100,000 per cubic 
millimetre.The upper limit of systolic blood pressure was set at 185 mm of Hg 
Nishant Kumar Mishra, 2011  Chapter 1, 67 
 
and diastolic blood pressure at 110 mm of Hg based on prior experience of Dr T 
Brott. Patients having symptoms which suggested that they suffered a 
subarachnoid haemorrhage were also recommended for exclusions. This was 
because at that time the CT imaging did not have great resolution and the 
investigators were afraid that they would miss a subtle SAH. Patients with 
seizures at symptoms onset were recommended for exclusions because if the 
patients had some of their symptoms because of Todd’s paralysis, its resolution 
might be due to natural history and not related to improvement of stroke. 
There was no vascular imaging at that time that would have allowed 
visualisation of occluded vessels patients suffering ischaemic stroke and also 
have seizures at stroke onset. It was not, therefore, possible to include patients 
with seizure at stroke onset in the trial. Patients who were taking 
anticoagulants or who had received heparin within 48 hours preceding the onset 
of stroke and had an elevated partial-thromboplastin time were also 
recommended for exclusion. At that time, investigators did not know if re-
occlusion was going to be a big problem. As is known, it is a problem in coronary 
recanalisation.  If it occurred, then the investigators were going to be more 
inclined to allow the use of anticoagulants since that was being done after t-PA 
use for patients with myocardial infarction.  It was an assignment meant for Dr 
J Grotta to examine evidence that re-occlusion occurred after stroke.  He was 
unable to find any reports documenting re-occlusion. He acknowledges that 
there were no good angiographic studies of acute stroke to rely on.  In addition, 
at that time there were no reports of improvement followed by deterioration 
which would have suggested recanalisation followed by re-
occlusion.  Therefore, the investigators didn’t think that the evidence for 
reocclusion was worth the risk of causing bleeding by allowing the use of 
anticoagulants, so they were very strict about the levels of PT and PTT that 
they would allow.  Investigators also prospectively built into the trial the 
objective of looking for deterioration following improvement (DFI) as a 
surrogate for reocclusion.  The reason they wrote the 48 hour heparin use was 
that because of the half-life of heparin, they were very sure it all would be 
gone within 48 hours if the PTT was normal. Regarding exclusion criteria of 
prothrombin times, cut-off at 15 seconds was a guess and the reasoning was 
based on Myocardial Infarction (MI) data.     Investigators had agreed to exclude 
patients from receiving alteplase if aggressive treatment was required to 
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reduce their blood pressure to the specified limits. This was based on the 
viewpoint of Dr Brott. Further by aggressive they meant IV infusions, in 
particular, nitroprusside.  At that point, nicardipine was not in use, but within 
a short time Dr Grotta’s department at Houston had begun using it and clarified 
with the steering committee that its use was allowed. (Source: personal 
communication with Prof James Grotta, UT Houston, USA) 
Exclusion criteria in other trials were similar to NINDS trial (See table 1-3), and 
probably had a similar logic. ATLANTIS B considered little additional exclusion 
like the presence of parenchymal hypodensity, loss of grey/white matter 
distinction, and/or effacement of cerebral sulci in 33% of the middle cerebral 
artery territory based on data from the ECASS trial.127 Exclusions resulted in 
serious reduction of sample size in each of these studies.   
The EMEA’S document “summary information on a referral opinion following an 
arbitration pursuant to article 29 of directive 2001/83/EC for actilyse” prepared 
by European Agency for the Evaluation of Medicinal Products (EMEA), London 
informs about the status of alteplase use within the European Union.23 The 
document states that within EU, alteplase is indicated for acute ischaemic 
stroke patients presenting within 3 hours of symptoms. The drug should be used 
at a dose of 0.9 mg/kg (maximum dose 90 mg/kg, 10% given as bolus) and cannot 
be given concomitantly with the aspirin or heparin.23 
 
Interestingly, the exclusions differ between the jurisdictions reflecting 
regulatory acceptance of either NINDS criteria (US and Canada) or ECASS criteria 
(EMEA). US guidelines include different restrictions for <3h and 3-4.5h use. (See 
table 1-1)25 
 
  
1.13 Utilisation of thrombolytic therapy in acute 
ischaemic stroke 
In cardiology, a large volume of data is available to show that thrombolytic 
therapy reduces mortality: Gruppo Italiano per lo Studio della Streptochinasi 
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nell’Infarto miocardico (GISSI-1; N=11806)205, Intravenous Streptokinase in Acute 
Myocardial Infarction (ISAM; N=1741)206, APSAC Intervention Mortality Study 
(AIMS; N=1004)207 , Second International Study of Infarct Survival (ISIS-2; 
N=17187)208,209, Anglo-Scandinavian Study of Early Thrombolysis (ASSETS; 
N=13318)210, Urochinasi per via Sistemica nell’Infarto Miocardico (USIM; 
N=2531)211, Third International Study of Infarct Survival) Collaborative Group 
(ISIS-3, N=41299)212, Estudio Multicentrico Estreptoquinasa Republicas de 
America del Sur (EMERAS;N=4534)213 and  Late Assessment of Thrombolytic 
Efficacy (LATE; N=5711)214. These trials showed strong and significant treatment 
effect and were published around a similar time period. The findings caught 
wide media attention and created enthusiasm and the thrombolytic agents were 
rapidly accepted by the cardiologists for the treatment of myocardial infarction. 
Large volume of these data on their own showed efficacy of thrombolytic 
therapy in AMI; and, when examined in meta-analysis reconfirmed the benefit 
(Mortality rate 9.6% vs. 11.5%, p<0.0001, N=58600).215 
In the case of ischaemic stroke, the story has been different. Though, efficacy of 
alteplase in acute ischaemic stroke had been endorsed by  several medical 
bodies (like American Academy of Neurology, American Heart Association or 
European Stroke Organisation), the claims for better outcomes were based on 
fewer data from only three randomised trials (the NINDS trial (two parts, N=291 
and 333, data published together, in 1995) and ECASS III study (N=821, published 
in 2008))122,129. Amongst the NINDS, ECASS, ECASS II and ATLANTIS, only NINDS 
trial was positive and reported efficacy of t-PA in acute ischaemic stroke in a 3 
hours’ time window.122 But, the NINDS trial was underpowered to detect any 
influence on mortality (t-pa vs. placebo 17% vs. 21%, p=0.3).122  The 
Streptokinase trials showed excess complications and therefore had to be 
abandoned.48-50 So far, only 7152 patients have been thrombolysed in 26 
thrombolysis trials; and, only 3670 patients received t-PA.92,131  Fewer patients 
have been enrolled in thrombolysis trials compared to cardiology trials for acute 
myocardial infarction.215 Despite FDA approval and upgrading of the level of 
evidence by American Heart Association (AHA, from Class IIb to Class I 
intervention i.e., from “optional” to “definitely recommended”), the drug was 
not widely accepted by physicians.122,123 216,217 Many physicians remained 
unconvinced by the data arguing that the data were few and were based on a 
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highly selected population; and, the treatment could only be given effectively  
by the experts.132-134,218  
Then there was a range of controversies about trial and AHA recommendations. 
In an article published in BMJ, in March 2002, Jeanne Lenzer, a medical 
investigative journalist, questioned the process leading to AHA recommendations 
for t-PA use in acute ischaemic stroke as it was based on just one single 
randomised trial.134 In that BMJ paper, the following issues were raised134: It was  
argued that the NINDS trial could have been positive merely by chance.218,219,134 
Questions were raised around imbalances in baseline severity data of those  
patients that were treated in the 91-180 minutes time window of the NINDS 
trial.134 So far, NINDS was the only positive study that had shown benefit while 
various others had failed to show benefit; and, had instead demonstrated excess 
mortality from use of thrombolytic agent. 134,218-222 Based on chart reviews of 
consecutive patients examined in emergency departments (between 1990 and 
1992), it was found that 19% of the patients were stroke mimics. Hence there 
was a logical worry that a physician might offer a t-PA therapy, which is 
associated with excess risk of haemorrhagic complications, to a patient who may 
not have a stroke. 223  Further, the public health impact from the use of t-PA was 
predicted to be minimal. 134,224 Emergency physicians favoured a more restrictive 
licensing than the one endorsed by the American Heart Association.132,221  
Standard Treatment with Alteplase to Reverse Study (STARS) had indicated 
effectiveness of t-PA. But, there is a question as to whether a study can be 
considered to be an “effectiveness” study if the participating centres had 
already had experience of working as the sites for the ATLANTIS trial. 134 The 
ATLANTIS trial had received sponsorship of Genentech, a pharmaceutical 
company that manufactures alteplase.134 Further, it was worrisome to see the 
reports from Cleveland study that had shown poor outcomes in patients treated 
with t-PA.134 The American Heart Association had claimed that t-PA saved lives, 
but the data did not show reduction in mortality.134 Lenzer highlighted that AHA 
had received massive funding from Genentech implying a strong conflict of 
interest.134 In summary, there were some controversies about the manner in 
which the t-PA guidelines were framed or NINDS trial findings were promoted.134 
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The European Medicines Agency did not license t-PA in European Union for 
several years, and when it did, it required the sponsors to show efficacy and 
safety by conducting what were later to be known as the SITS-MOST 
observational study and the ECASS III trial.23  It was only after several 
observational studies (see section 1.9) and importantly the SITS-MOST and a 
positive phase III ECASS III trial (see section 1.7), (confirming effectiveness of 
alteplase until 4.5 hours of symptoms onset) that the scepticism around the use 
of alteplase got considerably reduced. But the body of randomised clinical data 
continues to remain small.92,131  
It is expected that a larger body of trials data would influence clinical 
practice.225 In the case of cardiology, Ketley and Woods undertook to examine 
the temporal profile of the manner in which the thrombolytic therapy for acute 
myocardial infarction was adopted in the Trent Regional Health Authority Area 
after the thrombolysis trials got published.225 They based their analyses on the 
supply of thrombolytic drugs from all sources (district pharmacy services or trial 
organisations) for the period of 1987-1992.225 The results of the study are shown 
in figure 1-3. The study showed that the supply was negligible for the first two 
years after the GISSI study but gradually increased after ISIS-2 and reached an 
approximate plateau at around 1991-1992.225  
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Figure  1-4 Figure shows the trend in the thrombolytic use over time (1987-1992) for patients 
suffering acute myocardial infarction in the Trent Regional Health Authority area of Central 
England. The central thick line shows the mean values, the other two lines show the 
standard deviation.   
 
 
[Source: Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of 
thrombolysis for acute myocardial infarction. Lancet 1993; 342:891-4. Permissions obtained 
from Elsevier Limited, The Boulevard, Langford Lane Kidlington,Oxford,OX5 1GB,UK; License 
number 2783780816358]225 
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Ketley and Wood’s study shows that there was a lag phase after which  
thrombolytic therapy began to pick up its pace of usage in the community and 
then reached a plateau between 1991-1992.225   
But, it has not always happened that the trial findings influence clinical practice 
(for example, despite a showing that diethylstilboestrol did not benefit, 
pregnant women continued to use it during the 1950s).226,227  
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Figure  1-5 t-PA usage in the United States of America 
 
(Source: Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type 
plasminogen activator use for ischaemic stroke in the United States: a doubling of 
treatment rates over the course of 5 years. Stroke 2011; 42:1952-5. Permissions 
obtained from Wolters Kluwer Health 2783780982628) 228 
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In case of thrombolysis trials for stroke, the manner in which their data 
influenced stroke practices in the past (prior to ECASS III) may only be 
speculated upon. Unlike cardiology, there were fewer data of stroke patients 
having better outcomes after receiving thrombolytic therapy. There was an 
original scepticism about the efficacy of t-PA. These factors may have 
contributed to initial poor usage of thrombolytic therapy. Another reason would 
have been that the stroke care is resource intensive and requires the setting up 
of a stroke unit, imaging facilities and access to an experienced clinical staff. 
These things take a while to get organised in hospitals. Adeoye et al report that, 
in USA, there has been a significant increase in the t-PA usage between the 
years 2005 and 2009 (1.1% to 3.4%, p<0.001 for trend). The rates were stagnant 
between 2001 and 2005 (figure 1-4).228 The following reasons were cited for the 
increased rates of usage after 2005: financial incentive given to the hospital, 
Joint Commission certification of primary stroke centres, initiatives to 
standardise acute stroke care, and the aggressive Get With The Guidelines 
(GWTG) campaign.228  
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Figure  1-6 Figure shows number of patients recorded in SITS registry in each quarter  
 
Source:  Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of 
thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from 
SITSISTR. Lancet Neurol 2010; 9:866-74; Permissions obtained from Elsevier Limited The 
Boulevard, Langford Lane, Kidlington, Oxford, and OX5 1GB, UK, License number: 
2783781166304.229 
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After the NINDS trial, it was only the ECASS III trial that was positive and has 
shown better outcomes amongst stroke patients (in 3-4.5 hours’ time 
window).129 So, did it influence the clinical stroke practice? SITS-ISTR registry 
recorded an “immediate and lasting” effect of ECASS III publication with no 
change in the presentation-to-hospital to initiation-of-treatment time.229 
Similarly, a Swedish  Stroke Registry has reported that after the publication of 
ECASS III trial,  rates of t-PA utilisation increased from 0.5% to 2.1% (between 
2008-2010 in patients treated within 3-4.5 hours’ time window).230 The rates in 
0-3 hours had increased from 0.9% in 2003 to 6.6% in late 2008 and then levelled 
at a thrombolysis rate of about 6%230. There was no difference between the 
median time of arrival-to-hospital and the start-of-treatment (p=0.06).230  Here, 
the 0-3 hour time window thrombolysis program had developed over the years, 
but, the 3-4.5 hours t-PA use could be initiated soon after the ECASS III results 
went public. This was only possible because these centres had already developed 
the necessary infrastructure and the experienced physicians. Increased usage of 
t-PA after ECASS III trials suggests that the ECASS III trial had an impact on the 
clinical practice.230 
Further, the Swedish noted a plateau effect for the use of alteplase. It was 
attributed to the fact that the these hospitals had reached a saturation level for 
the rate of thrombolysis they could achieve within their jurisdiction.230  It may 
be speculated that the t-PA use in 3-4.5 hour time window might also level-off in 
a similar fashion when the hospitals would reach saturation levels for the use of 
t-PA.  So, for the next rise in t-PA usage to commence, one would need 
additional high quality clinical evidence for the treatment of some more 
additional patients that at present do not get treated with t-PA. This is possible 
because, some of the Swedish centres that practice off label use of t-PA report a 
higher rates of thrombolysis (≈10-15%).230  
So it can be thought that in order for change in current clinical practice to occur 
and to treat more patients, we should have more randomised controlled clinical 
data. Only randomised controlled trials can provide the best quality of clinical 
evidence and assuage the fears of poor outcomes in stroke patients. Data on 
subgroups that are currently excluded would allow physicians to better select 
patients. But, conducting such a trial would be a difficult task because 
Nishant Kumar Mishra, 2011  Chapter 1, 78 
 
physicians do not have uniform opinion regarding the effectiveness of t-PA 
therapy in the several patients’ subgroups (e.g. physicians differ in their opinion 
regarding treatment of mild ischaemic strokes or the elderly patients that suffer 
an ischaemic stroke) or for treatment approach, (like, intravenous vs. intra-
arterial); and, therefore there is a lack of equipoise. Alteplase is already an 
approved treatment for acute ischaemic stroke in most countries. Some centres 
employ practices in which they are extremely good (e.g. intra-arterial 
thrombolysis). Hence, participation in randomised controlled trials may be 
difficult for these physicians.231 Also, the enrolment of patients in t-PA trials is a 
slow process that takes a while to reach the target sample size. About a decade 
ago, IST-3 trialists set out with a target of 6000 patients to be randomised within 
6 hours of symptoms onset.232 So far, they have only been able to enrol about 
3000 patients.233,234 Recruitment would also be challenging because patients 
meant for exclusion constitute only a small fraction of those that get treated 
(e.g. in SITS-ISTR, 2.6% patients have concomitant diabetes and previous stroke, 
n/N=602/23062).   
1.14 Why aren’t many eligible patients treated with t-PA in 
the routine clinical practice? 
In routine clinical practice, there are other variables that influence patients’ 
selection: delay in arrival at a stroke treatment facility within the time window,  
lack of awareness (including amongst some physicians235)18, delay in admission to 
a stroke treatment facility and lack of local stroke care facility/expertise.236  
Many physicians fear excessively about the bleeding complications and therefore 
they do not thrombolyse those patients that belong to any of the exclusion 
mentioned in the list of the t-PA exclusion criteria.236,237  Some expert centres 
practise off-label use of t-PA based on a physician’s clinical judgement; but fear 
of litigations or causing harm (due to valid reasons that had originally influenced 
the drug authorities to considering patients for exclusion) prevent many others 
from using t-PA in scenarios that do not find clear mention in treatment 
protocol.203,204 
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In those countries where the costs of health care are borne by the patients and 
relatives, t-PA may not be used, because it is an expensive therapy.238 The loss 
of disability adjusted life years incurred by underuse of thrombolytic therapy 
carries a large economic and societal cost. Hence, national governments need to 
initiate programs to treat acute stroke patients.18,20  
There is wide variation in the usage of t-PA for ischaemic stroke between 
centres. For example, an analysis of Healthcare Benchmarking Systems 
International (HBSI) EXPLORE database showed that 35% of the community 
hospitals (profit and non-profit hospitals throughout USA) did not use t-PA at all; 
and the variables that significantly influenced the use of t-PA in these hospitals 
were race, age and disease severity(N=137 centres, 23058 patients).239  
There is an intra and inter country variability in the use of t-PA as well (figure 1-
6, for UK contribution to SITS-Centres).240,241 The variation between centres 
could reflect the limited evidence that is available for the use of t-PA in various 
subgroups. Physicians are also concerned about the patients’ safety and 
therefore might not treat those patients for whom, based on their clinical 
judgement, the potential for harm outweighs the possible benefit. 
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Figure  1-7  Figure shows UK SITS centres with size of circle denoting the number of 
patients recruited within the SITS registry from each of these centres 
 
 
 
Source: Lees KR, Ford GA, Muir KW, et al. Thrombolytic therapy for acute stroke in the 
United Kingdom: experience from the safe implementation of thrombolysis in stroke 
(SITS) register. QJM 2008;101:863-9; Permissions obtained from Oxford University Press, 
License Number: 2783781419775 240 
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Thrombolysis is a standard practice for the treatment of patients suffering 
myocardial infarction, but the acceptance rate is lower amongst physicians 
caring for acute stroke: only about 5% of the patients receive thrombolytic 
therapy.228  Alteplase is associated with absolute benefit of 10-15%, but because 
it is infrequently used, it hasn’t had the kind of public health impact it is 
expected to have. There is a need to enhance community awareness about the 
need for emergent stroke care and encourage participation of community 
hospitals in providing stroke care. 
Racial differences are known to influence stroke outcomes, and inter-ethnic 
differences in risk factor profiles are well described.242-244 The Japanese drug 
agency approved a lower dose of 0.6mg/kg in lieu of 0.9 mg/kg for the 
treatment of acute ischaemic stroke. 245-249251 The Chinese examined outcomes in 
patients treated with a lower dose of 0.6mg/kg (n=116) and standard 0.9mg/kg 
(n=125) and observed that there occurred excess symptomatic haemorrhages in 
the standard group (rates were, per NINDS, 10.4% vs. 5.2%; per ECASS definition, 
8.0% vs. 2.6%; SITS-MOST definition, 5.6% versus 1.7%, respectively) and 
mortality at 90 days (12.8% versus 6.9%) in the patients that received the 
standard 0.9mg/kg dose.250 These differences may be attributed to the ethnic 
variability in the rate of fibrinolysis.251-253 It is likely that certain ethnic groups 
respond differently to the use of t-PA; and, therefore these physicians might be 
cautious when extrapolating thrombolysis data on their population. 
 
1.15 Present Thesis 
When the NINDS trial proved the efficacy of alteplase, the US FDA promptly 
approved its use within its jurisdiction.123 However, EMEA was not immediately 
convinced and argued whether findings based on an non-European trial that 
studied only over a thousand patients could be extrapolated onto the European 
population.23 Proponents of alteplase argued that though European trials (ECASS 
I, II) had not shown favourable outcomes similar to the NINDS trial, failure could 
be attributed to differences in trial design.23 An ad hoc expert group had also 
failed to show a definitive and a big treatment effect from the use of alteplase 
in elderly stroke patients, patients having diabetes or patients having a severe 
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stroke.23 The expert group suggested that a randomised controlled trial in this 
subgroup of the patient population would be required to confirm the efficacy of 
use of the alteplase.23  The Committee for Proprietary Medicinal Product (CPMP) 
felt the need to undertake a randomised dose comparator study for time window 
0-3 hours, but conducting such a study was not considered feasible owing to 
ethical concerns.23 Several centres had already incorporated alteplase in their 
local clinical practice.23  Hence, it was proposed to study efficacy of alteplase in 
a 3-4 hour time window in a randomised controlled trial design and by 
undertaking a safety study of observational data for patients treated within the 
3 hour time window.23 While the ECASS III trial showed efficacy and safety of 
alteplase in acute ischaemic stroke patients when administered between 3 
and 4.5 hours after the symptoms onset, the SITS-MOST study confirmed that i.v. 
alteplase is safe and effective in routine clinical use when used within 3 h of 
stroke onset.129,146  
When formulating CPMP approval, the EMEA  recommended few exclusion 
criteria that were incorporated in ECASS III study.23  After outcomes were shown 
to be better for the patients treated in 3-4.5 hour time window in the ECASS III 
trials, uncertainties continue to persist for those that were excluded from 
trials.23 Now that alteplase is proven to be effective in ischaemic stroke, it is 
desirable to investigate if other exclusions are justified and if treatment could 
be extended to other patients that are included in current EMEA list of 
exclusions.23 
In the present thesis I have tackled following questions:  
 
1. Should elderly patients receive alteplase for their acute ischaemic 
stroke? [Chapter 3 and Chapter 4] 
2. Should patients having a concomitant diabetes and history of previous 
stroke receive alteplase therapy? [Chapter 5 and Chapter 6] 
3. Should patients having mild or severe stroke receive alteplase for acute 
ischaemic stroke?[Chapter 7] 
4. Should thrombolytic therapy be administered to stroke patients based 
on mismatch criteria and beyond 3 hours of symptoms onset? [Chapter 
8] 
    
 
 
 
 
 
Chapter 2 
 
 
Methodology
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2  Methodology 
Here I describe the methodology that I have used with its merits and limitations. 
2.1 Introduction 
Clinical Investigation refers to the examination of clinical data for the 
association of intervention(s) with the outcomes in a study population. Expert 
opinions based on anecdotal evidence are likely to result in flawed 
conclusions.254 Clinical trials are the best means of investigating treatment 
interventions.254  
I selected data from the Safe Implementation of Thrombolysis in Stroke-
International Stroke Thrombolysis Register (SITS-ISTR) and Virtual International 
Stroke Trials Archive (VISTA) for this thesis for reasons of time and practicality 
and undertook to examine outcomes in patients’ subgroups that were 
recommended for exclusion by the European drug authorities.147,255 I hoped that 
if my findings were consistent between the two datasets, I would have given a 
useful piece of evidence to support (or reject) thrombolytic therapy for those 
patients that are currently recommended for exclusions. These findings could be 
an important source of information for physicians until further confirmatory 
randomised data are available. 
For SITS- and VISTA- analyses, blinding and randomisation techniques could not 
be employed. These data were already collected per the protocol of SITS group 
or VISTA trialists. I undertook a controlled comparison using controls from VISTA 
dataset. VISTA controls were compared with patients that received alteplase in 
VISTA trials or in SITS-ISTR registry.147,255 
  
2.2 Data Source 
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VISTA is a collaborative, not-for-profit, register of stroke trials.255 The 
treatments studied in these trials range from putative neuro-protectants through 
anticoagulants and thrombolytic agents to simple rehabilitation measures. All 
trials in VISTA hold necessary review board and regulatory approvals, and 
patients consented to participation; only anonymised data are held by VISTA and 
the trial source is not disclosed as per VISTA guidelines. All stroke patients were 
treated as per institutional practice and stroke guidelines acceptable at the 
point of trial conduct. Monitoring for protocol compliance was undertaken on 
behalf of sponsors for these trials. This implies that where thrombolysis was 
administered, this was in accordance with marketing authorisation for the 
relevant country, i.e. that treatment commenced within 3 hours of stroke onset; 
however, the onset to treatment delay is not recorded for thrombolysis in these 
trials. Further, note that the reason for withholding thrombolysis in each patient 
was not recorded in VISTA, but will include absence of marketing approval in the 
region at that time, clinical uncertainty over the use of thrombolysis for stroke 
generally, absence of treatment facilities for thrombolysis in the hospital at that 
time, and contraindications to thrombolysis for the individual patient. These 
data were derived mainly from Northern American (60%), European (16%) and 
Australasian (13%) centres.255 
 
For my research, VISTA data were obtained from neuroprotection trials that 
were conducted between 1998 and 2007. These trials hold necessary review 
board and regulatory approvals. The patients had consented to participation. 
VISTA holds only anonymised data. These data were rigorously collected by the 
trialists. Some of the patients in the studies received an investigational 
neuroprotective agent. One or more of these neuroprotective agents could have 
interacted with thrombolysis; however each contributing trial has already tested 
for and excluded significant interaction. VISTA data handling procedures 
preclude further testing for effects of the original neuroprotection agent or 
identification of source trials. Hence, I cannot identify the trials that 
contributed to VISTA dataset, nor did I ever have access to these: I was given 
access to an anonymised dataset of 9665 patients from VISTA.  
SITS-ISTR is an ongoing internet-based, academic-driven, interactive 
thrombolysis register registry (www.sitsinternational.org), held at Karolinska 
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University Hospital, Stockholm. The methodology of the SITS-ISTR including the 
procedure for data collection and management, patient identification and 
verification of source data has been described in their early publications. It is a 
prospective, open, multinational, observational monitoring registry for clinical 
centres using thrombolysis and other interventions for the treatment of acute 
ischaemic stroke. The registry is open to all countries, and collects data on 
patients who receive thrombolytic therapy for acute ischaemic stroke.147,256  
I was given SITS-ISTR data after their extraction from the SITS-ISTR and on my 
arrival at the Department of Neurology, Karolinska University Hospital. For the 
present thesis, data were extracted for a period December 2002 to November 
2009. These data were then combined with a control group derived from 
untreated stroke patients (untreated for t-PA) within VISTA neuroprotection 
trials conducted between 1998 to 2007 and held within the Virtual International 
Stroke Trials Archive, VISTA (www.vista.gla.ac.uk). Referred to as “SITS-VISTA”, 
this combined dataset is employed for analyses in chapter 4 and 6.   
I show the details of data extraction in the figure 2.1.to indicate completeness 
of data that were available for present analyses. Further, information on missing 
data for various co-variates can be inferred from the baseline characteristics 
that I report in each chapter. 
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Figure  2-1 Flow chart showing the details of data extraction for VISTA 
(above) and SITS-ISTR (below) which are employed for analyses in the present 
thesis 2 
                                                
2
   I published these figures in two papers: Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR; VISTA Collaborators. 
Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual 
International Stroke Trials Archive (VISTA). Stroke. 2010 Dec;41(12):2840-8. and Mishra NK, Ahmed N, Andersen G, 
Egido JA, Lindsberg PJ, Ringleb PA, Wahlgren NG, Lees KR; VISTA collaborators; SITS collaborators. Thrombolysis in 
very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International 
Stroke Trials Archive. BMJ. 2010 Nov 23;341:c6046. doi: 10.1136/bmj.c6046 respectively; Permissions were obtained 
from Wolters Kluwer Health (License Number- 2790451375765) and BMJ Publishing Group Limited (License 
Number- 2783790122184) respectively. 
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When reporting findings from the analyses, I describe the baseline 
characteristics of the data and also examine them for completeness of 
covariates (Figure 2.1).  
Data on 9665 patients were collated from VISTA. Of these, 5342 (59%) were 
enrolled from non-European sites. To avoid dual publication with SITS-MOST, I 
excluded 2789 patients (28%) enrolled from European sites between 2002 and 
2006, and 177 patients for whom the data lacked information on nationality.146 
 
2.3 Ethics Approval 
Because clinical studies ought to be based on current ethical standards, and 
because there is a range of procedures that ought to be followed in order to 
obtain consent, it was necessary to clarify these requirements from VISTA and 
similarly later from SITS-ISTR.  Ethical considerations are an important 
component of clinical investigations. In VISTA, participating patients had already 
consented to their participation in VISTA trials, and therefore it was deemed 
unnecessary to seek additional consents from the patients for the projects that 
had been proposed for the present thesis; it would also have been impractical 
since most by now would have died, even if they could somehow be identified.  
In order to obtain an unbiased and blinded feedback from other experts, a study 
proposal was circulated between the VISTA steering committee members and 
similarly to the SITS-ISTR steering committee members. SITS Steering Committee 
members comprise members from all across Europe and the VISTA from all over 
the world. (See appendix)  
 
2.4 Outcome Measures 
Outcomes measured in randomised trials should be valid, reliable, robust and 
responsive. Common outcome measures that were employed in stroke research 
include the modified Rankin Scale, National Institute of Health Stroke Scales, 
Barthel Index and Scandinavian Stroke Scale.257   
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The Modified Rankin Scale (m-RS) was originally not meant for use in trials, but 
now, it is a commonly used measure of outcome assessment employed in Stroke 
Trials.257 It is an ordinal scale that scores patients for their functional status on a 
scale of  0 to 6 in which zero refers to the absence of any disability while  a 
score of six means that the patient is dead. Rankin scores are associated with 
substantial inter-observer variability that is most apparent for the Rankin scores 
1 to 4.258 Whereas one may find it easier to score a patient 0, 1, 5 or 6, it is 
often difficult to distinguish a 2 from 3 or 3 from 4 on this scale.  An 
examination of a hundred paired assessment suggested that kappa statistics for 
inter-observer variability were lower than those for intra-observer variability 
(0.57 vs. 0.72).258 There was no significant difference observed between a 
structured interview method and a standard m-RS method.258  But, two previous 
studies have also shown that weighted kappa statistics for agreement between 
raters of m-RS scores were greater when a structured interview was used instead 
of the conventional method (k 0.91 vs 0.71 and 0.93 vs 0.78)259,260In order to 
reduce bias arising from inter-observer variability, measures like structured 
interviews or video training are employed.  
Scores on a modified Rankin scale261 
• 0=no symptoms from stroke 
• 1=no severe disability, despite symptoms 
• 2=slight disability in which patients are unable to do all previous activities 
but able to look after themselves without help 
• 3=moderate disability that requires some help, but patients can walk by 
themselves 
• 4=moderately severe disability in which patients are unable to walk 
without assistance and need help for bodily needs 
• 5=bedbound patients who are incontinent or require personal attention 
• 6=death 
 
The National Institute of Health Stroke Scale (NIHSS) is a scale used to measure 
the neurological outcomes in stroke trials.262 Its use is associated with increased 
power.263 Baseline stroke severity measured on NIHSS is an excellent predictor of 
outcomes.264 Age and baseline stroke severity account for maximal variance in 
stroke outcomes; which is why these are employed as covariates for adjusted 
analyses when comparing outcomes from use of t-PA in present analyses.265 A 
Nishant Kumar Mishra, 2011                                                                                          Chapter 2, 90 
 
 
patient having a left sided brain lesion scores higher on NIHSS compared to a 
similar right sided brain lesion.266 By combining the NIHSS scale with 
neuropsychological tests like line bisection tests and visual perception tasks, one 
can augment its sensitivity for right brain lesions as well.267  
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Table  2-1 Modified National Institutes of Health Stroke Scale 
 
Source: Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J. 
Improved reliability of the NIH Stroke Scale using video training.NINDS TPA Stroke Study Group. 
Stroke. 1994 Nov;25(11):2220-6. Permissions obtained from Wolter Kluwer Health, License 
Number: 2813100962854 
Nishant Kumar Mishra, 2011                                                                                          Chapter 2, 92 
 
 
For analyses presented here, from VISTA, I had access to two measures of 
outcome: modified Rankin scale and NIH stroke scale both measured on day 90 
of the stroke occurrence. From SITS-ISTR, I had access to the baseline 
demographics and only m-RS score on day 90 of stroke as a measure of 
outcomes. 
 
2.5 Errors and Bias 
Before beginning to collect data, it is desirable to consider the measures that 
can reduce errors or bias in a study.  
 
Errors are of two types:  random errors and systematic errors.  Random sampling 
error refers to chance variation that is observed between one study population 
and another. Bias refers to the deviation from truth of inferred results. It is a 
form of systematic error that is ubiquitous, results in erroneous estimates of 
association, and cannot be completely removed. Methods to prevent it should be 
thought out early during the design and execution phase of the study. When 
attempting to reduce bias, an investigator may introduce another bias 
compromising generalisability of the results. A good understanding of bias 
permits better interpretation of the results in a more meaningful way. Bias 
occurs because of various reasons. For example, selection bias (sampling bias) 
occurs when a sample does not represent the population under study. For 
instance, predicting the rates of cardiac disease in athletes would introduce 
selection bias because athletes are less likely to suffer cardiac illness. Berkson’s 
bias refers to a bias that is introduced from the hospital stay. Measurement bias 
occurs when information gets distorted due to the unique characteristics of 
methodology by which the data were collected. These include instrument bias or 
insensitive measure bias. The Hawthorne effect refers to situations when 
attention is paid to the subjects under study that alters their behaviour and thus 
the outcomes. Intervention Bias  results from abnormal or distorted 
interventions and leads to bias like contamination bias where the control group 
mistakenly receives treatment, co-intervention bias  when some subjects receive 
treatment and an additional intervention, timing bias(es)  when treatment is 
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provided for a longer duration, compliance bias when there are differences in 
the compliances of the patients enrolled in the study arms, withdrawal bias 
because some subjects withdrew from the study, proficiency bias that occurred 
when the interventions are not equally applied to the various subjects owing to 
differences in the proficiencies of the investigator and/or the differences in the 
resources or procedures employed at different centres.  
 
Hypothetically, by increasing the size of data, it is possible to reduce random 
sampling error and bring it close to zero. On the other hand, bias has no 
relationship to population size of study. In order to reduce bias, one can take 
the following measures: incorporate a placebo arm; undertake a blinded study; 
consider a cross over study design; apply good randomisation techniques; train 
the investigators about various stages of the study (e.g. ECASS II study, in which 
the investigators were trained in reading CT scans).   Despite measures to reduce 
bias, some bias may persist in a study; and, an exact degree of bias is never 
precisely known. An investigator may want to consider a trade-off between bias 
and variance, and logically, accept the measurement with the lowest mean 
square of standard error.268 
 
For my thesis, I undertook analysis of data that were already lodged in VISTA and 
SITS-ISTR. I could only undertake a controlled comparison employing robust 
statistical techniques. It was not possible to employ principles of blinding or 
randomisation procedures in these datasets.  
 
2.6 Data Analyses 
The Global statistics method, responder analysis method and shift analysis 
method are often used to analyse data in stroke trials.261,269-274  In addition, 
simple analyses of dichotomised outcomes measures are also often used. In the 
global statistics method, one examines outcomes employing a combination of 
multiple outcomes scales.261,270 Responder analysis permits one to consider the 
prior disability  when examining the outcomes.261  Shift analysis has the merit in 
that it allows the investigator to capture signal indicating shift towards improved 
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(or poor) outcomes.261 In the case of stroke, this is a meaningful method of 
analysing data because the therapy does not always cure the patients, but shifts 
them in one or the other direction of the outcome spectrum. 261,271  Analysis of 
artificially dichotomised outcomes scales is a simple method but is associated 
with loss of information, confusing interpretation of results, an artificial 
creation of patients’ groups that are considered good or poor and loss of study 
power.261,272,273  For example, Jeffrey Saver discusses that “When the 7-level 
mRS is dichotomised as 0 to 2 vs. 3 to 6, a traditional breakpoint in binary trial 
analysis, the resulting analysis examines only one important transition in health 
state, from vocationally impaired, but able to live independently, to requiring 
assistance in daily living. However, this analysis places absolutely no value on 
other health state transitions that are pertinent to patients. For example, 
going from vocationally impaired (mRS=2) to no symptoms at all (mRS=0) is not 
counted as a clinically meaningful improvement, nor is going from dead (mRS=6) 
to moderately disabled and able to walk on one’s own (mRS=3). Binary outcome 
analyses prioritise only a single health state transition as clinically worthwhile, 
whereas patients naturally place great value on several health state 
transitions.”261 Nevertheless, dichotomisation has its advantages: analyses of 
ordinal data by dichotomisation of outcomes are simple and proportions so 
obtained can be easily converted to clinically intuitive values such as “number 
needed to treat”. Hence, the results so obtained are easy to interpret.261 
However, unlike dichotomisation where one examines a few arbitrarily selected 
health states, shift analyses examine all health states.261,269 For the present 
thesis, I decided to undertake “shift analyses” by employing ordinal analyses 
using proportional odds logistic regression analyses and a non-parametric 
Cochran-Mantel-Haenszel (CMH) test. In addition to this, I also analysed 
outcomes by dichotomising them. 
 
CMH is a non-parametric approach that avoids invoking an assumption of 
proportional odds in which the odds ratios are common across all cut points of an 
ordinal outcome scale. Koch and Edwards described the relationship between 
the van Elteren test275 and the extended Mantel-Haenszel276 procedure.277 In SAS, 
the CMH test is done by employing proc freq procedure (see appendix). It is a 
powerful procedure available to SAS users. “cmh” in the code tells SAS software 
to run the extended Mantel Haenszel test (referred to as CMH in SAS software). 
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Modified ridits (used to calculate within-stratum standardised midrank scores) 
are employed to undertake transformations that are necessary to run the right 
calculations. 
 
Mantel Haenszel methods can be employed in situations of IxJ tables, where I>2 
and/or J>2, that is, when in a case control study, the exposure levels and/or the 
outcome levels are more than 2.   
 
In the present analyses, there were two possible exposures with respect to use 
of the use of alteplase: thrombolysis or no-thrombolysis (controls). Outcomes 
had 6 levels in case of m-RS outcomes and 9 levels in case of NIHSS categorised 
outcomes. The CMH test tested for an association of “use of t-PA” (C) and 
“outcomes” (D) by controlling by stratification for covariates (A and B, see an 
example code in the appendix) that were introduced in the model. 275-277 
 
The CMH test gives 3 different sets of correlation statistics:  Non-zero 
correlation, Row Means Scores Differ and general association. If the p-value for 
Non-zero correlation is significant, results are interpreted as linear correlation 
between two ordinal variables for at least one stratum. If the p value for Row 
Means Scores Differ (RMSD) is significant, the interpretation is, for an ordinal 
column variable the mean CMH scores differ across the columns for at least one 
stratum. If the p-value for general association is significant, there is an 
association between the two variables for at least one stratum. The RMSD 
statistic when significant suggests that an effect across the m-RS spectrum is 
significant. RMSD is used for interpretation when the data are arranged such that 
only the columns have an order (in case of analyses presented in this thesis, the 
Rankin Scores or the NIHSS scores, that have an order).  
 
In order to undertake adjusted analyses, covariates were introduced into the 
CMH test. As mentioned earlier, adjusted analysis involving the CMH test occurs 
by means of stratification of outcome data of thrombolysed and non 
thrombolysed patients for various covariates. Therefore, this is limited by the 
sample size and can preclude simultaneous adjustment for several variables. 
Hence, I prospectively planned to adjust for age and baseline NIHSS and to 
consider other variables only in exploratory analyses. The choice of baseline 
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factors for adjustment was based on two influences.278 First, age and baseline 
severity are the two most powerful prognostic factors for stroke and are usually 
included in outcome distribution analyses. Baseline NIHSS accounts for about 80% 
of the variance in outcome data of stroke patients.265,279,280 Second, age and 
NIHSS data were available for our entire sample, whereas some of the other 
factors of potential interest were incomplete. However, I also undertook a 
sensitivity analysis by considering the combined effect of the variables that 
differed significantly at baseline.  
 
Because the CMH test does not measure the extent of association, I also 
undertook a proportional odds logistic regression analysis.  
 
Ordinal Regression Analysis (Proportional Odds Logistic Regression Analysis) is 
employed when the distribution of scores is not normal and the majority of 
respondents scores are at extremes of the scale.281,282 SAS software allows an 
analysis that fits a proportional odds model based on ranked scores and 
computes common odds at each cut-off level of ordinal scores. The proportional 
odds assumption is tested based on a score test which if significant, indicates 
that the proportionality assumption does not hold. The score test for 
proportionality assumption tends to be extremely sensitive for larger data. 281,282  
 
Analyses involved shift in outcomes (Rankin scores and NIHSS scores in case of 
VISTA only analysis and Rankin scores in case of SITS-VISTA (NIHSS data were 
unavailable in SITS-ISTR)) when patients received alteplase compared to those 
who did not receive alteplase. Choice of NIHSS as an additional measure of 
outcomes is supported by the European Medicines Evaluation Agency (EMEA) 
Points to Consider for reporting trials.283,284 As per this document, the EMEA  
allows the use of the full range of the Rankin scores and then further suggests 
that this can be supported by a secondary analysis of another outcome measure 
such as NIHSS.284 I analysed supporting endpoint, neurological outcomes 
measured by NIHSS scores, by grouping the NIHSS scores into categories: 0 (no 
measurable deficit), 1-4, 5-8, 9-12, 13-16, 17-20, 21-24, ≥25 (most severe 
neurological deficit) or dead. I then the compared distribution of patients across 
the NIHSS categories in a manner similar to one done for the mRS. Here again, to 
test for a significant association of outcome distribution with intervention/drug 
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exposure, I employed the Cochran-Mantel-Haenszel [CMH] test and calculated 
the odds ratio based on proportional odds logistic regression analyses. The 
ordinal outcomes can be compared, adjusting for covariates. 
 
Chapter 8 of this thesis examines data by means of meta-analyses. For detailed 
methodology refer to chapter 8. 
 
 
 
  
 
 
 
 
 
 
Chapter 3 
 
Influence of age on outcome from thrombolysis 
in acute stroke 
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3 Influence of age on outcome from thrombolysis 
in acute stroke 
3.1 Introduction 
Thrombolysis for acute ischaemic stroke has proven benefits but randomised 
trial data in patients >80 years are limited.92,122 To date, the European Medicines 
Evaluation Agency (EMEA) has not approved thrombolysis with alteplase amongst 
the very elderly.23 Patients older than 80 years represent about 30% of acute 
stroke incidence.285-287 Many experienced centres treat the elderly but others 
observe the terms of product approval.240 237,288-292 
 
 
 
 
Figure  3-1 Figure showing rapid increase in the proportions of elderly in European Union 
 
The coloured boxes represent age group with grey showing people older than 80 years, black 
showing age group 65 to 79 years and different shades of orange showing age group 0-14,15-24 
and 25 to 49. [Source: Features and Challenges of Population Ageing: The European 
Perspective by Asghar Zaidi; Permissions obtained by e mail from  Dr Asghar ZAIDI, Director 
Research European Centre for Social Welfare Policy and Research (Affiliated to the United 
Nations) Berggasse 17, A-1090 Vienna, Austria ]293 
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Figure  3-2 Projections for world population for age group 0-14, 15-59, 60-79 and 80 and 
above. 
 
(Source:  Implications of Population Ageing for Economic Growth  by David E. 
Bloom, David Canning, and Günther Fink; Permissions obtained from Oxford 
University Press for the publication “David E. Bloom, David Canning, Günther 
Fink, Oxford Review of Economic Policy content title Implications of population 
ageing for economic growth”, License Number 2784230886123).294  
 
The NINDS trial initially restricted enrolment to patients aged up to 80 years. 
The age criterion was lifted after enrolling 188 patients in part A of the trial but 
only 42 very elderly patients were enrolled.122 All ECASS trials applied an upper 
                                                
3
  I published Chapter 3 in Stroke(Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR; VISTA 
Collaborators. Influence of age on outcome from thrombolysis in acute stroke: a controlled 
comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke. 2010 
Dec;41(12):2840-8.) Permissions were obtained  from Wolters Kluwer Health (License Number: 
2790451375765) 
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age limit of 80 years, and recent studies with desmoteplase also excluded the 
elderly.109-111,121,124,129  
 
The main reasons advanced for withholding treatment from the elderly patients 
in clinical practice are fears that advancing age is associated with poorer 
prognosis with greater risk for haemorrhage and in-hospital mortality.23,295,296 
Conversely, a meta-analysis of pooled thrombolysis data concluded that the risks 
of symptomatic intra-cerebral haemorrhage ICH did not increase amongst the 
elderly despite less favourable outcomes.297  Less favourable outcomes are 
expected to occur in the elderly, mostly due to comorbidity.237,298 
 
The proportion of elderly is rising in our society.285-287,293,294 In the UK alone, the 
population aged >80 years has doubled since 1982.299 Effective treatments should 
not be withheld from the elderly in the absence of compelling data suggesting 
unacceptable risk or proven lack of benefit. It was therefore hypothesised that 
clinical practice over the last decade would have been sufficiently diverse to 
allow analysis of existing rigorously collected clinical data to construct a 
comparison of thrombolysis against matched controls, with the possibility of 
adjusting for any imbalance in severity. I anticipated that the use in the elderly 
would be sufficiently frequent to assess the influence of age on any association 
of stroke outcome with thrombolysis treatment.  
 
 
3.2 Methods  
3.2.1 Data Source and Patients  
Details of data source are provided in Chapter 2. Briefly, I collated data on 
demographics, clinical data and measures of functional outcome from 
neuroprotection trials conducted in the period 1998 to 2007, held within the 
Virtual International Stroke Trials Archive, VISTA [www.vista.gla.ac.uk] 255 
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3.2.2 Statistical Analyses  
I undertook a non-randomised, adjusted comparison of outcomes between 
patients who received rt-PA and patients who did not receive rt-PA (henceforth 
referred to as treated and control group respectively) amongst patients who met 
the age criterion for the European alteplase marketing authorisation. I repeated 
the comparison amongst patients aged ≥81 years. I then examined the 
association of thrombolysis treatment with outcome within each age decile to 
illustrate the strength of evidence across the full age range. For each contrast, I 
compared the overall distribution of all seven categories of day 90 mRS scores of 
the two groups, i.e. from 0 (asymptomatic) through 5 (bedbound and completely 
dependent), to 6 (dead). For analysis of the supporting endpoint, NIHSS, I 
grouped adjacent scores into categories: 0 (no measurable deficit), 1-4, 5-8, 9-
12, 13-16, 17-20, 21-24, ≥25 (most severe neurological deficit) or dead. The 
distribution of patients across these categories was then compared between the 
groups as for mRS. To test for a significant association of outcome distribution 
with thrombolysis exposure I employed Cochran-Mantel-Haenszel [CMH] statistic, 
adjusting for both age and baseline NIHSS.  Because CMH does not express the 
extent of the association, I also applied logistic regression analysis, also adjusted 
for age and baseline NIHSS, to estimate the odds ratio under the assumption of 
proportional odds and its associated 95% confidence interval.. In addition to 
undertaking an age and baseline adjusted analyses, I also undertook a sensitivity 
analysis by considering the combined effect of the variables that differed 
significantly at baseline (as shown in table 3.1). 
 
For comparison with prior randomised trial and registry reports, I also present 
dichotomised analyses of mRS, based on favourable outcome (mRS 0-1), 
independence (mRS 0-2) and survival; these analyses were expressed as odds 
ratios adjusted for age and bNIHSS, as for the primary and secondary endpoints. 
Proportional Odds ratios in these analyses express the common odds of an 
improved distribution of outcome in association with alteplase treatment. 
Reliable information on symptomatic haemorrhage was not available since post 
treatment imaging was not routinely applied in neuroprotection trials to patients 
who had not been treated with alteplase. 
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3.3 Results  
3.3.1 Patient Sample  
Complete data were available for analysis of mRS in 5817 patients and on NIHSS 
in 5715. (See figure 2.1 for information on completeness of VISTA data) Baseline 
characteristics are shown in table 3.1.  
 
Of the 5817 patients with mRS outcome data, 1585 (27.2%) received 
thrombolysis. Baseline severity was higher by one NIHSS point amongst the 
younger patients who received thrombolysis therapy compared to our control 
group; amongst patients aged ≥80, severity was equal between treated and 
control groups. The delay between stroke onset and initiation of alteplase was 
not recorded, but the delay to research enrolment and initiation of 
investigational product was shorter in the thrombolysis group than control 
patients irrespective of age (3.7 versus 5.1 hours, p=0.0001). Independently, 
baseline NIHSS accounted for 28% and age for 9.7% of the variation in 90 day 
outcome by mRS (both p<0.0001) and were included in all models, together 
explaining 33.5% of the variation. 
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Table  3-1 Baseline demographics of the VISTA data employed for present study 
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3.3.2 Overall Outcome  
Across the whole sample, the distribution of mRS scores was better amongst 
thrombolysed patients, CMH p<0.0001; OR: 1.39 (95% CI: 1.26-1.54). 
 
3.3.3 Outcomes amongst patients aged ≤80 years   
Amongst the 4623 patients with 90 day mRS data, treatment with thrombolysis 
was associated with a significantly more favourable distribution of mRS scores: 
CMH p<0.0001, adjusted odds ratio (a-OR) 1.4 (95%CI: 1.3-1.6). The unadjusted 
odds ratio was 1.2 (95% CI: 1.1-1.4). Dichotomised comparisons were also 
significant for independence (mRS 0-2 versus 3-6), OR=1.54 (95% CI 1.33-1.79, 
p<0.0001); for favourable outcome (mRS 0-1 versus 2-6), OR= 1.31 (95%CI 1.12-
1.53, p=0.0008); and for survival OR=1.44 (95% CI 1.18-1.76, p=0.0004). 
 
The functional outcomes were supported by the secondary endpoint. The 
spectrum of NIHSS scores at 90 days was significantly better amongst the 
thrombolysed patients than controls: CMH p<0.0001, a-OR = 1.6 (95% CI: 1.4-
1.8), n=4537. The unadjusted comparison yielded OR=1.3 (95%CI: 1.2-1.5). 
 
The sensitivity analysis, in which I adjusted for age, baseline NIHSS, previous 
stroke, hypertension and atrial fibrillation, as these differed at baseline (see 
table 3-1) also yielded OR 1.4 (95% CI 1.2-1.6), N=4387, CMH p<0.0001. 
 
3.3.4 Outcomes amongst patients aged ≥ 81 years   
Amongst the 1194 very elderly patients with 90 day mRS data, treatment with 
thrombolysis was associated with a significantly more favourable distribution of 
mRS scores : CMH p=0.002, a-OR= 1.34 (95%CI: 1.05-1.70). The unadjusted odds 
ratio was 1.26 (95% CI: 1.00-1.59), CMH p<0.05. The dichotomised comparison 
was significant for independence (mRS 0-2): OR=1. 52 (95% CI 1.06-2.17, 
p=0.022). For favourable outcome (mRS 0-1), the OR was 1.46 (95%CI: 0.97-2.20, 
p=0.07); and for survival the OR was 1.20 (95%CI: 0.90-1.65, p=0.20). 
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The functional outcomes were supported by the secondary endpoint. The 
spectrum of NIHSS scores at 90 days was significantly better amongst the 
thrombolysed patients than controls: CMH p=0.0004, a-OR= 1.4 (95%CI: 1.1-1.8), 
n=1178. The unadjusted comparison yielded a similar estimate: OR=1.4 (95%CI: 
1.1-1.7). 
The sensitivity analysis, in which I adjusted for age, baseline NIHSS, 
hypertension, previous stroke and atrial fibrillation, also yielded OR= 1.2 (0.96-
1.57), N=1152, CMH p=0.02. 
A figure showing proportions of patients within different Rankin categories of 
SITS-MOST and the pooled RCT data are pasted below (source: from SITS-MOST 
study 117). Proportion of patients in randomised data shown here are similar to 
the raw data of VISTA patients as shown figure 3-5. 
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Figure  3-3 Figure shows proportions for patients belonging to various Rankin categories in the SITS-MOST data and also the pooled randomised data 
 
   
Source: Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, 
Vanhooren G; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring 
Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27; 369(9558):275-82; Permissions obtained from Elsevier Limited The Boulevard, Langford Lane, 
Kidlington, Oxford, OX5 1GB, UK; License Number- 2783791420125146 
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Figure  3-4 Functional outcomes after use of thrombolytic therapy in patients suffering ischaemic stroke 
Diagram showing association of functional outcomes with use of rtPA in the younger patients (age <=80 years) and elderly patients (age >80 years) having acute ischaemic stroke. 
Each box of the horizontal bar corresponds to the mRS category specified by the colour code. Upper horizontal bar belongs to control group of young and elderly patients and 
lower to the rtPA-treated patients in each age group. Numbers in each box denote the percent of total patients belonging to a specific treatment category (tPA or control) and 
representing the mRS score corresponding to the box. 
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Figure  3-5 Neurological outcomes after use of alteplase in patients suffering acute ischaemic stroke 
Diagram showing association of neurological outcomes with use of tPA in the younger patients (age <=80 years) and elderly patients (age >80 years) having acute ischaemic 
stroke. Each box of the horizontal box corresponds to the mRS category specified by the colour code. Upper horizontal bar belongs to control group of young and elderly patients 
and lower to the tPA-treated patients in each age group. Numbers in each box denote the percent of total patients belonging to a specific treatment category (tPA or control) and 
representing the mRS score corresponding to the box. 
Nishant Kumar Mishra, 2011           Chapter 3, 110 
 
 
3.3.5 Association of thrombolysis with outcome by age decile 
Both functional outcome and neurological outcome were significantly better 
amongst thrombolysed patients than controls within each decile of age from 51 
years to 90 years; and except amongst the small sample of 21-30 year old 
patients, point estimates for the adjusted odds ratios were consistent across all 
age groups (Fig 3-7 and 3-8) 
 
 
 
Figure  3-6 Functional outcomes after thrombolytic therapy  
The Forest plot shows a significant association of use of alteplase with improved functional outcomes in 
age group from 41 to 50 until 81 to 90. Point estimates are indicative of improved outcomes even for 
age group 31 to 40 and 91 to 100.  The odds ratio (OR) are shown for age groups stratified by age 
ranges of 10. CMH P refers to the test statistic for Cochran-Mantel-Haenszel Test and N refers to total 
sample size. 
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Figure  3-7 Neurological outcomes after thrombolytic therapy  
 
The figure shows an association of neurological outcomes with improved outcomes in patients who 
received thrombolytic therapy. Patients are shown stratified by age groups and corresponding forest 
plot, OR, CI, CMH P, and sample size are marked. 
 
 
3.4 Discussion  
Analyses reported in this chapter demonstrate that the use of thrombolysis for 
acute stroke is associated with better functional and neurological outcomes, and 
probably lower mortality, in all adult patients who are treated irrespective of 
their age. It supports the limited randomised trial data and places data on safety 
from stroke registries in context.  
 
These data draw validity from four origins. First, the source clinical trials of 
investigational medicinal products were undertaken under strict controls on 
reporting of concomitant treatments and outcomes, and on-site data verification 
procedures were in place for each trial. Second, attitudes to treatment of the 
very elderly vary amongst clinicians, some European clinicians strictly following 
the EMEA marketing authorisation, others in Europe and North America treating 
without regard to age.240,300 Third, the estimates of control outcomes correspond 
closely to those from the published RCTs of thrombolysis,130,131 the estimates of 
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outcomes amongst the treated group aged ≤ 80 years are similar to those of the 
RCTs* 4,146 and the estimate of treatment odds ratios in the patients aged <=80 
years closely corresponds to treatment effects demonstrated in the RCTs.129-131 It 
should be acknowledged that dose finding studies have not been undertaken in 
the very elderly, however. Fourth, I chose as the primary endpoint the modified 
Rankin scale, which is the most prevalent outcome measure in recent stroke 
trials257 and I followed an approach to analysis that is described in the EMEA 
Points to Consider for interpretation of clinical trials in acute stroke.284 There, 
comparison of the distribution of the full range of the Rankin is proposed as 
acceptable, with supporting evidence from a secondary endpoint such as NIHSS: 
both are positive and give similar estimates of benefit in our comparison. 
Further, although the less powerful dichotomised analyses are not all significant 
amongst the very elderly, they each give point estimates for magnitude of 
association that correspond to the estimates derived in the young and from the 
full mRS or NIHSS distributions. 
                                               
4
  ** I obtained the SITS-MOST data from the figure 3.3. I undertook an unadjusted comparison of 
the Rankin scores in the non-elderly patients SITS-MOST data with the VISTA data (age below 
80 years) by employing proportional odds logistic regression analysis. The point estimates 
suggested  a shift towards better outcomes when the pooled data of the thrombolysed patients 
recruited in the randomised controlled trials (RCT) were compared with the VISTA non-
thrombolysed patients (OR 1.1, 95%CI 0.9-1.3).  When the VISTA controls were compared with 
the RCT placebo group, OR=0.9, 95% CI 0.8-1.1. When SITS-MOST patients were compared 
with the VISTA thrombolysed patients, OR=1.3, 95% CI 1.2-1.5. It should be noted that these 
are unadjusted analyses: influence of age and baseline severity on outcomes in these 
comparisons could not be incorporated in the proportional odds logistic regression analysis 
model as I donot have access to the SITS-MOST raw data. 
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Figure  3-8 Figure shows the relationship of onset to treatment time with adjusted odds for mortality in a pooled analysis of patients from randomisation 
controlled trials that investigated t-PA (N=3670) 
 
(Source: Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, 
Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, 
Levi C, Bladin C, Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, 
and EPITHET trials. Lancet. 2010 May 15; 375(9727):1695-703.Permissions obtained from Elsevier Limited, The Boulevard, Langford Lane, Kidlington,Oxford, 
OX5 1GB, UK; License Number: 2783800078653)
131 
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Present data indicate a reduction in mortality of non-elderly (12.3% vs. 14.8%) 
and elderly (32.2% vs. 36.1%) patients (figure 3-4) and confirm improved survival 
(1.4 (95%CI 1.2-1.8) amongst non-elderly. Pooled analyses of all trials have seen 
the trends for favourable outcomes in t-PA arm (see figure 3-8) through 
modelling.131 Also, these findings are consistent with the meta-analysis data:  
while odds for death or dependency  were OR 0.71 and 95% CI 0.52 to 0.96,  the 
odds for death were 1.1 with a confidence interval that was wide, 95%CI 0.9 to 
1.5.92 In the present analysis for the elderly, the odds for survival are 1.2 and 
confidence intervals wide, 95%CI 0.9-1.7 (N=301 patients in t-PA group). These 
data indicate benefit by reduction in mortality including amongst the elderly. 
Mortality was shown to have reduced owing to larger sample size, and thereby 
giving greater power to the subgroup age </=80 years (N=1284).  
 
Elderly patients usually do poorly after a stroke because of pre-existing illnesses 
and on-going poly-pharmacy.  For example, elderly are more likely to suffer 
from cardiac diseases like atrial fibrillation, cardiac failure, coronary heart 
disease and hypertension. Prevalence of cardiac disorders increases with age: in 
the Framingham Heart Study, incidence for atrial fibrillation was 0.2/1000 for 
age group 30-39 while 39/1000 for age group 80-89 years.301  With increasing age 
there is also a  steady rise in the proportion of patients who suffer stroke 
because of arrhythmia (in age group 80 to 89 years, the rates are 36.2%).301 
Patients suffering cardio embolic stroke are more likely to have larger infarcts or 
suffer multiple infarctions involving different territories. Further, the cardio-
embolic strokes are associated with greater risk of haemorrhagic transformation: 
it occurs in about a fifth of cardio-embolic stroke patients.302 Further, some data 
indicate that patients suffering cardio-embolic strokes may fail to recanalise 
despite the use of alteplase.303,304 This could be due to a unique clot composition 
in these patients that renders itself unresponsive to alteplase and because 
cardio-embolism occurs more frequently amongst the elderly, these patients 
could be the ones more at risk of not responding to the use of alteplase. But, the 
data presented in this chapter support the contrary: the elderly responded to 
the use of alteplase. Outcomes improved not only on Rankin scores but also on 
the NIHSS scores in the age group >80 years. 
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It is known that compared to younger population, elderly patients have larger 
deposits of cerebral amyloid material.305 These deposits could have contributed 
to increased risk of post-thrombolysis intracerebral haemorrhage. Further, these 
patients have poorer cognitive reserve and may be having poorer abilities to 
employ neuroplasticity and regain functions.306  Further, their abilities to recruit 
collaterals after an ischaemic insult might be poorer than the younger patients. 
These biological substrates are more likely to result in poorer outcomes in the 
elderly age group. In the present analysis, I failed to show that t-PA use in 
elderly interacts differently compared to the non-elderly population. Instead, I 
show that despite excess poorer outcomes in the elderly, these patients 
responded to the t-PA use and showed improved outcomes. Further, there is no 
evidence from other disease areas, like myocardial infarction, to support this.237  
 
There are also limitations to my study that must be considered. The data are 
based on a non-randomised comparison, and there is a high potential for 
selection bias for thrombolytic treatment. Although many of the usual 
descriptors of baseline prognosis are reasonably matched between the two 
groups, thrombolysis and controls, and although I have adjusted our analyses for 
the most important of these – age and baseline severity,265,307 which together 
account for 33.5% of the variation in outcome I could not adjust for every factor. 
I planned to adjust for all variables that differed at baseline but did not include 
presence of use of antithrombotic agents (prior use of antiplatelet and 
anticoagulant agents) in the sensitivity analyses. This is because on trying to 
adjust for antithrombotic agents, along with other variables that differed at 
baseline, the sample size for the analysis reduced dramatically both for elderly 
population (from 1193 to 454) and non-elderly (4624 to 1930) population. This 
occurred because observations got deleted (739 and 2694 respectively) by the 
program due to missing values for the response or explanatory variables. 
Further, atrial fibrillation, use of warfarin and prior diabetes were all less 
prevalent amongst the treated group. However, the magnitude of these 
differences was small, the absolute differences were equal for young versus very 
elderly, and the sensitivity analyses with adjustment for these additional factors 
also yielded significantly positive findings. This implies that although the 
estimate of the association of treatment with outcome may be imprecise, the 
estimates of trends in this measure across the age range are robust. Some of the 
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patients in this study received an investigational neuroprotective agent and it 
must be considered that one or more of these could interact with thrombolysis; 
however, each contributing trial has already tested for, and excluded, a 
significant interaction. VISTA data handling procedures preclude further testing 
for effects of the original investigational agent or identification of source trials. 
 
The delay between stroke onset and treatment initiation in the thrombolysis 
group was not known, but the time of baseline NIHSS assessment is earlier in the 
thrombolysed than non-thrombolysed patients. Presentation delay is associated 
with outcome, but this is mediated through earlier presentation of more severe 
stroke, a factor that favoured our control group in the young only. Last is the 
possibility of systematic bias in other aspects of care and thus outcome, 
between centres that used thrombolysis routinely versus those that did not, or 
that restricted use in the elderly. It is difficult to counter criticism on this point, 
except to indicate that the contributing trials sought to minimise such effects 
through site selection, training of investigators and monitoring of care and of 
outcomes; and to point again to the correspondence of outcomes in each of the 
treatment groups with those from RCT and registry data. 
 
Trials and registries of thrombolysis generally report three outcomes: functional 
attainment, mortality and symptomatic or serious intracranial 
haemorrhage.122,146 VISTA lacked data on the last of these, since patients who 
are not treated with thrombolysis generally do not undergo follow-up cerebral 
imaging for routine detection of haemorrhagic transformation. Fortunately, 
information on this aspect can be inferred from other sources: the rate of 
serious or symptomatic bleeding is very low amongst patients who do not receive 
thrombolysis –approximately 1%131 and registry data such as SITS inform us on the 
rate amongst treated patients and have found no significant increase in the very 
elderly compared to the young.292,308 
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Figure  3-9 Figure shows the functional outcomes in patients for various age bands in SITS registry 
 
Source: Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ, Toni D, Wahlgren N. Intravenous alteplase for stroke in those older than 80 years old. 
Stroke. 2010 Nov;41(11):2568-74.Permissions obtained from Wolters Kluwer Health, License Number 2783791484358 308
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Figure  3-10 Figure shows rates of symptomatic intracerebral haemorrhages per SITS-MOST definition, NINDS definition and parenchymal haemorrhage 
(including type II) in the SITS registry. 
 
Source: Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ, Toni D, Wahlgren N. Intravenous alteplase for stroke in those older than 80 years old. 
Stroke. 2010 Nov;41(11):2568-74.Permissions Obtained from Wolters Kluwer Health, License Number 2783791484358 308  
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A more important response on the issue of serious bleeding comes from our use 
of the full mRS distribution as our outcome measure. Bleeding is relevant only if 
it affects eventual functional outcome. Dichotomisation of mRS outcomes into 0-
1 versus 2-6 or 0-2 versus 3-6 could conceal harmful results of serious bleeding 
reflected by higher proportions of severely disabled patients within the 
unfavourable outcome group (for example more mRS 5 amongst patients with 
mRS 3-5). The data and analysis approach exclude this possibility: even if 
haemorrhage were more common in the very elderly than young, which has been 
discounted,308,309 this does not translate into poorer functional outcomes after 
adjustment for age and stroke severity. 
 
Data on stroke outcomes associated with thrombolysis use in the elderly come 
from 3 other sources. A meta-analysis of cohort studies by Ringleb and 
colleagues in 2007 found that the elderly experienced similar rates of 
symptomatic haemorrhage to the young (6.1% versus 5.1%) but higher mortality 
(32% versus 14%), with fewer attaining favourable outcome by 90 days (mRS 0-1: 
26% versus 41%).309However, within one of the largest studies in this analysis, the 
baseline severity of stroke was much higher in elderly than young patients (NIHSS 
16 versus 13.9 respectively).292Outcomes of very elderly patients described by 
the Safe Implementation of Thrombolysis in Stroke (SITS) registry reinforce these 
findings: stroke severity was higher in the 643 elderly versus 6749 younger 
patients, NIHSS 15 v 13. Symptomatic ICH was no more common in the very 
elderly (2.0 [95% CI 1.1-3.5] versus 1.5 [1.2- 1.8] per cent), but 90-day mortality 
was higher (31 [27-36] versus 15 [14-16] per cent); and independence (mRS 0-2) 
was achieved less frequently (30 [26-34] versus 52 [51-53] per cent).310 
Interpretation of these uncontrolled registry findings is compromised by the 
known influence of age and stroke severity on outcome in the absence of 
thrombolysis treatment. Only 164 patients aged >=80 years were included 
amongst the large randomised trials combined.311 The elderly group was again 
more severely affected at baseline than the younger patients, but there was also 
a severity imbalance amongst the elderly that favoured the controls. A pooled 
analysis of these data in the elderly (0-4.5 hours subgroup: N=137/2199) 
estimated odds ratios for independence (mRS 0-2 at day 90) and mortality under 
alteplase versus placebo of 1.09 and 1.28 respectively based on unadjusted data. 
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However, after adjustment for the demonstrable imbalance in baseline NIHSS 
the odds ratios respectively were 1.77 and 0.96. 311  The sample size was small 
and none of these outcomes reached statistical significance. Thus, the present 
findings are entirely consistent with the randomised trial data, not only in terms 
of the estimated extent of benefit from treatment but also with regard to the 
influence of baseline severity on the interpretation of outcomes. 
 
Treatment allocation in this study was not randomised, and a randomised 
controlled trial would more conclusively inform the influence of rt-PA on 
outcomes amongst elderly. Two trials currently aim to examine this 
topic.232,234,312 There is an Italian trial that has so far enrolled around 10% of the 
planned 600 patients, over a 2 year period.  The International Stroke Trial-3 
[IST-3] aims to examine outcomes amongst all patients who receive thrombolytic 
therapy and has prescribed no upper age limit.232,234  The trial has so far enrolled  
3035 patients from the originally planned 6000.233  1756 of these patients are 
very elderly and being treated within the time window of interest.233,313,314 
Though the present analysis is not a randomised controlled trial, it is the only 
source of evidence to support the registry and RCT data that currently 
available.290,292,297  
 
In summary, outcome amongst patients treated with thrombolysis as standard of 
care within clinical research trials is more favourable than amongst patients who 
are not offered thrombolysis, and this apparent advantage to patients who are 
treated extends to patients aged 81 years and older. From this analysis, I not 
only fail to find evidence to support the present restriction of the European 
marketing authorisation for alteplase use in the elderly; I  find positive evidence 
that alteplase is beneficial amongst patients aged 81-90 years and that this is 
likely to extend even to patients aged 91-100 years. These data support and 
extend the extensive uncontrolled data on outcomes from registries, and the 
limited randomised controlled trial data. Age is not a relevant factor when 
considering whether to use alteplase for acute stroke. 
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amongst elderly patients recruited in SITS 
Registry 
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4 Outcomes from thrombolytic therapy amongst 
elderly patients recruited in SITS Registry: 
validation of VISTA findings on SITS-VISTA data 
 
4.1 Introduction 
In chapter 3, I described findings from analysis of VISTA dataset and showed that 
outcomes improve amongst elderly patients who receive alteplase for acute 
ischaemic stroke. The results were based on a robust statistical analysis. 
Findings were consistent on two different measures of outcomes, namely, the 
NIHSS scale and the modified Rankin Scale. Point estimates for the approved 
population were similar to the ones observed in randomised trials, thus allowing 
us to anchor our results on the elderly onto the randomised data. Because it was 
not a randomised study, which I acknowledge as a weakness, I also looked at the 
prospects of the two on-going randomised trials, the IST III232,233,313 and TEPSI312, 
but from the rate at which these studies are recruiting patients, it appears that 
clinicians will have to wait for a while before the randomised data are available. 
IST-3 originally targeted to recruit 6000 patients.234 Per September 2011 issue of 
IST-3 times, the total recruitment figures were 3035. Of these, 1756 were 
elderly.233 
In order to confirm the findings from VISTA only analyses in previous chapter, I 
planned to validate results in another dataset. For this, I decided to examine 
outcomes in elderly patients whose data were held within the SITS-ISTR at 
Karolinska University Hospital. Below, I report methods and results from the data 
derived from SITS-ISTR registry.  
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5 
4.2 Method 
4.2.1 Data Source and patients 
I describe the SITS-ISTR data in chapter 2. Briefly, I collated the data of stroke 
patients who received thrombolytic therapy through the SITS-ISTR between 
December 2002 and November 2009. The control group comprised untreated 
stroke patients from neuroprotection trials conducted between1998 to 2007 held 
within the VISTA. From both of these sources, I collated the demographics, 
clinical data and information of functional outcome as measured with the 
modified Rankin scale (mRS) score after 90days. 
4.2.2 Patient Sample 
Details of data extraction are shown in figure 2.1. The sample for this analysis 
comprised 29500. Data on baseline NIHSS for 272 of these patients were missing, 
reducing the sample for the baseline severity adjusted analysis  
4.2.3 Statistical analysis 
I compared 90 days outcome between patients who received intravenous 
thrombolysis and non-thrombolysed controls for the whole cohort. I repeated the 
comparison amongst patients aged ≤80 and >80 years. I then examined the 
association of thrombolysis treatment with outcome within each age decile to 
illustrate the strength of evidence across the full age range. 
For each contrast, I compared the overall distribution of all seven categories of 
day 90 mRS scores of the two groups, i.e. from 0 (asymptomatic) through 5 
(bedbound and completely dependent), to 6 (dead).    
                                               
5
  I published this chapter in BMJ (Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, 
Ringleb PA, Wahlgren NG, Lees KR; VISTA collaborators; SITS collaborators. Thrombolysis in 
very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry 
and Virtual International Stroke Trials Archive. BMJ. 2010 Nov 23;341:c6046. doi: 
10.1136/bmj.c6046.). Permissions were obtained from BMJ Publishing Group Limited 
2783790122184 
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To test for a significant association of outcome distribution with thrombolysis 
exposure I used the Cochran-Mantel-Haenszel [CMH] statistic, adjusting for both 
age and baseline NIHSS as continuous variables. However, I also undertook a 
sensitivity analysis by considering the combined effect of the variables that 
differed significantly at baseline.  
Reliable information on symptomatic intracerebral haemorrhage (sICH) was not 
available from VISTA controls since post treatment imaging was not routinely 
applied in neuroprotection trials to patients who had not been treated with 
alteplase. However, the rates of sICH for the definitions used within SITS (local 
or remote parenchymal haemorrhage type 2 on the imaging scan at 22–36 h after 
treatment, combined with a neurological deterioration of 4 or more points on 
the NIHSS from baseline, or from the lowest NIHSS score between baseline and 
24 h, or leading to death) and the NINDS-study (any intracranial haemorrhage in 
the post-thrombolysis imaging scans if it was not seen on a previous imaging scan 
and any decline in neurological status) for younger and older patients of the 
SITS-ISTR registry was compared. 
 
4.3 Results 
4.3.1 Baseline Characteristics of the Patients 
Baseline characteristics are shown in table 4.1. Baseline stroke severity was 
similar between thrombolysed versus non thrombolysed patients amongst both 
the >80 elderly (p=0.6) and ≤80 years age groups (p=0.3).Independently, baseline 
NIHSS accounted for 25.5% and age for 7.4% of the variation in 90 day outcome 
by mRS (both p<0.001) and were included in all models, together explaining 
29.6% of the variation.   
It is to be noted that the number of patients in control arm differs between the 
SITS-VISTA analyses reported in this chapter and those shown in previous 
chapter. This is because, in the previous chapter, I had excluded 2789 patients 
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that were likely to have been in SITS-MOST. I did not employ a similar exclusion 
criterion for the analyses presented in this chapter. 
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Table  4-1 Baseline characteristics of patients enrolled in SITS-VISTA data 
 Thrombolysis Control P value 
Mean (SD) and median (range) age (years) 
All   67.1 (12.4), 69 (10-98);    n=23 334    70.1 (12.2), 72 (21-101);  n=6166 <0.001 
≤80   65.3 (11.63), 68 (10-80);  n= 21 099    66.5 (10.7), 69 (21-80);    n=4929 <0.001 
>80   84.4 (3.25), 84 (81-98);    n=   2235    84.84 (3.36), 84 (81-101); n=1237 <0.001 
No (%) of men 
All 13 594/23 334 (58.3) 3271/6166 (53.0) <0.001 
≤80 12 744/21 099 (60.4) 2783/4929 (56.5) <0.001 
>80 850/2235 (38.0 488/1237 (39.5) 0.41 
Median (range) baseline score on National Institutes of Health stroke scale 
All 12 (0-42), n=23 062 12 (2-37), n=6166 0.14 
≤80 12 (0-42), n=20 860 11 (2-32), n=4929 0.32 
>80 14 (0-39), n=2202 14 (2-37), n=1237 0.61 
No (%) who had previously taken antithrombotic agents 
All 8776/22 792 (38.5) 1267/2968 (42.7) <0.001 
≤80 7537/20 623 (36.5) 977/2414 (40.5) <0.001 
>80 1239/2169 (57.1% 290/554 (52.3) 0.04 
No (%) with known diabetes mellitus 
All 3962/22 968 (17.2) 1449/5896 (24.6) <0.001 
≤80 3570/20 784 (17.2) 1203/4704 (25.6) <0.001 
>80 392/2184 (17.9) 246/1192 (20.6) 0.06 
No (%) with previous stroke 
All 3005/23 013 (13.1) 2014/5993 (33.6) <0.001 
≤80 2629/20 840 (12.6) 1521/4776 (31.8) <0.001 
>80 376/2173 (17.3) 493/1217 (40.5) <0.001 
No (%) with congestive heart failure 
All 1932/22 840 (8.5) 277/3167 (8.7) 0.59 
≤80 1581/20 697 (7.6) 185/2579 (7.2) 0.39 
>80 351/2143 (16.4) 92/588 (15.6) 0.67 
No (%) with hypertension 
All 14331/22 875 (62.6) 4170/5896 (70.7) <0.001 
≤80 12687/20 683 (61.3) 3273/4704 (69.6) <0.001 
>80 1644/2192 (75) 897/1192 (75.3) 0.87 
No (%) with atrial fibrillation 
All 5835/22 753 (25.6) 1712/5896 (29.0) <0.001 
≤80 4837/20 613 (23.5) 1147/4704 (24.4) 0.19 
>80 998/2140 (46.6) 565/1192 (47.4) 0.67 
*Of patients with baseline National Institutes of Health stroke scale score in SITS datasheet, two 
(0.32%) in age group 31-40, five (0.30%) in age group 41-50, nine (0.25%) in age group 51-60, six 
patients (0.1%) in age group 61-70, eight (0.09%) in age group 71-80, and two (0.1%) in age group 
81-90 were coded as having baseline score of 0 and treated with alteplase. They were assumed to 
have neurological deficit considered potentially disabling but not measured by restricted rules of the 
scale (such as distal limb weakness). These few cases will have no material impact on findings. 
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4.3.2 Overall outcome 
Across the whole sample, the distribution of mRS scores at 3 months was better 
amongst thrombolysed patients, p<0.0001; OR: 1.59 (CI: 1.51-1.67). (Figure 4-2) 
4.3.3 Outcomes amongst patients aged ≤80 years 
Treatment with thrombolysis was associated with a significantly more favourable 
distribution of mRS scores at 3 months:  CMH p<0.0001, adjusted odds ratio (a-
OR) 1.6 (95%CI: 1.5-1.7); N= 25789. (Figure 4-3) The unadjusted odds ratio was 
1.5 (95% CI: 1.4-1.6) [N=26028]. Dichotomised outcomes were also significantly 
favourable for thrombolysed patients compared to control (mRS 0-2 versus 3-6), 
OR=1.87(95% CI 1.74-2.01); for excellent outcome (mRS 0-1 versus 2-6), OR= 1.55 
(95%CI 1.44-1.67); and for mortality OR= 0.87 (95% CI 0.79-0.95).  
The  sensitivity analysis, in which in addition to age and baseline stroke severity, 
I also adjusted for  sex, history of either diabetes or previous stroke, use of prior 
antithrombotic agents, and hypertension, for they differed at baseline, yielded  
CMH p<0.0001 and proportional odds of 1.6 (95% CI 1.4-1.7), N= 22148 in favour 
of thrombolysis. 
4.3.4 Outcomes amongst patients aged >=81years 
Amongst the 3439 elderly patients above 80 years old with 90 day mRS and 
baseline stroke severity data, treatment with thrombolysis was associated with a 
significantly more favourable distribution of mRS scores at 3 months compared 
to control CMH p<0.0001, a-OR= 1.43 (95%CI: 1.26-1.63), [N=3439] (Figure 4-4).  
The unadjusted odds ratio was 1.4 (95% CI: 1.23-1.58), CMH p<0.0001 [N=3472]. 
The dichotomised outcome analysis was significantly in favour for thrombolysed 
patients compared to control, for favourable outcome (mRS 0-2): OR= 2.06 (95% 
CI 1.72-2.48). For excellent outcome (mRS 0-1), the OR was 1.87 (95%CI: 1.53-
2.29); and for mortality the OR was 0.89 (95%CI:  0.76-1.04).  
The sensitivity analysis, in which, in addition to baseline NIHSS and age, I also 
adjusted for  sex, history of either diabetes or previous stroke, use of prior 
antithrombotic and hypertension, for they differed at baseline, yielded  CMH 
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p=0.003 and proportional odds OR: 1.5,95% CI: (1.3-1.8), N=2593 favourable for 
thrombolysis. 
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Figure  4-1Figure shows proportions for patients belonging to various Rankin categories in the SITS-MOST data and also the pooled randomised data 
 
(Source: Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, 
Vanhooren G; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring 
Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27;369(9558):275-82; Permissions obtained from  Elsevier Limited The Boulevard, Langford Lane, 
Kidlington, Oxford,OX5 1GB,UK; License Number- 2783791420125)146 
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Figure  4-2 Outcomes after thrombolytic therapy in the entire population 
Scores on modified Rankin scale (from 0=no symptoms from stroke to 6=death) at three months between patients who underwent thrombolysis with alteplase and 
controls, indicating shift towards improved outcomes with thrombolysis. Numbers within coloured cells are percentages. Total Patients in alteplase arm 23 3334 and 
control arm 6166. 
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Figure  4-3 Outcomes after thrombolysis amongst the patients </= 80 years 
 
Scores on modified Rankin scale (from 0=no symptoms from stroke to 6=death) at three months between patients who underwent thrombolysis with alteplase and 
controls, indicating shift towards improved outcomes with thrombolysis. Numbers within coloured cells are percentage. Total patients in alteplase arm 21 099 and 
control arm 4929.
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Figure  4-4 Outcomes after thrombolytic therapy amongst patients older than 80 years 
 
Scores on modified Rankin scale (from 0=no symptoms from stroke to 6=death) at three months between patients who underwent thrombolysis with alteplase and 
controls, indicating shift towards improved outcomes with thrombolysis. Numbers within coloured cells are percentages. Total patients in alteplase arm 2235 and 
control 1237.
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mRS distributions at 90 days were significantly better amongst thrombolysis 
patients than controls within each decile of age from 40 years to 90 years and, 
except amongst the small samples of patients younger than 30 years and older 
than 90 years, point estimates for the adjusted odds ratios were consistent 
across all age groups. (Figure 4-5) 
Functional outcome measured by mRS 0-1, mRS 0-2 and survivor analysis showed 
similar results in favour of thrombolysis. (Figure 4-6, 4-7 and 4-8) 
 
Figure  4-5 Shift towards better outcomes on mRS at 90 days adjusted for age and baseline 
severity  
Number of patients shown for age groups do not add up to 29228 because numbers of patients ages <21 
(n=38) and >100 (n=2) were too low to allow any comparison. All patients aged <21 were from SITS and 
underwent thrombolysis; 15 patients reached a 90 day modified Rankin score of 0, 10 patients attained a 
score of 1, eight patients reached a score of 2, one patient achieved a score of 3, and two a score of 4; two 
died. Two patients aged 101 did not undergo thrombolysis in VISTA neuroprotection trials; they achieved 
modified Rankin score of 0 and 4 at 90 days 
Nishant Kumar Mishra, 2011  Chapter 4, 134 
 
 
 
Figure  4-6 Age and baseline severity adjusted odds for the mRS score 0-1 at 90 days 
amongst patients treated with alteplase 
 
 
 
Figure  4-7 Age and baseline severity adjusted odds for the mRS score 0-2 at 90 days 
amongst patients treated with alteplase 
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Figure  4-8 Age and baseline severity adjusted odds for mortality amongst patients treated 
with alteplase 
 
4.3.5 Post Thrombolysis Intracerebral Haemorrhage 
The symptomatic intracerebral haemorrhage (SICH) rate per SITS definition (4 or 
more point increase in NIHSS from baseline or death within 24 hours and PH2 or 
PHr2 haemorrhage at 22-36h imaging scans) was 2.5% (54/2163) among >80 years 
compared to 1.9% (398/ 20759) among ≤80 years, and thus insignificantly higher 
(OR 1.31, 95%CI 0.96-1.75, p= 0.07). The corresponding rates for SICH per NINDS 
definition (any increase in NIHSS from baseline and any parenchymal 
intracerebral haemorrhage) were significantly higher, 11.0% (229/ 2087) vs. 8.3% 
(1670/ 20220), (OR1.37, 95%CI 1.18-1.58, p<0.0001).  
4.3.6 Onset to Treatment Time 
The stroke onset to treatment time (OTT) of the administration of thrombolytic 
therapy to patients in SITS-ISTR was calculated. The median OTT was similar, 
145 minutes (p= 0.25), between younger (<=80 years) and older (>80 years). Data 
on OTT for thrombolytic therapy were not collected in VISTA. 
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4.4 Discussion 
Comparing patients from SITS-ISTR who were treated with alteplase at an 
average of 145 minutes after stroke onset against controls from VISTA who 
received no alteplase a more favourable outcome across the entire range of 
modified Rankin Scores with alteplase is observed (Cochran-Mantel-Haenszel 
p<0.0001; Odds Ratio: 1.59 CI: 1.51 to1.67). The nature and extent of this effect 
of alteplase is comparable to results from pooled analysis of randomised 
controlled trials, confirming the validity of the controlled but nonrandomised 
analysis.28 I could therefore examine outcomes separately among nonelderly 
patients (aged </=80 years) and elderly patients (age group> 80 years). In each 
subgroup a more favourable functional outcome was noted: Odds Ratios 1.6 
(95%CI: 1.5 to 1.7), N=25789 and 1.4 (95%CI: 1.26 to1.63), [N=3439] respectively.  
 
Extending the analysis to smaller subgroups of age, I found independently 
significant benefits from alteplase in each 10-year age range from 40 to 90 
years. I found no interaction of age with alteplase efficacy and across the full 
age range from under 20 years to over 100 years. Only at under 30 years did the 
trend not favour outcomes after alteplase use.  
 
In summary, I show that association between thrombolysis treatment and 
outcome is maintained in all patients, even in the elderly regardless of generally 
poorer outcomes in these age groups. 
 
The analysis of SITS-VISTA data is based on almost 30,000 patients and confirms 
that improved outcomes occur after acute ischaemic stroke among patients who 
are offered thrombolytic therapy. The extent of the apparent benefit matches 
that from published randomised trials. These observations extend to the elderly 
age groups and it is only in a small group of patients in age group 91 to 100 (137 
patients in alteplase group and 77 in the non thrombolysed group) that it fails to 
achieve a statistical significance where the point estimates are consistent but 
confidence intervals are wide. The point estimates for improved outcomes in age 
group 91 to 100 are also consistent with the published data.131,315120 247  
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I undertook the primary analyses employing “shift analysis”, an analytical 
approach accepted by the European Drug Licensing agency. 284 The Cochran-
Mantel-Haenszel test is a non-parametric approach that avoids invoking an 
assumption of a common odds ratio (i.e. proportionality) across all cut points on 
the ordinal outcome scale. It provides a conservative estimate of statistical 
significance. Because it does not express the extent of the association, I also 
applied an ordinal logistic regression analysis to estimate a common odds ratio 
across modified Rankin scale categories. Again, I found significantly better 
outcomes, though the proportionality assumption was not satisfied. Whereas a 
non-significant test for proportionality would imply that common odds may be 
assumed, the converse does not necessarily apply.282 The proportionality 
assumption test may be over-sensitive when applied to large sample sizes.316 
Further, it is a global test that cannot differentiate the heterogeneity resulting 
from alteplase or other covariates316 The sample sizes were large and so I may 
still be justified in using the odds estimated from ordinal logistic regression. 
Even so, for final confirmation we tested using a less powerful dichotomised 
approach. 272,273 With all three methods I reach similar conclusions.   
 
There were improved outcomes among thrombolysis patients belonging to age 
groups encompassing 31 to 90 years. Analysis did not show improved outcomes 
for patients aged below 30 and above 90 years, but the small number of patients 
in these groups greatly reduced statistical power for these analyses and the 
trends mostly followed the same pattern as for intermediate ages. 
 
I chose age and baseline NIHSS for adjusted analysis mainly because of their 
established roles of influence on stroke outcomes.265 However, I also undertook 
sensitivity analysis adjusting for differences in age, sex, history of either 
diabetes or previous stroke, use of prior antithrombotic, baseline National 
Institutes of Health Stroke Scale score and hypertension between the 
thrombolysed and non-thrombolysed groups.278 The adjusted analyses for these 
variables confirmed significant findings for improved outcomes from 
thrombolysis regardless of age.  
 
The baseline demographic characteristics for the complete dataset give an 
advantage to the thrombolysis group. This influence does not extend to patients 
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aged >80 years, however. As a result, though the estimates of overall effect of 
alteplase may be biased, the relative differences between subgroups should 
remain reliable.  I did not match patients by co-morbidity score or baseline 
functional status, which may be considered a limitation. However, premorbid 
functional status is difficult to establish reliably in stroke and the strong 
influence of baseline severity on outcome, for which I did adjust, is known and is 
discussed in chapter 7. A corresponding analysis examining the influence of 
baseline severity on outcomes in SITS and VISTA data is underway.317 
 
The conclusions derive merit from having been based on a huge patient 
population who were treated in routine clinical practice [N = 28136] and 
compared against controls from rigorously conducted neuroprotection trials: any 
bias in quality of care should favour the control group.  The limitation of SITS-
ISTR data has been discussed extensively in previous publications.146,147,229,318 In 
short, SITS-ISTR is a registry and therefore, it is impossible to guarantee 
completeness of inclusions and to exclude selection bias.146,147,229 The SITS-MOST 
publication reports: “Sample source data verification was done by professional 
monitors working with national coordinators in collaboration with the study 
sponsor (Boehringer Ingelheim). A minimum of 10% of patients recruited in SITS-
MOST was monitored. In the UK, source data verification was done by 
independent clinical staff under the direction of the UK national coordinators. 
This monitoring also checked for completeness of registrations at all sites.” 146 
The SITS-MOST investigators also report that: “Incomplete data entries could be 
saved for later updating, but data were not deemed to be complete or included 
in report generation unless confirmed by the investigators by electronic 
signature. To be included in the SITS-MOST cohort, all baseline data entry had 
first to be confirmed by the investigator. SITS-MOST report generation was 
updated every 24 h via an automatic statistical package, which displayed main 
outcome details, demographic and baseline statistics, logistic information, and 
a recruitment report with indication of complete and delayed data. Registered 
centres could review statistical details for their own centres, and compare with 
country statistics and with the total SITS-MOST dataset.” 146 Finally, the SITS-
MOST publication reports that “in the UK, source data verification was done by 
independent clinical staff under the direction of K R Lees and G A Ford”. 146 
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In SITS-MOST, individual investigators’ results are not published, limiting the 
incentive for selection; in contrast, the sharing of total enrolment numbers may 
act as an incentive to be inclusive.115 Almost identical main outcomes in SITS-
MOST146 and RCTs131 after adjustment for baseline differences suggests that the 
influence from such potential bias is limited. Subsequent studies based on SITS-
ISTR data also show the similar outcome for the overall study population as 
compared to the SITS-MOST.129,229 None of the neuroprotective agents used for 
the patients in the VISTA control group has an influence on outcome, and over 
half of the VISTA cohort received only placebo. 
 
Because VISTA lacks data on repeat brain imaging among non-thrombolysed 
patients, I had no data on SICH in the control group. Therefore, I compared the 
SICH rates between over 80 years and ≤ 80 years old patients only with SITS 
data. There was no difference in SICH rates between over 80 years and ≤ 80 
years as per SITS-MOST definition but slightly higher as per NINDS definition. In a 
complementary per-protocol analysis of SITS-ISTR data (i.e. patients’ selection 
based on SITS-MOST criteria115 except for its age criterion), no significant 
difference in SICH rate was noted amongst very elderly patients compared to the 
younger cohort [per SITS 1.8% VS. 1.7%, P=0.70, adjusted odds ratio (aOR)=0.90 
(95%CI 0.73 to 1.09) 308 The SITS patients in the SITS-VISTA dataset are 
unselected and therefore SICH rates are slightly higher in the current study. 
Regardless, I now show that even if there were any more haemorrhages amongst 
elderly patients who receive thrombolysis, based on a conservative definition, 
there appears to be no adverse influence on the distribution of outcomes. In 
fact, one observes a beneficial effect on mortality of these patients. Others 
have concluded that factors such as comorbidity rather than alteplase use are 
responsible for the observed increase in late case fatality among the elderly.319-
321 
 
The present analyses reach the same conclusions as analyses employing VISTA 
data, as shown in previous chapter, or the limited pooled randomised trial data 
in the elderly (supplemental data).311 Elderly patients treated with thrombolysis 
in trials reported from VISTA in the previous chapter (N= 5817) had significantly 
better adjusted outcomes than nonthrombolysed comparators (p=0.002; Odds 
Ratio=1.34, 95%CI 1.05 to 1.70).311 Elderly patients treated in the pooled 
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randomised trials showed a trend towards better adjusted outcomes (modified 
Rankin score 0 to 2 versus 3 to 6) than non thrombolysed comparators (Odds 
Ratio 1.77; 95% CI 0.73–4.25, N=137). Previous studies have shown findings 
consistent with results in present chapter, but on very small data sets. 
290,292,297,315,320,322,323  Despite these points, treatment allocation in this study was 
not randomised. More extensive randomised controlled trial data could more 
conclusively answer this question. Two trials currently aim to examine this 
topic.232,312 There is an Italian trial that has so far enrolled around 10% of the 
planned 600 patients, over a 2 year period.312  A trial from UK, International 
Stroke Trial-3 [IST-3], aims to examine outcomes amongst all patients who 
receive thrombolytic therapy and has no upper age limit prescribed in its 
inclusion criteria.232,234,313  Over more than a decade, the trial has enrolled 
around 3035 patients from the originally planned 6000, 1756 patients are very 
elderly and being treated within the time window of interest.233  
 
In this analysis, patients who were treated with intravenous alteplase had better 
outcomes than their untreated comparators, and this effect was not dependent 
on their age. In particular, patients aged over 80 years derived similar benefit 
from treatment as younger patients. The weight of evidence to date indicates a 
potential for benefit in the elderly and there is no a priori reason to suspect a 
diminished effect compared to the non-elderly. Furthermore there are 
reassuring safety data on the risk of intracerebral haemorrhage. It may be 
concluded that clinical treatment guidelines should be revised to remove the age 
restriction in use of intravenous alteplase for acute ischaemic stroke. Age alone 
should not be a barrier to treatment. 
  
  
 
 
 
Chapter 5 
Presence of Diabetes and Previous Stroke in 
Acute Ischaemic Stroke Patients: Is it a valid 
exclusion criterion? 
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5 Presence of Diabetes and Previous Stroke in 
Acute Ischaemic Stroke Patients: Is it a valid 
exclusion criterion? 
 
5.1 Introduction 
The European Medicines Agency (EMEA) recommends that the ischaemic stroke 
patients suffering from hypo- or hyperglycaemia (blood glucose levels at baseline 
<50 and > 400 mg/dl respectively) should be excluded from receiving the 
thrombolytic therapy.23 EMEA also recommends that if a patient suffering from 
the onset of new ischaemic stroke has diabetes and a prior  stroke, he should not 
be thrombolysed with the t-PA.23 These recommendations often put a stroke 
physician into a difficult situation. This is because the hyperglycaemia occurs in 
about 70% of the ischaemic stroke patients and only 20% of these patients report 
suffering from diabetes mellitus.324,325 Hyperglycaemia at baseline may be 
associated with the diabetes (uncontrolled or unrecognised diabetes or poor 
glucose tolerance) or it may be a response to an acute stress (stress 
hyperglycaemia).325  It should be noted  that, though overlapping, true diabetes 
and post-stroke hyperglycaemia are distinct entities.326 E Melamed describes 
transitory reactive hyperglycaemia in about a third of ischaemic stroke patients 
who had no history of diabetes mellitus and also in those who had history of 
diabetes prior to stroke.327 The following reasons have been attributed to the 
hyperglycaemic reaction to the acute ischaemic stroke: “a non-specific reaction 
to acute stress and tissue injury with the associated autonomic, hormonal and 
metabolic alterations; uncovering of underlying latent diabetes by the acute 
stroke; increased secretion of growth hormone due to stroke-induced 
hypothalamic dysfunction; and irritation of the glucose regulatory centres in the 
hypothalamus and brain stem by blood-laden cerebrospinal fluid or local 
ischaemia”.327 
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The thrombolytic therapy is the only proven therapy known to enhance 
outcomes in ischaemic stroke patients.122,129 Its mechanism involves a 
recanalisation and a rapid reperfusion of the critically hypoperfused brain tissue, 
which in turn restores the function of ischaemic brain parenchyma.122,328 
Reperfusion induced improvement in outcomes depend on local factors in the 
ischaemic brain tissue such as the extent of neuronal damage, cerebral perfusion 
pressure (systemic blood pressure), oxidative stress, intracellular acidosis and 
mitochondrial dysfunction.328,329 Animal studies indicate that, following a 
cerebral ischaemia, hyperglycaemia enhances the super-oxide anion production, 
the local acidosis and the production of the advanced glycation end products 
that are damaging to the blood vessels.330,331,328,332-335 Superoxide production may 
predispose the brain to greater risk of blood brain disruption and thereby 
intracerebral haemorrhage.336-338 A systematic review of the animal studies that 
examined association of the infarct volume with the hyperglycaemia in the 
ischaemic stroke animal models (streptozotocin induced hyperglycaemia models, 
N=303 animals and dextrose induced hyperglycaemia models, N=356 animals), 
hyperglycaemia was associated with a 94% larger infarct size. 325 Infarct volume 
in streptozotocin model was greater than the infarct volume in dextrose model 
(140% vs. 48% increase). 325 However, in seven studies, there were non-
significant reduction of infarct size if insulin were used.325 The authors 
concluded: “Although hyperglycaemia exacerbates infarct volume in MCAO 
models, studies are heterogeneous, and do not address the common clinical 
problem of post stroke hyperglycaemia because they have used either the 
streptozotocin model of type I diabetes or extremely high glucose loads. Insulin 
had a nonsignificant and significantly heterogeneous effect. Further studies with 
relevant models may inform clinical trial design.”325  
 
Because post-stroke hyperglycaemia results in poor outcomes, trialists 
investigated the outcomes after treatment with the insulin in the patients having 
post-stroke hyperglycaemia. A meta-analysis of randomised controlled trials (16 
studies, 2459 patients) showed that the use of insulin in these patients does not 
affect the mortality (OR 1.1, 95% CI 0.9 to 1.5, p=0.29, n= 1236) or the 
favourable functional outcome (OR 1.03, 95% CI 0.7 to 1.5, p=0.88, n=1217), and 
instead,  may put the patient to the risk of hypoglycaemia ( range: 8% to 80%).339 
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6 
Clinical studies have largely shown adverse influence of hyperglycaemia on the 
outcomes of non-lacunar ischaemic stroke patients. 328,329,340 Poorer response to 
thrombolysis in these patients is considered to be a result of increased 
plasminogen activator inhibitor-1 activity, resistance to antithrombotic agents, 
excessive up regulation of metalloproteinase and higher prevalence of 
atherosclerosis. 328,340-342 Stroke recurrence is another major problem 
encountered in clinical practice, and prior stroke in patient is suspected to 
reduce the benefits attainable from thrombolytic therapy. 343 Because these 
patients are already on antithrombotic therapy, several clinicians mostly worry 
about haemorrhagic complications when administering the thrombolytic therapy. 
An analysis of patients who were treated during 0-6 hours of stroke onset 
(N=2184) enrolled in 5 thrombolysis trials122,124,127,128 has shown that a previous 
stroke and diabetes mellitus may predict poor outcome (p for t-PA-prior stroke 
interaction <0.05; p for diabetes <0.0001, p for prior stroke= 0.06).343 
7 
Whereas the clinical trials have shown improved outcomes amongst patients who 
receive alteplase for acute ischaemic stroke, t-PA was granted marketing 
authorisation in Europe in 2002 and patients with prior stroke and concomitant 
diabetes mellitus were excluded from the approval.23 The basis for this 
restriction is described in the review documents: “The therapeutic benefit is 
reduced in patients that had a prior stroke or in whom an uncontrolled diabetes 
is known, thus the benefit/risk ratio is considered less favourable, but still 
positive in these patients.”23  These were based on unpublished results of data 
analysed by regulatory authorities. Hence, ECASS III trialists excluded patients 
having diabetes mellitus or a history of stroke when designing ECASS III study.23 
As per the recent press release of Boehringer Ingelheim dated 4th 
November,2011, “Actilyse® has been approved through a mutual recognition 
                                               
6
  
7
  I published Chapter 5 in Diabetes Care (Mishra NK, Davis SM, Kaste M, Lees KR; VISTA 
Collaboration. Comparison of outcomes following thrombolytic therapy among patients with prior 
stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care. 
2010 Dec;33(12):2531-7. Epub 2010 Sep 15.)  As per Diabetes Care “The costs of publication 
of this article were defrayed in part by the payment of page charges. This article must 
therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 
solely to indicate this fact.” Further see  http://creativecommons.org/licenses/by-nc-
nd/3.0/  
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procedure for 15 European countries* for thrombolytic treatment of acute 
ischaemic stroke up to 4.5 hours of onset of stroke symptoms and after prior 
exclusion of intracranial haemorrhage.”344  Now, the European drug labelling 
continues to retain those exclusion criteria that have not been formally tested.23  
For example, the use of rt-PA in acute stroke is not recommended in Europe 
amongst patients who suffer from concomitant presence of diabetes mellitus and 
previous stroke.23   Regardless, physicians still treat these patients in routine 
clinical practice.345 In the current scenario, an ideal approach would be to 
conduct a randomised controlled trial and examine the influence of thrombolytic 
therapy on outcomes of these patients. But, running a clinical trial for this 
subgroup would not be feasible. Patient recruitment in stroke trials takes a long 
time. The IST-3 trialists started with an enrolment target of 6000 patients and 
have so far been able to enrol only 3035 patients.234 Further, these patients 
constitute a small proportion of all thrombolysed patients.  Within SITS-ISTR, of 
all the patients that were recruited between December 2002 and November 2009 
(N=23062), only 602 patients had suffered from both diabetes and previous 
stroke. To the best of my knowledge, there is not any plan of any trial group to 
conduct such a trial. Therefore, I planned for an alternative approach. Similar to 
the method adopted in chapter 3, I decided to examine outcomes of patients 
who received rt-PA against those who did not, from the data of the 
neuroprotection trials conducted between 1998-2007; and obtained these data 
from Virtual International Stroke Trials Archive [VISTA]. Employing an analytical 
approach recommended by EMEA, I compared outcomes amongst patients having 
diabetes, previous strokes and a combination thereof.284  
 
 
5.2 Methods 
5.2.1 Data Source and patients 
I collated the demographics, clinical data and measures of functional outcome 
from neuroprotection trials conducted in the period 1998 to 2007, held within 
the Virtual International Stroke Trials Archive, VISTA. (See Chapter 2) 
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5.2.2 Statistical analysis 
I compared outcome between patients who received thrombolysis and non-
thrombolysed controls amongst patients who had diabetes, prior stroke or their 
combination. For each contrast, I compared the overall distribution of all seven 
categories of day 90 mRS scores of the two groups, i.e. from 0 (asymptomatic) 
through 5 (bedbound and completely dependent), to 6 (dead), and also NIHSS 
categories  For analysis of the supporting endpoint, NIHSS, I grouped adjacent 
scores into categories: 0 (no measurable deficit), 1-4, 5-8, 9-12, 13-16, 17-20, 
21-24, ≥25 (most severe neurological deficit) or dead. To test for a significant 
association of outcome distribution with thrombolysis exposure I used the 
Cochran-Mantel-Haenszel [CMH] statistic, adjusting for both age and baseline 
NIHSS as continuous variables. Because CMH test does not express the extent of 
the association, I also applied logistic regression analysis, also adjusted for age 
and baseline NIHSS, to estimate the odds ratio under the assumption of 
proportional odds and its associated 95% confidence interval. I also undertook a 
sensitivity analysis by considering the combined effect of the variables that 
differed significantly at baseline, but if this resulted in excessive diminution of 
study sample, I did not quote the findings. The objective was mainly to 
undertake ordinal distribution or “shift” analysis. I also present dichotomised 
analyses of mRS, based on excellent outcome (mRS 0-1), favourable outcome 
(mRS 0-2), and survival; these analyses were expressed as odds ratios adjusted 
for age and bNIHSS, as for the primary and secondary endpoints. In order to 
remain consistent with the current age criteria of the EMEA, I examined if the 
interaction of age with t-PA had influence over outcomes; and further, 
estimated CMH p and proportional odds by ordinal logistic regression analysis for 
patients belonging to age group</=80.  
 
Odds ratios in the ordinal analysis express the common odds of an improved 
distribution of outcome in association with alteplase treatment. Reliable 
information on symptomatic haemorrhage was not available since post treatment 
imaging was not routinely applied in neuroprotection trials to patients who had 
not been treated with alteplase.  
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5.3 Results 
5.3.1 Patient sample 
Complete data were available for analysis of mRS in 5817 patients and on NIHSS 
in 5711 (see figure 5.1).Baseline characteristics are shown in table 5.1.  
 
5.3.2 Analysis of outcomes  
I have shown the findings on the analyses of outcomes in patients having 
diabetes or no diabetes, outcomes in patients having previous stroke or no 
previous stroke and the outcomes in patients having concomitant diabetes and 
previous stroke or their absence in figures 5-2 to 5-6. 
 
In a proportional logistic regression analysis adjusting for age and baseline 
NIHSS, we did not find any interaction of diabetes [p=0.49], prior stroke [p=0.72] 
and diabetes and prior stroke [p=0.8] with use of rt-PA. For each of the analyses 
above, I also considered the subgroup of patients aged <=80 years; and also 
sought evidence of any interaction with age. I failed to find evidence of a 
differential effect or interaction with age. 
 
 
Figure  5-1Flow chart showing the description of the VISTA data employed for present analyses 
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Figure  5-2 Outcomes in approved population (i.e. patients having absence of diabetes or previous 
stroke or both) 
 
 
 
Figure  5-3Outcomes in patients population having diabetes prior stroke or both 
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Figure  5-4 Figure shows outcomes in patients receiving alteplase or no alteplase in subgroups of 
patients  belonging to subgroups diabetes or no diabetes, previous stroke or no previous stroke 
and presence of diabetes and previous stroke together and absence thereof  
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Table  5-1 Baseline characteristics of patients enrolled in the VISTA trials 
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5.4 Discussion  
The present analysis reconfirms the occurrence of improved outcomes amongst 
patients who do not have diabetes and prior stroke, with significant odds of 1.4. 
These odds were comparable to the odds obtained from large thrombolysis 
trials,131 suggesting outcomes following thrombolysis are similar in these patients 
to those seen in the trials. The present analysis shows a significant association of 
improved outcomes with the use of thrombolytic therapy in patients having 
diabetes or prior stroke. However, I failed to confirm statistical significance for 
a small group of patients that concomitantly had previous stroke and diabetes 
[OR 1.5, 95% CI: 0.98-2.3]. I attribute this to a type 2 error in this smaller 
subgroup of sample size, N=491. The findings from shift analyses were also 
supported by similar results from the analyses of dichotomised outcomes. It 
should be noted that the European license restrictions for the use of t-PA in 
ischaemic stroke includes the subgroup of patients that have concomitant 
presence of diabetes and previous stroke (and not “only diabetes” or “only prior 
stroke”).23 The analysis failed to show significant odds ratios at p=0.05 for this 
particular subgroup of patients.  
 
These findings can be generalised not only because of the comparable odds to 
those obtained from the large trials data131  but also because these results were 
replicated on another analysis involving the comparison of  thrombolysed 
patients [in SITS dataset] with the non-thrombolysed controls [from VISTA] 
(reported in  chapter 6). In addition, I was informed of supportive findings that 
were available from the analyses of a collaborator, Prof Markku Kaste at Helsinki 
Thrombolysis Register. In their data, from 1200 consecutively treated patients, 
complete information was available for 1104 patients, 51% patients were treated 
despite licence contraindications. The analysis of 26 patients aged </=80 years 
who had both DM and previous stroke suggested poorer favourable outcomes 
(mRS 0-2) in univariate analysis when compared to those treated according to 
the European licence of alteplase; but, not in multivariate analysis. These 
patients had more symptomatic intracerebral haemorrhages than those treated 
on-label in univariate analysis but 95% CI was not significant and in a 
multivariate analysis there was no trend for symptomatic haemorrhage. I could 
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not however examine the symptomatic brain haemorrhages in the VISTA 
patients, as these data were derived from neuroprotection trials, which had not 
routinely obtained imaging information of the untreated patients.  
 
I based the conclusions on adjusted analyses, adjusting for age and baseline 
NIHSS, because prognostic variables differed at baseline; and, age and baseline 
severity have an established influence on stroke outcomes.131 However, I could 
not adjust for all variables, as data were incomplete. Despite robust analyses 
and adjustment for important variables, it needs to be acknowledged that a 
randomised study would have the best design. But, there are no such studies 
conducted yet, or are on-going. The present study is the only analysis that is 
based on the largest dataset on thrombolysis patients available up to the present 
date.(except the data that are presented in the following chapter). It employs 
an analytic approach recommended by EMEA, and replicates findings of 
functional outcomes on neurological outcomes.  
 
It is known that patients with premorbid m RS >1 were excluded from the VISTA 
trials, but the pre-stroke functional status of individual patients was not 
recorded in VISTA. Hence, it is likely that any effect of pre-stroke disability in 
the patients having prior stroke(s) would only lead to an underestimation 
treatment effect in the analyses. 
 
I acknowledge that there could be differences on outcomes owing to centre 
specific effects on treatment of patients. This would however occur if the 
patients were part of routine clinical care, and not enrolled in a rigorously 
controlled clinical trial. Because the patients in VISTA were enrolled in 
neuroprotection clinical trials during 1998-2007, I assume that they all received 
best standard of care at each participating centre.  60% of VISTA patients were 
from American centres where the thrombolytic therapy was approved soon after 
the NINDS trial results were published in 1995.122 During the next years, even 
other centres [including European (16% patients)] practised thrombolytic therapy 
based on clinicians’ choice.146 In 2002, the alteplase was approved in Europe as 
well.23 This would imply that all those stroke patients who were eligible for 
thrombolysis in the physician’s opinion received therapy. However, I could not 
adjust for centres, as centre-specific information was missing in the dataset. 
Nishant Kumar Mishra, 2011                        Chapter 5, 153 
 
 
 
Table  5-2 Acute stroke treatment with respect to hyperglycaemia at base line in European 
Federation of Neurological Society member states 
(“a” refers to national estimates. The other numbers are from the stroke panel member centre.) 
(Source: Thomassen L, Brainin M, Demarin V, Grond M, Toni D, Venables GS; EFNS Task Force on 
Acute Neurological Stroke CareAcute stroke treatment in Europe: a questionnaire-based survey 
on behalf of the EFNS Task Force on acute neurological stroke care.Eur J Neurol. 2003 
May;10(3):199-204.Permissions obtained from John Wiley and Sons, License number: 
2811330661886 ) 
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It should however be noted that the European centres/countries differ in their 
practices with regard to the treatment of hyperglycaemia at the stroke onset 
(table 5-2).346 For example, some centres employ insulin infusion to control 
blood sugars when the patient presents with stroke with hyperglycaemia. 
Physicians may differ in their choice of drugs for the secondary prevention of 
diabetes during the follow-up period. These variables are likely to influence the 
outcomes on day 90. It can be guessed that the participating centres in the 
neuroprotection trials would have been inconsistent with regard to the 
recommendations for the control of hyperglycaemia at stroke onset and the 
subsequent secondary prevention treatments. Treatments are likely to have 
been different between the individual studies. In conclusion, the differences 
arising from the varying practices across the participating centres in the 
neuroprotection trials would have resulted in bias in my present study. Further 
because the data lack in the information on specific centre specific clinical 
practices with regard to control of hyperglycaemia, I could not control for the 
resulting bias. 
 
In the present analysis, the 95% confidence interval for improved outcomes were 
0.98 to 2.3 and marginally missed the level of significance at p=0.05.One must 
consider that analyses like these are based on probabilistic models where level 
of significance is arbitrarily chosen (and conventionally set at 5%), and decision 
to thrombolysis is left to the clinicians who determine their own limits regarding 
taking chances whilst offering the therapy. The group of patients having 
concomitant diabetes and previous strokes missed statistical significance, but 
had a favourable point estimate of 1.5. Had I considered a higher level of 
significance, the results would have been significant for outcomes amongst all 
subgroups of patients.   
 
In summary, the analysis shows improved outcomes amongst patients with 
diabetes, prior stroke and those with diabetes and/or prior stroke; though 
marginally failed to show a statistically significant improvement in the patients 
who had both diabetes and prior stroke together. A potential benefit might exist 
for the combined group too, and withholding a proven therapy amongst these 
patients would not be justified. Treatment may be offered to a carefully 
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selected patient, and trialists should now be encouraged to consider examining 
these patients by conducting a randomised controlled trial. Finally, it can be 
recommended that withholding treatment from these patients would be 
unjustified.  
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6 Presence of Diabetes and Previous Stroke in 
Acute Ischaemic Stroke Patients: A validation 
study to confirm findings from VISTA data  
 
6.1 Introduction 
Intravenous alteplase administration is a proven treatment for acute ischaemic 
stroke.122,129 In Europe, it was granted marketing authorisation in 2002 but 
patients with prior stroke and concomitant diabetes mellitus were excluded from 
approval.23 The basis for this restriction is described in the review documents: 
“The therapeutic benefit is reduced in patients that had a prior stroke or in 
whom an uncontrolled diabetes is known, thus the benefit/risk ratio is 
considered less favourable, but still positive in these patients.”23 Because of this 
restriction, the EMEA-mandated third European Cooperative Acute Stroke Study, 
ECASS-III, was required to exclude patients with prior stroke and concomitant 
diabetes from its protocol. In routine clinical practice many such patients are 
treated but others will be excluded due to confusion over the evidence.129  In 
chapter 5, I reported the findings from data held within VISTA and suggested 
that the exclusion of patients based only on the basis of the presence of 
diabetes and previous stroke would be unjustified.  
In the present chapter, I describe the findings from another controlled 
comparison, in which I examine thrombolysed patients from SITS-ISTR compared 
against control patients within VISTA. Here, I examine the treatment effect of 
intravenous alteplase in patients with diabetes, prior stroke and their 
combination, in order to clarify the validity of restriction on the latter group. 
For EMEA’s restriction to be valid, one ought to find that the benefit/risk would 
be diminished independently in each sub-group, or at least diminished within the 
combined group due to an interaction of diabetes with prior stroke. 
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8 
6.2 Methods 
6.2.1 Data source and patients 
I collated the data of stroke patients who received thrombolytic therapy through 
the SITS-ISTR between December 2002 and November 2009,  and the controls 
were derived from the non-thrombolysed control stroke patients from the 
neuroprotection trials of the duration 1998 to 2007 held within the Virtual 
International Stroke Trials Archive, VISTA (www.vistacollaboration.org) 
6.2.2 Patient Sample 
Patient sample employed for present analyses are shown in figure 2.1.  
 
6.2.3 Statistical analysis 
I compared the outcomes between patients who received thrombolysis and non-
thrombolysed controls amongst patients who had diabetes, prior stroke or both 
together. For each contrast, I compared the overall distribution of all seven 
categories of day 90 mRS scores of the two groups, i.e. from 0 (asymptomatic) 
through 5 (bedbound and completely dependent), to 6 (dead). To test for a 
significant association of outcome distribution with thrombolysis exposure I used 
the Cochran-Mantel-Haenszel [CMH] statistic, adjusting for both age and baseline 
NIHSS. Then I also employed proportional odds logistic regression analyses in 
order to calculate age and baseline stroke severity adjusted odds for better 
outcomes in each subgroup of patients’ population. Then, I undertook a 
sensitivity analysis by considering the combined effect of the variables that 
differed significantly at baseline (at p < 0.05). Adjusted analysis was expected to 
result in reduction of number of patients, owing to missing data for certain 
                                               
8
  I published Chapter 6 in Neurology (N.K.Mishra, N.Ahmed   A.Davalos  H.K.Iversen  L.Soinne   
N.Wahlgren  K.R.Lees Post thrombolysis outcomes amongst patients with prior stroke and 
diabetes: controlled comparison of SITS international registry (SITS-ISTR) versus Virtual 
International Stroke Trials Archive (VISTA) Neurology, 2011;77:1866-1872.) Permissions were 
obtained from Wolters Kluwer Health, License Number 2790960994499. 
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variables. Hence, when reporting results, I also quote the corresponding sample 
size. 
In addition to calculating the proportional odds ratios (that express the common 
odds of an improved distribution of outcome in association with alteplase 
treatment), I also undertook an interaction test between the alteplase and 
presence of diabetes, previous stroke or both. Reliable information on 
symptomatic haemorrhage was not available since post treatment imaging was 
not routinely applied in neuroprotection trials to patients who had not been 
treated with alteplase.  
 
6.3 Results 
6.3.1 Baseline demographics 
The data comprised 29500 patients for this analysis. Data on baseline NIHSS for 
another 272 patients were missing and had to be excluded leaving 29228 
patients whilst undertaking the baseline severity adjusted analysis (Figure 
2.1).271  The baseline characteristics of the patients included for this analysis are 
shown in Table 6.1. 
6.3.2 Analysis 
I undertook comparison of outcomes for patients who suffered from diabetes, 
previous stroke or both concomitantly. The findings are shown in figures.  
I found no interaction of variables prior stroke (t-PA * PS, p=0.9), diabetes (t-
PA*DM, p=0.19). I also found no interaction of use of alteplase with presence of 
diabetes and previous stroke (t*PA*DM*PS, p=0.5). 
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Table  6-1 Baseline characteristics of the patients.  
 
 
  Thrombolysis Control P-values 
Age All 67.1 (12.5),N=23062 70.1(12.2), N=6166 <0.0001 
 DM 69.9(9.5), N=3905 70.5(10.4),N=1449 0.06 
 No DM 66.5(12.9),N=18799 70.1(12.6),N=4447 <0.0001 
 PS 70.1(10.5),N=2972) 72.9(10.8), N=2014 <0.0001 
 No PS 66.6(12.7),N=19782 69(12.5),N=3979 <0.0001 
 DM+PS 71.0(9.4), N=602 71.6(9.7), N=534 0.31 
 Neither DM nor PS 65.9(13.1), N=16275 68.7(13), N=3064 <0.0001 
Gender (Male) All 13437/23062(58.3%) 3271/6166(53.1%) <0.0001 
 DM 2355/3905(60.3%) 781/1449(53.9%) <0.0001 
 No DM 10873/18799(57.8%) 2351/4447(52.9%) <0.0001 
 PS 1748/2972(58.8%) 1059/2014(52.6%) <0.0001 
 No PS 11521/19782(58.2%) 2121/3979(53.3%) <0.0001 
 DM+PS 363/602(60.3%) 285/534(53.4%) 0.02 
  
 
Nishant Kumar Mishra, 2011.                Chapter 6, 161 
 
 
 Neither DM nor PS 9410/16275(57.8%) 1625/3064(53.0%) 0.001 
Baseline NIHSS* All 12[0-42],N=23062 12[2-37],N=6166 0.14 
 DM 13[0-40],N=3905 11[2-29], N=1449 0.04 
 No DM 12[0-42], N=18799 12[2-37],N=4447 0.002 
 PS 12[0-42],N=2972 11[2-37],N=2014 0.75 
 No PS 12[0-40],N=19782 12[2-31],N=3979 0.02 
 DM+PS 12[0-40],N=602 11[2-29],N=534 0.08 
 Neither DM nor PS 12[0-40],N=16275 12[2-31], N=3064 0.002 
Hypertension All 14163/23062(61.4%) 4170/5896(70.7%) 0.001 
 DM 3235/3878(83.4%) 1170/1449(80.8%) 0.02 
 No DM 10736/18509(58%) 3000/4447(67.5%) 0.001 
 PS 2247/2936(76.5%) 1491/1917(77.8%) 0.31 
 No PS 11711/19414(60.3%) 2679/3979(67.3%) 0.001 
 DM+PS 538/600(89.7%) 441/534(82.6%) 0.0005 
 Neither DM nor PS 8918/16018(55.7%) 1950/3064(63.6%) 0.001 
Atrial  Fibrillation All 5753/22493(25.6%) 1712/5896(29%) 0.001 
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 DM 1130/3814(29.6%) 365/1449(25.2%) 0.001 
 No DM 4533/18397(24.6%) 1347/4447(25.2%) 0.001 
 PS 799/2893(27.6%) 624/1917(32.6%) 0.0002 
 No PS 4853/19353(25.1%) 1088/3979(27.3%) 0.003 
 DM+PS 179/591(30.3%) 141/534(26.4%) 0.15 
 Neither DM nor PS 3850/15948(24.1%) 864/3064(28.2%) 0.001 
Congestive Heart Failure All 1914/22583(8.5%) 277/3167(8.8%) 0.61 
 DM 538/3802(14.2%) 79/800(9.9%) 0.001 
 No DM 1349/18503(7.3%) 198/2367(8.4%) 0.06 
 PS 312/2898(10.8%) 70/711(9.8%) 0.47 
 No PS 1567/19444(8.1%) 207/2456(8.4%) 0.53 
 DM+PS 92/584(15.8%) 19/222(8.6%) 0.008 
 Neither DM nor PS 1108/16044(6.9%) 147/1878(7.8%) 0.14 
Prior use of antithrombotic agents All 8672/22543(38.5%) 1267/2968(42.7%) 0.001 
 DM 1920/3795(50.6%) 367/751(48.9%) 0.39 
 No DM 6649/18430(36.1%) 900/2217(40.6%) 0.001 
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 PS 2140/2863(74.7%) 442/687(64.3%) 0.001 
 No PS 6397/19413(33%) 825/2281(36.2%) 0.002 
 DM+PS 442/574((77%) 141/213(66.2%) 0.002 
 Neither DM nor PS 4888/15998(30.6%) 599/1743(34.4%) 0.001 
Systolic Blood  Pressure All 151.3(21.1),N=22 736 156.6(26.9),N= 6156 0.001 
 DM 154.6(20.7), N=3848 159.7(27.5),N=1446 <0.0001 
 No DM 150.5(21.1),N=18540 155.9(26.8),N=4440 <0.0001 
 PS 152.1(20.4), N=2925 160.3(27.1),N=2013 <0.0001 
 No PS 151.1(21.2), N=19510 155.1(26.7), N=3970 <0.0001 
 DM+PS 154.0(20.5),N=589 163.2(27.8),N=534 <0.0001 
 Neither DM nor PS 150.3(21.2), N=16052 154.3(26.6),N=3058 <0.0001 
Diastolic Blood Pressure All 82.6(13.5),N=22710 84.0(16.1),N=6156 <0.0001 
 DM 81.9(13.4), N=3841 83.4(15.7),N=1446 0.0007 
 No DM 82.7(13.4),N=18521 84.3(16.3),N=4440 <0.0001 
 PS 82.4(13.4),N=2921 84.9(15.7),N=2014 <0.0001 
 No PS 82.6(13.5),N=19489 83.6(16.3),N=3969 <0.0001 
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 DM+PS 81.7(13.6),N=587 84.2(15.8),N=534 0.005 
 Neither DM nor PS 82.7(13.5),N=16036 83.8(16.5),N=3057 <0.0001 
 
Numbers do not add to a total of 29228 due to missing data for some of the variables. () records standard deviation and  [] the range, * p statistics were calculated by 
employing Wilcoxon non- parametric test.
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Figure  6-1  Bar Diagrams showing the distribution of 
patients in each risk factor category.  
The numbers in the box denote percentage. Colour codes 
refer to modified Rankin Scale. 
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Figure  6-2 Forest Plot showing outcomes for various 
analyses in affected patients’ population.  
 
 
Unadjusted, and age and baseline adjusted analyses refer 
to ordinal regression analysis. Odds Ratio refers to common 
odds for improved outcomes at each Rankin category. 
Favourable outcomes refer to Rankin 0-2 whereas the 
Excellent outcomes refer to the Rankin score 0-1. All 
adjusted analyses refer to an adjusted analysis in which 
adjustments were made for all variables that differed at 
baseline.  
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Figure  6-3 Forest Plot showing outcomes for various analyses in 
unaffected patients’ population.  
 
Unadjusted and age and baseline adjusted analyses refer to ordinal 
regression analysis. Odds refer to common odds for improved 
outcomes at each Rankin category. Favourable outcomes refers to 
Rankin 0-2 whereas the Excellent outcomes refers to the Rankin 
score 0-1. All adjusted analyses refers to an adjusted analyses in 
which adjustments were made for all variables that differed at 
baseline. 
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6.4 Discussion  
The patients who suffer from the concomitant presence of diabetes and previous 
stroke are currently recommended for exclusion from receiving thrombolysis for 
acute ischaemic stroke. Employing a robust analytical methodology [shift 
analysis] and a large number of patients [N=29500], I have again shown improved 
outcomes across patients having diabetes, previous strokes or both who received 
thrombolytic therapy compared to those who were excluded from receiving this 
therapy.  
I have first shown improved outcomes amongst patients who did not have 
diabetes and prior stroke, each having adjusted odds of 1.7 and 1.6 respectively, 
each of which is comparable to the odds for a similar time window obtained 
from the analysis of pooled data from all of the large trials conducted to date. 
131 This concordance of odds anchors my findings from patients having diabetes 
and previous stroke to established randomised control trial results.29 In the 
populations of patients with diabetes, prior stroke or either condition, this 
better outcome amongst the group who received thrombolysis with intravenous 
alteplase versus untreated comparators is maintained. I confirm the finding 
using both ordinal and dichotomised analysis approaches, and whether or not the 
analyses are adjusted for baseline variables known to associate with prognosis. I 
find no interaction between diabetes and prior stroke with the effect of 
alteplase to justify further subgroup analysis. However, in the small group of 
patients having both diabetes and prior stroke, I no longer confirm a better 
distribution of outcome with alteplase [OR 1.2, 95% CI: 0.996-1.5] 
though dichotomisation reveals favourable outcomes [m RS 0-2], OR=1.3(95% CI 
1.008-1.8)]. This discordance may arise from the smaller sample size, N=1141, 
which yields less precise point estimates and may be associated with a type II 
error. The point estimates remain consistent with those from the more reliable 
main analyses. This could also be explained by the fact that I did not account for 
the baseline disability amongst patients who had a previous stroke, and one does 
not expect the patients’outcomes would shift and get better than their pre-
stroke disability. 
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In the present chapter, I have analysed a large dataset, N=29500. The findings 
are reassuring because these patients have a clinical profile similar to the one 
often seen in clinical practice. More patients in the diabetic group had 
hypertension, history of previous stroke, atrial fibrillation, and heart failure and 
used antithrombotic agents. Here the patients who received treatment had 
suffered a severe stroke at baseline compared to the untreated patients [NIHSS: 
13 vs. 11]. Similarly, more patients having previous stroke(s) had hypertension, 
diabetes, atrial fibrillation, and heart failure, and use of antithrombotic agents 
before stroke.  
In addition, this analysis supports the findings obtained from VISTA-only analysis 
[N=5817] reported in chapter 5, where employing a similar approach I compared 
the patients in VISTA who received thrombolytic therapy against those who did 
not. That analysis reported similar odds: patients having diabetes, OR= 1.3 
[95%CI: 1.05-1.6]; patients having previous stroke, OR= OR: 1.3 [95%CI: 1.04-
1.6], and both together, OR= p-OR: 1.5 [95%CI: 0.98-2.3].  
A limitation of this study is that the data are non-randomised. However, I 
adjusted the analysis for age and baseline NIHSS scores. 278,279,347,348    (and then 
also for other variables that differed at baseline) and employed robust statistical 
tools [Cochran-Maentel-Haenszel Test, proportional odds logistic regression; and 
analysis by dichotomisation of Rankin scores]. I believe that I have attained a 
reliable statistical result.  One may anchor the findings on the fact that the odds 
in the group of patients who did not have DM or PS were comparable with the 
published randomised trial data [In NINDS, OR 1.6 (95%CI 1.2-2.1)]269, while 
acknowledging the caveat that there are no analyses of RCT data that 
specifically examined outcomes after excluding those patients that had diabetes 
or prior stroke. Next, although prior stroke patients who were offered 
thrombolysis may have had higher premorbid mRS than patients who had no prior 
stroke, it is known that patients with premorbid mRS >1 were excluded from the 
VISTA trials from which comparators for analysis are derived.  This potential bias 
would be expected to lead to underestimation of any benefit from alteplase in 
that subgroup of patients.  
Hyperglycaemia after stroke occurs in about 60% of patients and only 20% of 
these patients report a history of diabetes mellitus.324 As discussed previously in 
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the Chapter 5, hyperglycaemia and diabetes are overlapping but two different 
conditions. Hyperglycaemia at baseline may be associated with diabetes 
(uncontrolled or unrecognised diabetes or poor glucose tolerance) or it can be a 
response to the acute stress (stress hyperglycaemia). The EMEA recommends 
that patients suffering from blood glucose levels at baseline <50 and > 400 mg/dl 
should be excluded from receiving therapy. The purpose of analysis that I 
present in this chapter was to examine outcomes amongst patients who already 
had diabetes and prior stroke as these are distinct exclusion criteria specifically 
mentioned in the EMEA document. I realise that denominators in my analyses 
(“non-diabetic patients”) might be having hyperglycaemia (due to unmasking of 
diabetes, poor glucose tolerance, unknown case of diabetes or stress 
hyperglycaemia) at baseline. What proportions of non-diabetics had raised blood 
sugar levels in this dataset is unknown. Examination of outcomes for different 
levels of hyperglycaemia (with or without presence of diabetes/previous stroke) 
would require another analysis. In summary, the analysis shows improved 
outcomes amongst patients with diabetes, or prior stroke. The magnitude of 
benefit is comparable to that in other patient groups. This finding contrasts with 
EMEA’s justification for restricting use of intravenous alteplase. The analysis did 
not confirm a significant benefit in the small subgroup of patients who 
had concomitant diabetes and prior stroke but here the confidence intervals 
were wide, and there was no interaction between these two risk factors with the 
treatment effect of alteplase. Hence, I find no justification to exclude patients 
from receiving alteplase for acute ischaemic stroke if they suffer from a previous 
stroke and also have diabetes mellitus.  
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Should patients having mild or severe stroke receive 
alteplase? 
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7 Should patients having mild or severe stroke 
receive alteplase? 
 
7.1 Introduction 
Intravenous thrombolysis with alteplase is a proven therapy for acute ischaemic 
stroke patients presenting within 4.5 hours of symptom onset.122,129,131 However, 
some patients are denied therapy for fear of poor outcomes. European 
guidelines recommend that patients with baseline stroke severity NIHSS >/=25 
and minor/rapidly improving strokes should not be given alteplase.23 But, there 
is a lack of consensus on what defines a “mild stroke”.349 Heinrich Mattle and 
colleagues349 undertook a Medline search to look for papers published between 
1950 and 2009 by using a search term “ Minor Stroke”. They extracted 670 
papers and found that most of these had not defined a minor stroke.349 However, 
some of the definitions have been used to define mild stroke are: 
 
1. Definition A:  baseline NIHSS score of 0 or 1 in each NIHSS component 
except the items 1a, 1b and 1c that deal with the level of 
consciousness.349 350 
2. Definition B: lacunar strokes at baseline.349 350 
3. Definition C: presence of motor symptoms (including dysarthria or ataxia 
+/-sensory symptoms).349 350 
4. Definition D: NIHSS Score </=9), excluding all patients with extinction or 
neglect, aphasia or having level-of-consciousness.349 350 
5. Definition E:  maximum NIHSS score of 9.349 350 
6. Definition F: NIHSS </=3.349 
7. Definition G: NIHSS <5. 
 
 
Employing definition A to E NINDS investigators examined outcomes in 624 
patients that were enrolled in the NINDS trial.350 They used a global test statistic 
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based on a logistic model to examine patients who had favourable outcome on 
day 90. In addition, they also examined the rates of symptomatic intracerebral 
haemorrhages.  Data comprised N=28 patients as per definition A, N=81 per 
definition B, N=439 per definition C, N=173 per definition D and N=177 per 
definition E.  Based on an Intention-to-treat analysis, investigators showed that 
the odds for better outcomes ≈ 2 for all the definitions (p<0.05) (lower limit of 
confidence interval between1.4 to 1.5; upper limit between 2.7 and 2.9). 
Symptomatic Intracerebral Haemorrhage occurred in 0-4% of patients per 
definition.350   
 
Employing the definitions A to F, Fischer et al349 reported analysis of Bernese 
Stroke Registry data (N=760) and examined short term outcomes (patient goes 
home) and a favourable medium term outcomes (m-RS 0-2 on day 90) for 
patients. In addition, they also analysed data for various subgroups of patients 
defined by their sex, age, laterality of lesions (left-right) or circulation 
(anterior-posterior) and temporal profile of admissions (early versus late). This 
study reported that median NIHSS were lowest for the definitions A and F. 
Definition A and definition F were associated with most favourable short and 
medium term outcomes. Per definition C, more numbers of patients with 
anterior circulation infarction were discharged home compared to posterior 
circulation stroke (p=0.02). Rankin scores on day 90 were less favourable for 
elderly patients per definition E (p<0.05). Definitions A, D and F were not 
associated with differences on outcomes across the subgroups.  Authors 
recommended for the need of a consensus definition of a mild stroke.349 
 
Several stroke trials explicitly exclude patients with NIHSS of 5 or less (definition 
G).46,247,351,352 9 
 
Patients having rapidly improving stroke symptoms are also recommended for 
exclusion because these patients are assumed to have improved outcomes.122 But 
                                               
9
 I published Chapter 7 in Stroke (Mishra NK, Lyden P, Grotta JC, Lees KR; VISTA Collaborators. 
Thrombolysis is associated with consistent functional improvement across baseline stroke 
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data indicate that this may not always be the case.142,353-356  Nedeltchev et al357 
show that about 75% of patients that present with mild or rapidly improving 
stroke symptoms achieve a Rankin score of </=1 by day 90. Those that have 
persistent proximal vessel occlusion and a baseline NIHSS of >/=10 suffer 7 times 
the excess risk of unfavourable outcomes.357 Persistent occlusion of blood vessels 
was shown to be associated with poor outcomes in patients.356,358-360 Additional 
data are needed so that one can reliably select phenotypes of those patients 
that would either undergo spontaneous recovery or need thrombolysis. 
 
t-PA guidelines were framed under an assumption that  many patients who show 
rapid improvement/ have minor strokes would not display residual deficit, but 
treatment with thrombolytic therapy would expose them to risk of complications 
such as cerebral haemorrhage.23 Similarly, those patients who present with 
baseline NIHSS >/=25 are also supposed to have poorer outcomes because of 
excess symptomatic haemorrhages.23 Baseline stroke severity (b-NIHSS) is known 
to affect outcomes amongst thrombolysed patients, and was therefore 
incorporated for patients’ selection in ECASS III trial.23 Though the regulatory 
authorities have recommended withholding thrombolytic therapy amongst 
patients with minor/rapidly improving strokes and for those with severe stroke 
at baseline, poorer response to therapy in these subgroups has never been 
demonstrated in randomised controlled trials.23 Indeed, post hoc analyses of the 
NINDS and ECASS-III trials suggest equal efficacy across severity ranges, though 
power to examine subgroups is inevitably lower than that chosen for the primary 
analyses and patients at extremes of severity were under-represented.361-363 The 
logistical challenges involved in generating randomised trial evidence for these 
limited subgroups militate against any prospect for producing a definitive answer 
in the foreseeable future. Therefore one must turn to alternative sources of 
evidence.  
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7.2 Methods 
7.2.1 Data Source and patients 
As discussed in Chapter 2, I collated the demographics, clinical data and 
measures of functional outcome from neuroprotection trials conducted in the 
period 1998 to 2007, held within the Virtual International Stroke Trials Archive, 
VISTA (www.vista.gla.ac.uk).   
 
7.2.2 Statistical analysis 
I compared outcomes between patients who received thrombolysis and patients 
who did not receive thrombolysis (controls) amongst categories of baseline NIHSS 
scores (below 4, 5-8, 9-12, 13-16, 17-20, 21-24 and >/=25). For each contrast, I 
compared the overall distribution of all seven categories of day 90 mRS scores of 
the two groups, i.e. from 0 (asymptomatic) through 5 (bedbound and completely 
dependent), to 6 (dead). For analysis of the supporting endpoint, NIHSS, I 
grouped the adjacent scores into categories: 0 (no measurable deficit), 1-4, 5-8, 
9-12, 13-16, 17-20, 21-24, ≥25 (most severe neurological deficit) or dead. The 
distribution of patients across these categories was then compared between the 
groups as for mRS.    
 
To test for a significant association of outcome distribution with thrombolysis 
exposure I used the Cochran-Mantel-Haenszel [CMH] statistic, adjusting for both 
age and baseline NIHSS as continuous variables. Further, I applied logistic 
regression analysis, also adjusted for age and baseline (b-) NIHSS, to estimate 
the odds ratio under the assumption of proportional odds and its associated 95% 
confidence interval. Reliable information on symptomatic haemorrhage was not 
available since post treatment imaging was not routinely applied in 
neuroprotection trials to patients who had not been treated with alteplase.  
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7.3 Results 
7.3.1 Patient sample 
Complete data were available for analysis of mRS in 5817 patients and on NIHSS 
in 5715 (see chapter 2 for details of VISTA data). Of the 5817 patients with mRS 
outcome data, 1585 (27.2%) received thrombolysis. 
 
7.3.2 Does baseline stroke severity influence stroke outcomes?  
In an ordinal logistic regression analysis, I found that baseline severity 
(p<0.0001), use of rt-PA and age were significant predictors of outcomes. Then, 
in an age adjusted ordinal logistic regression analysis, I found that baseline 
stroke severity (p<0.0001) and the interaction between severity and use of 
alteplase (p=0.04) were associated with outcome from stroke, but I did not see 
an independent effect of alteplase (p=0.65). 
 
Supported by this interaction test, I classified the baseline stroke severity into 
seven baseline NIHSS score categories:1-4,5-8,9-12,13-16,17-20,21-24,and>/=25, 
and undertook tests of association for thrombolysis with outcomes in each of 
these categories. 
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Figure  0-1 7-1 Figure showing details of 
selection of patients from VISTA for this 
analysis. 
 
VISTA data (1998-2007)
N=9665 patients
Ischaemic Stroke patients
N=9058
VISTA analysis
N=6092
Exclude missing m-RS 
data: 5817 patients for 
analysis
Exclude missing NIHSS 
data: 5711 patients for 
analysis
Potential SITS MOST Overlap 
N=2789
Patients with unknown 
nationality N=177
Intracerebral haemorrhage
N=571
Undetermined
N=36
 Nishant Kumar Mishra, 2011.                      Chapter 7, 178 
 
 
 
 
 
 
Table  0-1 7-1 Baseline characteristics of the patients studied in VISTA. 
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7.3.3 Are there improved outcomes across all baseline stroke 
severity categories? 
7.3.3.1 Primary analysis: functional outcome by modified Rankin Scale.  
I report the findings in figure 7-2 below. 
 
 
 
Figure  0-2 7-2 Forest plot showing age and baseline stroke severity adjusted outcomes across 
categories of baseline severity level 
 
7.3.4 Secondary analysis: neurological outcomes by NIHSS. 
Findings are shown in figure 7.3. 
 
7.3.5 Sensitivity analysis  
I also performed unadjusted analysis, and analysis in which I adjusted for 
additional factors.  Results are shown in figure 7.3 
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Figure  0-3  7-3 Findings from secondary and sensitivity analyses 
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I could not adjust for onset to treatment [OTT] time because time to initiation 
of thrombolytic therapy was not recorded within the source neuroprotection 
trials.  
Fifty-nine per cent of records lacked coding for the variable “antithrombotic” 
(i.e. antiplatelet and anticoagulants) (N=3432), 4.8% for atrial fibrillation 
(N=278) and 3.2% for patients with prior strokes (N=186). Because the analyses 
were to be conducted within each stratum of baseline stroke severity, these 
differences were more pronounced limiting the analyses of data controlled for 
all variables that differed at baseline: age, baseline NIHSS, prior use of 
antithrombotic drugs, previous stroke and atrial fibrillation). 
 
7.4 Discussion  
Patients with mild and severe strokes are under-represented in randomised trials 
and post marketing analyses. The  EMEA marketing authorisation for alteplase in 
acute ischaemic stroke lists minor neurological deficit or symptoms rapidly 
improving before start of infusion, and severe stroke as assessed clinically (e.g. 
NIHSS>25) and/or by appropriate imaging techniques, as contraindications.23  
Such patients do present to hospital services, however, and this places the 
physicians in a dilemma whether or not to offer treatment. Some experienced 
physicians treat such patients. For example, 12% of patients in the SITS-ISTR 
thrombolysis registry had a baseline NIHSS score in the range 0 to 4 and 4% had 
severe stroke with NIHSS >/=25. Many more patients were probably not included 
for thrombolysis treatment: a Canadian series found that 31% of patients were 
considered too mild or improving too rapidly for treatment.142 About 20-46% of 
patients that present in emergency departments do not receive thrombolytic 
therapy because of presence of mild or rapidly improving stroke.142,364-367  This 
cannot be justified on the basis of observed outcome. In dataset of 93517 
patients that suffered stroke, 29200 patients had mild or rapidly improving 
stroke. Of these, 28 % of the patients failed to go home on discharge. A similar 
proportion was unable to move around without assistance.368  Randomised trials 
to establish the existence or extent of benefit at extremes of baseline severity 
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may be difficult to conduct and delayed in execution. Other sources of evidence 
must be examined, and high quality registry data are the obvious choice. 
 
In the present non-randomised comparison of data held in VISTA, outcomes after 
thrombolysis were significantly better than in untreated comparators across 
baseline NIHSS scores 5 to 24. This significant association was lost only at 
extremes of b-NIHSS (i.e. 1-4 and >/=25). Although the point estimates for both 
adjusted and unadjusted odds ratios remain favourable in the extreme groups, 
they are lower than those observed at other levels of stroke severity and 
confidence intervals include the possibility of significant harm as well as benefit. 
In these extreme groups the small sample size seriously undermines the power of 
the statistical tests and with wide confidence intervals the true point estimate is 
not reliably indicated. There is a second statistical issue to consider, relating to 
the outcome measure that I used. By examining the full distribution of the 
modified Rankin scale I have used a test that is less dependent on case mix than 
dichotomisation:  I was able to use the same test for patients with mild stroke as 
severe stroke and still detected benefit. 
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Figure  0-4 7-4 Distribution of outcomes in patients with baseline severity NIHSS score of 0-4 
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Figure  0-5 7-5  Outcomes in patients having baseline severity NIHSS >/=25 
3.1 
1.7
1.6
3.4
7.8 
3.4 8.9 19 
7.8 21.9 14.1 
17.3 
43.8 
46.4 
TPA
Control
0 1 2 3 4 5 dead
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Even so, at the extremes of baseline severity, outcomes are generally so good or 
so poor that only a few mRS categories are well represented in the control 
groups.  Both the Cochran-Mantel-Haenszel test and the proportional odds 
estimations will be compromised if some categories are not contributing to the 
analysis:  effectively, the test of treatment effect will be diluted by the non-
contributing groups. For CMH this means that it becomes harder to reach 
statistical significance but for the proportional odds tests, the basic assumption 
has been breached:  the effect is not proportional. There is no easy solution to 
this problem:  if case mix is altered to deliver a significant result then patients 
with mild or severe stroke must be excluded – the solution used by the trials.  
Conversely if the outcome measure is varied according to the sample case mix 
(the sliding dichotomy approach discussed by Murray et al)283 then interpretation 
is rendered difficult:  is an odds ratio for achieving mRS 0 versus 1-6 equivalent 
to an odds ratio for achieving mRS 0-5 versus 6, i.e. is survival free from 
symptoms equivalent to survival at any cost? 
Here, I have chosen to present one analytic approach for all severities of stroke 
but I also illustrate the range of outcomes at extremes of severity. From these, 
although the summary statistics show only a non-significant but favourable 
trend, I can draw further conclusions. Amongst patients with severe stroke, 
there appears to be a trend towards benefit across almost all boundaries of mRS 
(Figure 7-5). Amongst patients with mild stroke, all boundaries except 0-1 versus 
2-6 show benefit but four of the mRS categories are entirely unrepresented 
(Figure 7-4).  Findings derived from the VISTA data show no reason to withhold 
treatment from either group of patients but are not in themselves sufficient 
evidence to justify treatment. 
My findings draw validity from the fact that the source clinical trials rigorously 
reported outcomes, and had strict on-site data verification procedures. 
However, the non-random allocation to treatment versus control groups is a 
significant weakness of our design. One cannot determine the degree and cause 
of exclusion of patients from our database; one can only consider factors known 
to associate with prognosis.  Further, information on variables like do-not-
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resuscitate order for severe strokes or complete list of concomitant treatments 
were not captured in the VISTA datasets. These could have introduced bias as 
well. 
I have adjusted statistically for factors that have a large influence on outcome. 
One can also ‘anchor’ the findings by comparison of treatment associations for 
patients with moderate stroke severity in our study against known treatment 
effects in comparable patients from randomised trials. For example, I found an 
OR for favourable outcome of 1.3 – 1.6 for patients with b-NIHSS 9-12 and 13-16;  
the comparable estimate from treatment within 3 hours of stroke onset in RCT 
would be 1.64 and for 3-4.5 hours would be 1.34.131 The estimates are 
comparable and perhaps conservative.  
The decay of benefit across later onset to treatment times raises a second issue. 
I do not have information on the onset to treatment delay for alteplase in the 
current analysis. Since the patients were permitted only one investigational drug 
in the participating VISTA trials, alteplase being used as standard of care, and 
since these trials were closely monitored by their sponsors, one can assume that 
patients were largely treated within 3 hours of stroke onset. I also assume that 
the onset-to-treatment time is comparable to those from the CASES and SITS-
MOST registries (155 (130-175) minutes and 140 (115-165) minutes [n=6483] 
respectively).146,369  Unfortunately, the latency between stroke onset and 
recording of initial severity differed between the treatment group (3.7 hours) 
and controls (5.1 hours) in the VISTA data. Severity is associated with onset to 
hospital arrival time: patients with more severe stroke present earlier.370 I 
adjusted the analyses for stroke severity but it is conceivable that residual bias 
persists. Such a bias would cause underestimation of true initial severity 
amongst the controls and through the baseline adjustment would have led to 
overestimate treatment effect. It will influence all patients across the severity 
range but may be less evident at extremes of severity: the NIHSS criterion will 
be responsible for discouraging use of alteplase, and so the proportion of 
patients who are treated with alteplase will fall at extremes of NIHSS.  
I lacked data on symptomatic haemorrhages, since patients who are not treated 
with thrombolysis generally do not undergo follow-up cerebral imaging for 
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routine detection of haemorrhagic transformation. However, the outcome 
measure that I used takes into account effects of haemorrhage or other adverse 
events on function. 
I adjusted for age and baseline severity as these are the established most 
important variables known to influence outcomes.265 I could not adjust for all - 
age, baseline NIHSS, prior use of antithrombotic drugs, previous stroke and atrial 
fibrillation together - as one of the contributing trial programs did not record 
pre-treatment medications. However I was able to undertake an adjusted 
analysis for the variables that were found significant in ECASS III, namely 
diabetes and prior stroke, and the estimates remained consistent.  
 
Some of the patients in this study received an investigational medicinal product. 
Each contributing trial has already tested for, and excluded, a significant 
interaction of that product with alteplase, both in vitro and in vivo. 
 
Individual patient data analyses from pooled randomised data131 could be the 
most informative method to assess the influence of baseline severity on outcome 
response to alteplase.  Unfortunately, the pooled data have a median baseline 
NIHSS of 11 and interquartile range of 7 to 16, that would weaken analyses to 
guide use of t-PA in the patients at the extremes of baseline NIHSS categories.  
Enrolment to extreme subgroups is generally limited.41 Pooja Khatri and 
colleagues have applied for funding to seek support a placebo-controlled trial of 
alteplase in patients suffering mild stroke. The trial would be called Potential of 
rtPA for Ischaemic Strokes with Mild Symptoms (PRISMS) (International Stroke 
Conference, Los Angeles, 2011).  
 
Analyses of VISTA data imply that patients at extremes of NIHSS scores recorded 
at baseline may still benefit from treatment but the supporting evidence 
remains weak. 
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8 Mismatch based delayed thrombolysis: a meta-
analysis 
8.1 Introduction 
Thrombolysis is the principal therapy for acute stroke patients in the early hours 
after symptom onset but has a short treatment window.122,129 In a meta-analysis 
of data derived from 2775 patients (pooled from the ATLANTIS, ECASS, and 
NINDS trials), there was a gradually diminishing benefit toward 6 hours from 
stroke onset [(odds ratio [OR]=2.8; 95% CI, 1.8 to 4.5) for 0 to 90 minutes, 1.6 
(95% CI, 1.1 to 2.2) for 91 to 180 minutes, 1.4 (95% CI, 1.1 to 1.9) for 181 to 270 
minutes, and 1.2 (95% CI, 0.9 to 1.5) for 271 to 360 minutes].130 Recently, the 
ECASS III trial (N=821; treatment vs. placebo 1:1; median time for administration 
of alteplase=3 hours, 59 minutes) confirmed clinical benefit within 4.5 hours of 
stroke onset. (OR=1.34; 95% CI, 1.02 to 1.76; P=0.04). 129 However, the wider 
95% CI at 6 hours (0.9 to 1.5 for 271 to 360 minutes in the meta-analysis130) have 
suggested that there may still be patients able to benefit from thrombolysis 
even beyond 4.5 hours. Conversely, others may be at increased risk from late 
treatment. The use of imaging approaches to select patients who have remaining 
salvageable tissue for delayed treatment has been proposed, most notably 
approaches that include magnetic resonance imaging (MRI) perfusion/diffusion 
“mismatch.”371,372  
 
Several trials have tested thrombolysis in patients selected after MRI. Even some 
centres have incorporated mismatch imaging and delayed thrombolysis into their 
routine clinical practice.45,373 Safety and efficacy data were reported for those 
patients that received thrombolysis beyond 3 hours of symptoms onset in a MR 
based selection paradigm (n=180) and also CT or MR based patients thrombolysis 
within 3 hours of their symptoms onset (714 and 316 respectively). These were 
pooled data from four German and one Spanish centres (N=1210). These data  
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showed that the rates of symptomatic haemorrhages or mortality were similar 10 
between the three groups (p=0.2 and 0.7 respectively).45 Symptomatic 
haemorrhages were significantly reduced in case of patients selected by MRI. 
(p=0.5).45  
 
I undertook a meta-analysis of data in the public domain to examine whether 
extension of the treatment window among patients selected according to the 
presence of mismatch can be recommended for routine clinical practice.  
 
8.2 Methods 
8.2.1 Selection of Trials 
I planned to include only relevant papers that described  findings of studies 
which either undertook prospective enrolment of consecutive stroke patients 
with mismatch profile for delayed thrombolysis [beyond 3 hours of stroke onset] 
or had studied mismatch-based, delayed thrombolysis in a randomised controlled 
design. I excluded case reports, case series and studies restricted to specific 
anatomical brain locations.374 I defined (1) mismatch profile as a perfusion 
volume at least 1.2 times that of the infarction core utilising the imaging 
methodology available with the concerned trial centre, (2) Symptomatic 
Intracerebral Haemorrhage (SICH) as radiologically confirmed cerebral 
haemorrhage in association with clinical worsening following thrombolytic 
therapy [within 36 hours in case of t-PA and 72 hours in case of desmoteplase]   
(3) reperfusion and/or recanalisation  according to the respective studies’ 
definitions (4) favourable clinical outcome as an NIHSS improvement of 8 points 
from the baseline or attainment of NIHSS of 0 or 1 and / or m-RS of 0 or 1 and 
(5) Mortality as death (m-RS 6) in the 90 days following thrombolytic therapy.  
 
I considered the rt-PA and desmoteplase together as both are thrombolytic 
agents.70,106-108,375,376  These differ in some features: desmoteplase lacks the 2nd 
                                               
10
 I published Chapter 8 in Stroke (Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, 
Hacke W, Lees KR. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke. 2010 
Jan;41(1):e25-33.) Permissions were obtained from Wolters Kluwer Health, License Number:  
2783790733330 
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kringle site in its molecular structure; does not need to be cleaved by plasmin; is 
active in its single chain form; has reduced neurotoxicity; limited passage 
through the blood-brain-barrier. 70,106-108,375,376   Desmoteplase has a theoretical 
advantage over rt-PA as it is almost non-functional if fibrin is absent. 70,106-
108,375,376   Alteplase is already a proven therapy for treating stroke patients in 
the early hours of its onset [NINDS, ECASS III]122,129 and doses that carry 
acceptable safety and efficacy have been identified109-111. Both desmoteplase 
and alteplase remain investigational for delayed thrombolysis. However, I 
undertook a sensitivity analyses for any differential effect between 
desmoteplase versus alteplase.  
 
Until the DIAS II study the identification of ischaemic penumbra was based on 
magnetic resonance perfusion-diffusion weighted imaging (MR PI-DWI) 
mismatch.111 For the first time, the DIAS II investigators were permitted to select 
patients based on the visual appreciation of mismatch on perfusion CT images as 
an alternative to MR perfusion studies depending upon the local expertise of the 
imaging centre. I included data from either method as reported in the DIAS II 
publication.111  
 
I included all trials that defined the mismatch profile as the perfusion volume 
being 1.2 times of the infarction core. I placed no restriction on the manner in 
which perfusion was measured in these trials. For example, in DIAS 2, the 
mismatch population was identified, based on either CT perfusion or MR 
perfusion according to centre preference. The determination of mismatch in 
DEFUSE and EPITHET was based on post-processed PWI data that included 
correction for arterial input and thresholding. In contrast, in the desmoteplase 
studies mismatch was determined “real time” without post-processing by the 
investigator using the “eyeball” technique.   
 
 
8.2.2 Endpoints 
Endpoints of interest for our meta-analysis were comparisons between 
thrombolysed and non-thrombolysed patients in (1) favourable outcome (2) 
reperfusion and/or recanalisation (3) mortality and (4) SICH.  I also examined 
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the rates of favourable versus unfavourable clinical outcome amongst 
successfully reperfused patients. 
 
8.2.3 Search 
I first searched the “Web of Knowledge” for ten broad terms [“Clinical Trial*”, 
“Prospective Study”, “stroke trial*”, “thrombolytic agent”,  “desmoteplase”,  
“tissue plasminogen activator”, “recanalisation in stroke”,  “ reperfusion 
therapy in stroke”, “penumbra in stroke”, and “mismatch hypotheses”]. Then, I 
refined the search by combining these with terms that underline the mismatch 
hypotheses and thrombolysis. My last search was undertaken on 19th December, 
2008. From review of the title and abstract I selected for further examination all 
relevant papers describing the original findings of studies that used the 
mismatch hypotheses and selected patients for thrombolysis despite delay 
beyond 3 hours of stroke onset. I checked whether any later paper or abstract 
offered supplemental data. Once selected, each paper was read completely and 
the relevant data extracted. I also searched the bibliography of each of these 
papers for further articles.  
 
  
8.2.4 Statistical Analysis 
For this meta-analysis, I retrieved “estimate(s) of effect” from the abstract(s). 
When relevant data were missing, I searched the full text and any 
supplementary articles.377 Primarily, I wished to analyse data derived from the 
patients with mismatch profile on an intention-to-treat (ITT) basis but where the 
ITT data were unavailable we accepted ‘per protocol’ data and described the 
underlying limitations. The comparisons were mainly planned between patients 
offered any dose of any thrombolytic agent against the corresponding placebo 
treated patients.377  
 
I performed sub-group analysis amongst patients who were treated with 
thrombolytics at doses approved or still under clinical investigation, i.e. 90µg/kg 
desmoteplase or 0.9mg/kg of rt-PA. Comparisons (summary estimates) are 
expressed as odds ratio [OR] and their 95% confidence interval [CI]. Whereas I 
applied both fixed [inverse-variance weighting method] and random methods to 
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calculate the summary estimate [adjusted OR (a-OR)],377 I report only the 
findings of  fixed method here. But, I have indicated the instances where the 
results have diverged. I assessed the heterogeneity using the tests statistics for 
the heterogeneity and I2 for inconsistency supported by the examination of 
L’Abbé’s plots.  
 
The analysis included data derived from those patients who were selected (or 
could have been selected) based on mismatch profile. In order to assess if 
favourable outcomes (clinical outcomes at day 90) were more common amongst 
the patients who had successful reperfusion, I retrieved data on 242 patients for 
whom the reperfusion findings were available [the DIAS I trial109 (N=97), the 
DEDAS trial110 (N=34), the EPITHET trial181 (N=77; “Good Neurological Outcome” 
with reperfusion : 30 and without reperfusion : 47 (for mismatch patients only) 
and the DEFUSE trial183 (N=34; mismatch  with early reperfusion: 18 patients, 
mismatch without early reperfusion: 16 patients)]. Corresponding information 
was not reported in the DIAS II trial.111 Similarly, in order to answer if favourable 
clinical outcome occurred more frequently in the thrombolysed group of 
patients, information on 410 patients was available [DIAS I trial (N= 102), DIAS II 
trial (186), DEDAS trial (N=37) and the EPITHET trial (N=85; mismatch patients 
with/without “Good Neurological Outcome” in the thrombolysis group: 42; and 
placebo group: 43)] in which the patients were thrombolysed with any 
thrombolytic agent at any dosage. Next, to answer if reperfusion or 
recanalisation occurred more frequently amongst those who were thrombolysed, 
I retrieved data on 211 patients who received thrombolytic therapy at any dose 
[DIAS I: 97 patients; DEDAS (ITT): 37 patients, [Target Population, (TP) = 23 
patients]; EPITHET: 77 patients]. To assess mortality between thrombolysed and 
non-thrombolysed patients, I extracted data on 410 patients [DIAS I=102, DIAS 
II=186, DEDAS= 37, EPITHET = 85 (mismatch only)]. To assess SICH between 
thrombolysed and non-thrombolysed patients, I extracted data on 405 patients 
[DIAS I=102, DIAS II=186, DEDAS= 37, EPITHET =80 (mismatch group only)]. Owing 
to mathematical difficulties involved in calculating OR when the numerator is 
zero, I combined the DEDAS data with DIAS I data for mortality analysis.  
 
I undertook sensitivity (subgroup) analyses in which I compared the data after 
excluding the data from doses of desmoteplase that have been abandoned for 
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further evaluation. I also analysed differences in clinical outcome between the 
patients who were thrombolysed within 3-6 hours of stroke onset versus beyond 
6 hours. Finally, I compared and contrasted the attributes of the studies and 
assessed their quality based on the manner in which patients were enrolled and 
the resulting baseline characteristics.  
 
 
 
8.3 Results 
8.3.1 Literature search 
The literature search (Table 1) led to 13 citations on the DEFUSE trial (6 
articles),183,378-385 two on the DEDAS trial (1 article),110 6 on the DIAS trial,109 9 on 
the EPITHET trial (three articles)181,386-388 and 2 on DIAS II(1 article).111,389 The 
information on 502 patients was obtained from the five main articles109-111,181,183 
describing the relevant trials [(DIAS (104 patients), DIAS II(186 patients), DEDAS 
(37 patients), DEFUSE (74 patients) and EPITHET (101 patients)] and the data 
corresponding to the patients with mismatch profile were retrieved for 
subsequent analysis.  
 
8.3.2 Comparative analysis of the “Mismatch” Trials: 
I compared the attributes that differed between the trials to highlight the 
underlying heterogeneity in the manner the selected trials were conducted DIAS 
II enrolled the least severely affected stroke patients (median NIHSS 9) and 
EPITHET the most severe (median NIHSS 14 in the treatment arm and 10 in the 
placebo arm). Median baseline NIHSS scores were 11.5 and 12 respectively in the 
DEFUSE and DIAS I trials.  I also compared the time since stroke onset until 
thrombolysis [OTT] and we assessed qualitatively the proportion of patients 
treated in each trial after 4.5 hours. Detailed analysis of OTT could not be 
undertaken without raw data. 
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Table  8-1  Characteristics of the trials included for the meta-analysis 
 
Attributes DIAS I109 DIAS II111 DEFUSE183 DEDAS110 EPITHET181 
Drug  Desmoteplase Desmoteplase t-PA Desmoteplase t-PA 
Doses  Fixed doses: 25mg, 37.5 
mg, 50 mg and later 
weight adjusted doses of 
62.5µg/kg, 90 µg/kg and 
125 µg/kg. 
90 µg/kg and 125µg/kg; 
permissible maximal 
dose: equivalent to 100 
kg. 
0.9mg/kg; 10% dose bolus, rest over 
one hour; no upper limit to dose. 
90µg/kg and 125 µg/kg; 
no upper limit to the 
maximal dose. 
0.9mg/kg;10% dose bolus, rest 
in 1 hour; permissible upper 
limit 90mg. 
Age (years) 18 to 85  18 to 85 18 + 18 to 85 18+ 
NIHSS 
Eligibility 
criteria  
8 TO 20 4 TO 24 ≥5 4 T0 20 ≥5 
Method used 
to evaluate 
mismatch 
Mean Transit Time 
(MTT) 
CT&MRI; selection 
based on visual 
impression of the 
Tmax MTT; based on visual 
impression 
Tmax 
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investigator. 
Primary 
Endpoints of 
the study  
Reperfusion† in 4 to 8 
hours post treatment and 
clinical outcome at day 
90.  
8 points improvement 
or score of 0-1 on the 
NIHSS scale; a score of 
0 to 2 on mRS and BI 
score of 75-100. 
8 points improvement or score of 0-1 
on the NIHSS scale; a score of 0 to 2 
on mRS and BI score of 75-100. 
Reperfusion† in 4 to 8 
hours post treatment and 
clinical outcome at day 
90. 
Infarct growth attenuation in 
mismatch patients between 
alteplase and placebo 
analysed. 
SICH 
definitions 
Any ICH associated with 
a worsening of 4 points 
or more on the NIHSS 
and confirmed by CT 
within 72 hours of 
treatment. 
ICH confirmed by 
“appropriate imaging 
tool and clinical 
worsening of 4 or more 
points on NIHSS at 72 
hours 
Any degree of brain haemorrhage 
identified along with worsening on 
NIHSS greater than or equal to 2 with 
in 36 hours of t-PA [major SICH if 
NIHSS deterioration is 2 or 3 points 
on NIHSS and major SICH if the 
deterioration on NIHSS is 4 or more] 
Any ICH associated with 
a worsening of 4 points 
or more on the NIHSS 
and confirmed by CT 
within 72 hours of 
treatment 
(As per SITS-MOST criterion) 
Clinical deterioration of 4 or 
more on NIHSS scale within 
36 hours of thrombolysis, 
parenchymal haemorrhage of 
grade 2 on CT scans. 
 
 
Legend: †Reperfusion defined as either 30% reduction of MTT volume of abnormality or 2 points improvement on the adapted Thrombolysis In Myocardial Infarction 
(TIMI) grading scheme using MRA. 
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Table  8-2: Baseline characteristics of Onset-to-Treatment time in the Mismatch Trials  
 
Clinical 
Trial 
                                 OTT data 
DIAS II • 43 patients thrombolysed in 3-6 hours against 26 in placebo arm. 
• 80 patients thrombolysed in 6-9 hours against 37 in placebo arm.  
DEDAS • OTT (median) for treatment group (n=29): 7 h 29 min [Range: 3 h 42 min 
– 9 h 28 min] 
• OTT (median) for placebo group (n=8): 7 h 23 min [Range:  3 h 40 sec – 8 
h 36 min].  
DIAS I • OTT (median) for treatment group (n=75) : 5 h 24 min  
• OTT (median) for placebo group (n=27) : 5 h 25 min 
• OTT (median) for total population : 5 h 25 min.  
EPITHET • OTT (mean) for the treatment group: 4 h 57 min [standard deviation (SD) 
= 42 min]  
• OTT (mean) for the placebo group: 4 hours 54 minutes [SD=50 min]  
• OTT (mean) mismatch profile group: 4 h 53 min. SD= 45 minute 
• OTT (mean) mismatch profile placebo group : 4h 51 min, SD = 51 min. 
 
 
 
8.3.3 Statistical Analyses 
 
8.3.3.1 Did reperfusion or recanalisation occur more frequently in the 
patients who were thrombolysed?  
The data from 211 patients showed greater individual odds for reperfusion 
and/or recanalisation amongst the patients who received thrombolytic therapy 
[statistically significant in the DIAS I trial (OR = 4.1, 95% CI = 1.3-15.2) the 
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EPITHET trial (OR = 3.7, 95% CI = 1.3 – 10.8) but non-significant in DEDAS trial 
[(OR=0.9, 95% CI =0.1-6.9]. Here, the combined data gave a greater adjusted 
odds for reperfusion / recanalisation for the patients who had thrombolytic 
therapy (at any dosage) [a-OR: 3.0; 95% CI = 1.6-5.8; P<0.05, P for heterogeneity 
=0.26 and I2: 25.7%]   
 
I repeated the analysis after excluding desmoteplase doses that have been 
abandoned for clinical development:  the sub-analysis restricted to 
desmoteplase 90 µg/kg or rt-PA gave a-OR=2.28; 95%CI =0.7-7.3, P=0.165 
[Random Method] and a-OR=2.65, 95%CI = 1.3-5.5, P=0.007 [Fixed Method], P for 
clinical heterogeneity =0.13 and I2: 50.5%]. I examined the underlying 
heterogeneity by L’Abbé plot. 
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Figure  8-1Did reperfusion or recanalisation occur more frequently in patients who were 
thrombolysed?  
Findings are shown from the fixed-method analysis of combined data (a) after exclusion of 
abandoned doses by fixed (b) and random-method (c) analyses. 
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Figure  8-2 Did reperfusion or recanalisation occur more frequently in patients who were thrombolysed?  
L’Abbé plot shows (a) the complete data set and (b) the abandoned doses excluded for heterogeneity. The circle size denotes the sample size; DIAS, grey circles; DEDAS 
open circles; and EPITHET, black circles. 
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8.3.3.2 Are favourable outcomes more common in the patients who had 
reperfusion?  
The individual odds for favourable clinical outcome in the four studies reporting 
this endpoint were greater in the patients who had reperfusion as compared to 
those who did not reperfuse (DIAS I : OR = 3.4, 95% CI = 1.3 – 8.8;  DEDAS : OR = 
9.6, 95% CI = 1.5 – 64.6; EPITHET : OR=7.2, 95% CI :2.3 to 23.2; DEFUSE : OR = 
5.4, 95% CI = 0.94 – 38.1). For all trials combined, the adjusted odds were 
greater for the patients who had successful reperfusion as compared to those 
who did not [a-OR = 5.2, 95% CI = 3 to 9.1], P for clinical heterogeneity = 0.60, I2 
:0%]  
 
In a sensitivity analyses in which the DEFUSE trial data were excluded [as the 
DEFUSE was (unlike others) a non-randomised prospectively conducted study], 
the a-OR remained greater amongst patients with successful reperfusion (a-OR = 
5.2, 95% CI = 2.8 to 9.5, P =0.00; heterogeneity statistics p: 0.4 and I2:0% )  
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Figure  8-3 Are favourable outcomes more common in patients who underwent reperfusion?  
Findings are shown from the fixed-method analysis of combined data (a) and after excluding 
DEFUSE data (b). 
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8.3.3.3 Did favourable clinical outcome occur more frequently in the 
thrombolysed group of patients?   
With the exception of DIAS II, all trials had reported non-significantly improved 
odds of favourable clinical outcome in the thrombolysis group of patients. (DIAS 
I: OR = 2.2, 95% CI = 0.7 – 7.44; DEDAS (19): OR = 2.4, 95% CI = 0.4 – 28.0; 
EPITHET: OR = 1.7, 95% CI= 0.7-4.4; DIAS II: OR=0.8, 95% CI =0.4-1.6). The 
combined data analysis failed to show significant benefit (a-OR = 1.28 95% CI = 
0.84-1.97), P for clinical heterogeneity = 0.28 and I2=20.9%. On excluding the 
DIAS II data, a-OR: 1.96, 95%CI: 1.06-3.63 and for clinical heterogeneity the I2:0% 
and P=0.89.    
 
I repeated the analysis after excluding desmoteplase doses that have been 
abandoned for clinical development: with 90ug/kg desmoteplase and rt-PA 0.9 
mg/kg data alone, I found a-OR = 1.4; 95% CI = 0.9-2.3, P=0.16; for clinical 
heterogeneity p=0.56 and, I2:0%.On excluding the DIAS II data, OR=1.88, 95% CI: 
0.95-3.72 and heterogeneity statistics: I2= 0%; and p=0.69. L’Abbé’s plots were 
examined for the underlying heterogeneity in these analyses. 
 
Under sensitivity analysis, no differential effect of desmoteplase versus alteplase 
was found, with the ratio of OR=. 0.7 [95%CI: 0.24 to 1.920; P: 0.46]. 
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Figure  8-4 Did a favourable clinical outcome occur more frequently in the thrombolysed 
group of patients? 
Findings are shown from the fixed method analysis of combined data (a), after exclusion of DIAS II 
data (b), and after exclusion of abandoned doses (c). 
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Figure  8-5 Did a favourable clinical outcome occur more frequently in the thrombolysed 
group of patients?  
 
L’Abbé plot examining heterogeneity in the analysis (a) for complete data, (b) for DIAS II data 
excluded, (c) for complete data but abandoned doses excluded, and (d) for DIAS II data and 
abandoned-dose data excluded. The size of the square denotes the sample size. 1 indicates 
DEDAS; 2, DIAS I; 3, EPITHET; and 4, DIAS II (black rectangle). 
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8.3.3.4 Was there a greater probability of mortality in thrombolysed patients 
compared to those not thrombolysed?   
Here, the individual odds for mortality were non-significant in the thrombolysis 
group. [DIAS II:OR= 2.4, 95% CI =0.7-10.1) ; DIAS I: OR= 3.6, 95%CI = 0.5-
161.3;EPITHET trials (OR: 2.7, 95% CI: 0.8-10.9) and the DEDAS  trial (OR: 0.5, 
95% CI=0.0-34.9)]. The combined-data analysis found a significant increase in 
mortality in the thrombolysis group of patients compared to the placebo group 
[a-OR =2.4, 95% CI =1.2-4.9; P=0.02 and P for heterogeneity =0.67 and I2:0%]. 
 
Repeating the analysis after excluding data from abandoned desmoteplase 
doses, i.e. restricting the analysis to patients treated with 90 µg/kg of 
desmoteplase or 0.9 mg/kg rt-PA, then a-OR= 1.6 [ 95%CI: 0.7 - 3.7 ], P = 0.28 ; 
P for heterogeneity = 0.56 and I2:0%. 
 
Under sensitivity analysis, no differential effect of desmoteplase versus alteplase 
was found, with the ratio of OR=. 0.8 [95%CI: 0.2 to 3.5; P:0.8] 
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Figure  8-6 Was there a greater probability of mortality in thrombolysed patients compared 
with those not thrombolysed?  
 
 
Findings are shown from the fixed-method analysis of combined data (a) and after exclusion of the 
abandoned-dose data (b). 
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8.3.3.5 Was there a greater probability of SICH in thrombolysed patients 
compared to those not thrombolysed?  
The individual odds for SICH were non-significant for the combined data (DIAS I: 
OR=7.9, 95%CI =0.7-infinity; DIAS II: OR=5.9, 95%CI: 0.5-infinity; EPITHET: OR= 
152.6, 95%CI: 15.9-infinity) but the combined odds for SICH were significantly 
greater for the group that underwent thrombolytic therapy (a-OR: 24.7, 95%CI : 
5.2-118.2. Heterogeneity statistics: I2:35.4%, and P=0.2]. On combining data 
from DEDAS with DIAS I, the findings remained non-significant for the individual 
odds (DIAS I + DEDAS: OR=7.1, 95%CI=0.7-infinity) but were significant for the 
combined analysis [a-OR: 6.5, 95%CI: 1.2-35.4 and for clinical heterogeneity 
p=1.0 and I2:0%]  
 
Repeating the analysis by excluding the data of abandoned doses, the  findings 
were non-significant both for individual odds (DIAS I+DEDAS OR=3.7, 95%CI: 0.03-
infinity; DIAS II: OR=5.7, 95%CI: 0.2-infinity; EPITHET: OR=6.5, 95%CI: 0.4-
infinity)  and by combining it with the DIAS I data (a-OR 5.4, 95%CI  0.9-31.8), P 
for heterogeneity = 0.97 and I2:0%  but attained a marginal significance of the 
adjusted odds derived by excluding DEDAS trial (a-OR: 6, 95%CI 1.00-35.8; 
heterogeneity statistics: p:1 and I2 : 0%). 
 
There occurred no SICH in placebo arms and therefore a sensitivity analysis to 
assess any differential effect of desmoteplase versus alteplase could not be 
undertaken. 
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Figure  8-7 Was there a greater probability of SICH in thrombolysed patients compared with 
those not thrombolysed?  
Findings are shown from the fixed-method analysis for all studies combined but with DEDAS data 
excluded (a), DEDAS combined with DIAS I data (b), and after exclusion of the abandoned-dose 
data (c). 
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8.3.3.6 Were there better clinical findings (outcomes or reperfusion) if 
treatment commenced within 3 to 6 hours versus 6 to 9 hours?  
 
Limited data were available to examine OTT and neither the DIAS I (20) nor DIAS II 
individually suggested significantly greater odds (DIAS I: OR= 1.07, 95%CI = 0.4-
2.9, P= 0.9; DIAS II: OR= 0.8, 95%CI: 0.4- 1.8, P= 0.7). When combined, the a-OR 
= 0.9, 95%CI: 0.5- 1.7, p=0.8) 
 
 
 
 
 
Figure  8-8:  Were there better clinical findings (outcomes or reperfusion) when treatment 
was commenced within 3 to 6 hours vs. 6 to 9 hours? 
 
 
8.3.4 Analysis of Mortality 
In DIAS I trial, one placebo and two desmoteplase deaths occurred due to cardiac 
causes. In the DIAS II trial, only one of three deaths in the 90 µg/kg group and 
three of 14 deaths in125 ug/kg were considered related to the trial medication. 
In the DEDAS trial, the sole death in the 90 µg/kg groups was due to aspiration 
pneumonia while that in the 125 µg/kg groups was due to evolving neurological 
deterioration of a left MCA infarct, leading to pneumonia.  
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8.4 Discussion  
I undertook a meta-analysis of all previous studies that evaluated the principle 
of physiological selection for delayed thrombolysis, based on the presence of 
potentially viable tissue in the ischaemic penumbra.29,390,391 These trials utilised 
the mismatch hypothesis using either MRI (perfusion/diffusion mismatch) or CTP 
(perfusion/cerebral blood volume mismatch) as a signature of the putative 
penumbra.109-111,181,183 Apart from the recent DIAS-II trial111, these trials had 
supported the physiological basis of the mismatch concept. The disappointing 
findings of the DIAS II trial have been attributed to limitations of the study and 
to chance.111,389 To test for consistency, I undertook a meta-analysis of the 
studies that studied the mismatch hypothesis to select and thrombolyse patients 
despite delays beyond 3 hours. Five trials (DIAS I, DIAS II, EPITHET, DEFUSE and 
DEDAS) 109-111,181,183 were available for inclusion.  
 
It was a priori decided that those studies would be excluded which did not 
undertake prospective enrolment of consecutive stroke patients with mismatch 
profile (for treatment in delayed time window, i.e., beyond 3 hours of stroke 
onset) or did not study mismatch-based delayed thrombolysis in a randomised 
controlled design. Hence, I did not include the study by Schellinger et al45 as it 
was based on pooled data (and not a pre-planned prospective trial) from 5 
different centres and lacked in a control arm that would have prevented 
calculation of odds ratio in the absence of a denominator. DEFUSE trial was 
included in this meta-analysis because it was a prospectively conducted clinical 
trial. Further, it reported reperfusion data that could be considered for the 
analysis.   
 
The results from this metaanalysis indicate that reperfusion and/or 
recanalisation is more common with thrombolysis when all doses are considered 
together but the significance is lost with the exclusion of data on abandoned 
doses of desmoteplase that reduced the power of this analysis through effects on 
sample size.  
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Furthermore, favourable clinical outcome is more common amongst patients 
with successful reperfusion of the ischaemic parenchyma, despite delays beyond 
three hours from stroke onset. This conclusion is not influenced by inclusion of 
the non-randomised DEFUSE trial data. The DIAS II trial did not report 
reperfusion findings.   
 
However, I did not find evidence from the current analysis that favourable 
clinical outcome was significantly improved in the group that underwent 
thrombolysis. Neither did I find a significant benefit if I excluded doses of 
desmoteplase that have been abandoned for clinical development. The 
confidence interval around the estimate of effect remains wide and would be 
consistent with a doubling of odds for favourable outcome, though in this 
respect DIAS-II suggests that the likely upper limit may be 1.5.  Even so, odds of 
1.5 remain greater than those achieved in unselected patients treated with rt-PA 
in the ECASS-III trial and have been regarded as sufficient to influence national 
and European stroke treatment guidelines (SIGN or ESO )392.   
 
Late treatment even among selected patients may carry some risk. I found a 
marginally significant increase in the odds of death among all treated patients, 
with a point estimate of 2.4. When I restricted the analysis to rt-PA 0.9 mg/kg 
and to the dose of desmoteplase that remains under development (90 µg/kg), 
the odds ratio for mortality fell to 1.6 and the risk was not significant. Higher 
doses of desmoteplase were clearly linked to excessive SICH and were 
abandoned for this reason. The current analysis does not take into account the 
attributed cause of death.  Many deaths in DIAS-II and in EPITHET were 
considered unrelated to treatment. The attribution may be important for 
understanding of the mechanism of effect but caution is required when drawing 
conclusions from subjective assessments such as these.  Treatment failure can 
contribute to late death, just as unrecognised excitotoxic damage may represent 
a potential mechanism. Regardless, if mortality is increased, this may be 
mediated via haemorrhagic transformation.  
 
Despite lack of significance in the individual odds for the SICH in the patients 
given thrombolytic therapy, the adjusted OR indicates a statistically significant 
increase in SICH after delayed thrombolysis. Similarly, an increased risk of sICH 
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has long been recognised for time-based tPA in the established clinical windows, 
but this is offset by the improved clinical outcomes in the treated patients. On 
excluding doses of desmoteplase that have been abandoned for clinical 
development, the adjusted odds for SICH again lost significance.  
 
Caution is required in interpreting these post-hoc sub-group analyses. Although 
the inclusion of data from all doses may give a falsely pessimistic view of the 
risk/benefit profile after mismatch-based thrombolysis, post-hoc exclusion of 
doses that have been abandoned in clinical development is a data-driven 
decision and raises statistical concerns of bias that can only be assuaged by 
further prospective trials. 
 
I find no evidence that relatively earlier (3-6h) versus later (6-9h) treatment 
influence my findings.  This is of particular relevance, since ECASS-III has 
recently shown unselected patients benefit from alteplase given within 4.5 h of 
stroke onset, and a small proportion of patients in the mismatch trials would 
now be considered eligible for such treatment:  I cannot exclude the possibility 
that some of the potential benefit amongst mismatch patients may be time-
dependent but it appears unlikely that this is sufficient to explain all effects.  
 
Now that ECASS-III results are known, a further meta-analysis using individual 
patient data from the trials studied here should be undertaken to assess clinical 
and radiological outcomes for the patients who were thrombolysed beyond 4.5 
hours of the stroke onset. Similarly, an additional analysis comparing outcomes 
in patients with mismatch versus without mismatch is desirable but was beyond 
the scope of our meta-analysis. 
 
The current meta-analysis included data from five different trials of which 
DEFUSE could be considered only in the analysis of favourable clinical outcome 
amongst patients with reperfusion vs. no-reperfusion. DIAS II did not report the 
reperfusion findings and had to be excluded where these data were needed. The 
L’Abbe plot393,394 suggests that DIAS II contributes to the heterogeneity in the 
combined analysis of favourable outcomes in all thrombolysed patients, and the 
DEDAS trial to the analysis of reperfusion and recanalisation in patients 
thrombolysed with the abandoned doses excluded. Both these sources of 
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heterogeneity appeared to affect the results by virtue of the effects of sample 
size on the power of a study. 
 
We know that the number needed to treat to achieve enhanced favourable 
outcome with alteplase may be as few as seven within 3h but that this has risen 
by 3-4.5 h to approximately fourteen. When treatment with alteplase is started 
between 4.5 hours and 6 hours OTT the number needed to treat rises to 25. 
Hence, the challenge is to establish whether any patients benefit or donot based 
on multimodal imaging approaches and delayed time wondow. The use of either 
MR imaging to identify perfusion/diffusion mismatch or a CT-based alternative is 
attractive. It is clear from current data that delayed thrombolysis amongst 
patients selected according to mismatch imaging is associated with increased 
reperfusion and/or recanalisation and that recanalisation and/or reperfusion is 
associated with improved outcomes. At present, whilst the data remain 
consistent with improved functional outcome from delayed thrombolysis 
amongst mismatch patients, statistically significant benefit on functional 
outcomes has not been confirmed. Although the pooled results suggest that 
mortality may be higher, the retention of excessive doses of desmoteplase in the 
analysis is likely to lead to overestimation of any risk.   
 
It should be noted that existing methods for defining mismatch may be optimised 
in future resulting in greater power of the mismatch-based thrombolysis studies. 
For example, in this analysis, I considered 1.2 as the cut-off for defining a 
mismatch profile. However, a post-hoc analysis of the DEFUSE study has recently 
shown that highest sensitivity and specificity occur at a mismatch ratio of 2.6; 
suggesting that the previous studies were probably underpowered and lacked a 
sufficiently rigorous definition for mismatch ratio.182 Further, the 2-second 
threshold for T max is likely also suboptimal, as a post-hoc analysis of DEFUSE 
data have shown a significantly better correlation between infarct growth and 
penumbra salvage volume for PWI lesions defined by Tmax > 6 seconds.383 The 
EPITHET investigators have reported similar findings.386 It is now clear that both 
trials included significant volumes of benign oligemia in their mismatch 
assessments. Recently, automated online analysis of MR mismatch has been 
described that facilitates the rapid selection for delayed treatment. In summary, 
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the continued refinement in the definitions of different perfusion parameters 
would result in better choice of the best measure of perfusion [T max, TTP, 
MTT, CBV or CBF] and correction for arterial input functions.  
 
Thus, the definitions used in the published trials to date have been generous, 
including many patients who had limited penumbral tissue and limited prospect 
of clinical improvement in response to thrombolysis. The recently formed Stroke 
Imaging Repository (STIR) collaboration has initiated a detailed examination of 
this topic.395 The diversity of mismatch definitions and large number of 
investigators involved in these studies weaken conclusions about the potential 
value of mismatch in future clinical management of patients with stroke.198,199  
However, these weaknesses do not extend to our conclusions about the status of 
existing evidence for use of thrombolysis amongst mismatch patients:  patients 
were selected according to the best intentions of the investigators under 
protocols which were state of the art when written, though they have already 
been overtaken.  Prospective phase III trials are required to test whether 
thrombolysis is associated with a favourable risk/benefit ratio when used under 
modified circumstances.  In Australia, the Extending the Time for Thrombolysis 
in Emergency Neurological Deficits (EXTEND) trial,396 which will use a phase III 
design and randomisation of patients 4.5-9 hours alteplase or placebo, using 
automated mismatch selection, will test this hypothesis.  
 
These data show that delayed thrombolysis amongst patients selected according 
to mismatch imaging is associated with increased reperfusion/recanalisation and 
that recanalisation/reperfusion is associated with improved outcomes. But, not 
all patients that receive alteplase improve in their outcomes. From an analysis 
of combined DEFUSE and EPITHET dataset, treatment effect of t-PA was shown 
to be greater amongst those patients that had vessel occlusion at baseline.46,397  
Further, in a meta-analysis, Rha and Saver have also shown strong  association of 
recanalisation with improved outcomes and reduced mortality in a meta-
analysis.151  It appears logical that the target of thrombolytic therapy should be 
to achieve recanalisation. Hence trialists now aim to select patients with  
“Vessel occlusion or high-grade stenosis in proximal cerebral arteries” for 
treatment until 9 hours of symptoms onset.46    
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Meantime, while the concept of selection of patients based on their individual 
pathophysiology rather than a rigid time window remains attractive, delayed 
treatment according to mismatch selection cannot be recommended as part of 
routine care until or unless further trials show benefit. 
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Conclusions and future directions 
    
 
 
9  Conclusions and future directions 
Thrombolytic therapy is the therapy of proven efficacy for the treatment of 
acute ischaemic stroke.131 However, it has not yet made a significant public 
health impact; very few patients receive this therapy.228  Many physicians fail to 
administer t-PA because they adhere strictly to the stroke guidelines and fear 
that any deviation would increase the risk of haemorrhage. It is known that most 
of the exclusion criteria are based not on negative evidence (showing harm from 
t-PA use), but on absence of data from the original trials. Many of the exclusions 
were based on expert opinion which was originally framed to assist recruitment 
of a homogeneous patient population for the trial. Soon after the NINDS trial was 
published, showing better outcomes in a 3 hour time window, the drug was 
approved in the USA.24 The European Medicines Agency was reluctant to approve 
its use  (because ECASS I, ATLANTIS and ECASS II failed to confirm the NINDS 
findings), but later did, subject to the fulfilment of conditions that the SITS-
MOST study and ECASS III trials would be conducted by the sponsors.23 While 
SITS-MOST showed that the outcomes from the t-PA use in 3-hours window were 
similar to the pooled RCT data (and can also be used by less experienced 
centres), the ECASS-III trial showed that t-PA use improved outcomes even in a 
3-4.5 hour time window.129,146,147 After it was shown that t-PA is efficacious until 
a 4.5 hours’ time window, there was a felt need to answer other exclusions that 
were listed in the EMEA document.23  
 
The purpose of this thesis was to examine those exclusion criteria, and 
therefore, I decided to examine the following questions: (a) Whether the benefit 
from t-PA use extends to those older than 80 years? (b) Whether those suffering 
from concomitant diabetes and previous stroke have improved outcomes after 
the use of alteplase? (c) Whether the patients having a mild stroke or a severe 
stroke should be treated with alteplase? In addition, I also planned to examine 
whether use of thrombolytic therapy beyond 3 hours and based on mismatch 
criteria could be recommended for routine clinical practice?   
 
So in Chapter 3, I examine Virtual International Stroke Trials Archive (VISTA) 
data to test whether current European recommendation suggesting exclusion of 
    
 
 
elderly patients (older than 80 years) from thrombolysis for acute ischaemic 
stroke is justified. Employing non-randomised controlled comparison of 
outcomes, I show better outcomes amongst all patients (P < 0.0001; OR, 1.39; 
95% CI, 1.26 to 1.54), young patients (P < 0.0001; OR, 1.42; 95% CI, 1.26 to 1.59) 
and the elderly patients (P = 0.002; OR, 1.34; 95% CI, 1.05 to 1.70). Odds Ratios 
are consistent across all age deciles > 30 years. Outcomes assessed by National 
Institutes of Health Scale (NIHSS) score and dichotomised modified Rankin Scale 
score are consistently similar.  
 
In Chapter 4, I compare thrombolysed patients in Safe Implementation of 
Thrombolysis in Stroke International Stroke Thrombolysis Register (SITS-ISTR) 
with VISTA non-thrombolysed patients ("comparators" or "controls") and test 
exactly similar question as in Chapter 3.  Distribution of scores on modified 
Rankin scale are better amongst all thrombolysis patients than controls (odds 
ratio 1.6, 95% confidence interval 1.5 to 1.7; Cochran-Mantel-Haenszel P<0.001). 
Association occurs independently amongst patients aged ≤80 (0R 1.6, 95%CI1.5 to 
1.7; P<0.001; n=25,789) and in those aged >80 (OR 1.4, 95% CI 1.3 to 1.6; 
P<0.001; n=3439). Odds ratios are consistent across all 10 year age ranges above 
30, and benefit is significant from age 41 to 90; dichotomised outcomes (score 
on modified Rankin scale 0-1 v 2-6; 0-2 v 3-6; and 6 (death) versus rest) are 
consistent with the results of ordinal analysis. These findings are consistent with 
results from VISTA reported in Chapter 3. Age alone should not be a criterion for 
excluding patients from receiving thrombolytic therapy. 
 
In Chapter 5, I employ VISTA data to examine whether patients having diabetes 
and previous stroke have improved outcomes from use of alteplase in acute 
ischaemic stroke. Employing a non-randomised controlled comparison, I show 
that the functional outcomes are better for thrombolysed patients versus 
nonthrombolysed comparators amongst non-diabetic (P < 0.0001; OR 1.4 [95% CI 
1.3-1.6]) and diabetic (P = 0.1; OR 1.3 [95% CI1.05-1.6]) patients. Similarly, 
outcomes are better for thrombolysed versus nonthrombolysed patients who 
have not had a prior stroke (P < 0.0001; OR 1.4 [95% CI1.2-1.6]) and those who 
have (P = 0.02; OR 1.3 [95% CI1.04-1.6]). There is no interaction of diabetes and 
prior stroke with treatment (P = 0.8). Neurological outcomes (NIHSS) are 
consistent with functional outcomes (mRS).  
    
 
 
 
In Chapter 6, I undertake a non-randomised controlled comparison of SITS-ISTR 
data with VISTA controls and examine whether patients having diabetes and 
previous stroke have improved outcomes from use of alteplase in acute 
ischaemic stroke. I show that adjusted mRS outcomes are better for 
thrombolysed versus non-thrombolysed comparators amongst patients with 
diabetes mellitus (OR 1.45[95% CI1.30-1.62], N=5354), previous stroke (OR 
1.55[95% CI1.40-1.72], N=4986), or concomitant diabetes mellitus and previous 
stroke (OR 1.23 [95% CI 0.996-1.52], P=0.05, N=1136), all CMH p<0.0001. These 
are comparable to outcomes between thrombolysed and non-thrombolysed 
comparators amongst patients suffering neither diabetes mellitus nor previous 
stroke: OR=1.53(95%CI 1.42-1.63), p<0.0001, N=19339. There are no interaction 
between diabetes mellitus and previous stroke with alteplase treatment (t-
PA*DM*PS, p=0.5). Present data supports results obtained from the analyses of 
VISTA data in chapter 5. There is no statistical evidence to recommend exclusion 
of patients with diabetes and previous stroke from receiving alteplase.  
 
In Chapter 7, I examine VISTA data to test whether exclusion of patients having a 
mild or severe stroke at baseline would be justified. Stratifying baseline stroke 
severity for quintiles of NIHSS scores, I observe that there are significant 
associations of use of alteplase with improved outcomes for baseline NIHSS 
levels from 5 to 24 (p<0.05). This association lose significance for baseline NIHSS 
categories 1 to 4 (P = 0.8; OR, 1.1; 95% CI, 0.3-4.4; N = 8/161) or ≥ 25 (P = 0.08; 
OR, 1.1; 95% CI, 0.7-1.9; N = 64/179) when sample sizes are small and 
confidence interval wide. These findings fail to provide robust evidence to 
support the use of alteplase in the mild or severe stroke patients, though 
potential for benefit appears likely. 
 
In Chapter 8, I present a meta-analysis of trials that investigated mismatch 
criteria for patients’ selection to examine whether present evidence supports 
delayed thrombolysis amongst patients selected according to mismatch criteria. 
I collate outcome data for patients who were enrolled after 3 hours of stroke 
onset in thrombolysis trials and had mismatch on pre-treatment imaging. I 
compare favourable outcome, reperfusion and/or recanalisation, mortality, and 
symptomatic intracerebral haemorrhage between the thrombolysed and non-
    
 
 
thrombolysed groups of patients and the probability of a favourable outcome 
among patients with successful reperfusion and clinical findings for 3 to 6 versus 
6 to 9 hours from post stroke onset. I identify articles describing the DIAS, DIAS 
II, DEDAS, DEFUSE, and EPITHET trials, giving a total of 502 mismatch patients 
thrombolysed beyond 3 hours. The combined adjusted Odds Ratios (a-ORs) for 
favourable outcomes are greater for patients who had successful reperfusion (a-
OR=5.2; 95% CI, 3 to 9; I2=0%). Favourable clinical outcomes are not significantly 
improved by thrombolysis (a-OR=1.3; 95% CI, 0.8 to 2.0; I2=20.9%). Odds for 
reperfusion/recanalisation are increased amongst patients who received 
thrombolytic therapy (a-OR=3.0; 95% CI, 1.6 to 5.8; I2=25.7%). The combined 
data show a significant increase in mortality after thrombolysis (a-OR=2.4; 95% 
CI, 1.2 to 4.9; I2=0%), but this is not confirmed when I exclude data from 
desmoteplase doses that are abandoned in clinical development (a-OR=1.6; 95% 
CI, 0.7 to 3.7; I2=0%). Symptomatic intracerebral haemorrhage is significantly 
increased after thrombolysis (a-OR=6.5; 95% CI, 1.2 to 35.4; I2=0%) but not 
significant after exclusion of abandoned doses of desmoteplase (a-OR=5.4; 95% 
CI, 0.9 to 31.8; I2=0%). Delayed thrombolysis amongst patients selected 
according to mismatch imaging is associated with increased 
reperfusion/recanalisation. Recanalisation/reperfusion is associated with 
improved outcomes. However, delayed thrombolysis in mismatch patients was 
not confirmed to improve clinical outcome, although a useful clinical benefit 
remains possible. Thrombolysis carries a significant risk of symptomatic 
intracerebral haemorrhage and possibly increased mortality. Criteria to diagnose 
mismatch are still evolving. Validation of the mismatch selection paradigm is 
required with a phase III trial. Pending these results, delayed treatment, even 
according to mismatch selection, cannot be recommended as part of routine 
care. 
 
In summary, by employing rigorous analysis techniques, I provide some data that  
would serve as a useful source of evidence to the practicing physicians.398  
 
However, there are challenges that are associated with the use of historical 
controls (like VISTA non-thrombolysed patients as used in chapters 3-7). In some 
cases, it is possible to adjust for potential sources of bias or to interpret findings 
through internal controls. For example, in assessing effects of thrombolysis on 
    
 
 
age, the results in the elderly could be compared to those in younger patients 
for whom RCT data are available to support the effect size estimate. Bias is less 
easy to control in the analyses for which comparable RCT data are unavailable. 
Owing to differences in population characteristics, one may observe excessive 
heterogeneity between patients’ subgroups. If the contributing VISTA controls 
data used entry criteria for severity that did not fully encompass those of the 
thrombolysed group, then a systematic bias in outcomes would be likely. 
Further, geographical or temporal variation in management can generate bias as 
well. Although the historical outcomes in VISTA were rigorously collected, the 
SITS-ISTR data (Chapters 4 and 6) are open to bias through knowledge of 
treatment. Further, because SITS-ISTR is a registry, one cannot guarantee its 
completeness.  
 
Bias may manifest as overly-estimated point estimate: bigger treatment effect 
(point estimates > 1.6 for improved outcomes)269 for patients with moderate b-
NIHSS may indicate an imbalance in case mix (possibly leading to large 
heterogeneity between each subgroup) rather than a strong treatment effect 
from the use of t-PA. I undertook analyses adjusting for age and baseline 
severity, and then for those covariates that differed at baseline ( if data were 
completely available), but, numerous other potential confounders remain 
unmeasured or unknown.  For example, the time from stroke onset to use of t-
PA could not be considered in these analyses. The onset to treatment time was 
known for SITS-ISTR but an equivalent value was not available in VISTA, where 
onset to randomisation for an investigational product was instead recorded (and 
was different between the t-PA and control groups).  Further, these analyses did 
not control for the centre effect which may have influence on patients’ 
outcomes.399  Baseline NIHSS accounts for about 80% of variance in outcomes of 
acute ischaemic strokes, and together with age should normally control for the 
variability in the adjusted analysis.265,280 The most compelling bias arises from 
the fact that the control patients were not given thrombolysis through clinician 
choice, implying that they may have been ‘unsuitable’ in an immeasurable or 
unrecorded way. The magnitude of these biases is unknown in these present 
analyses. Methods employed to adjust for differences at baseline do not confirm 
bias-removal.400 Despite availability of good prognostic data, residual 
    
 
 
confounding may still persist.400 Even alternative methods like the propensity 
scores method do not guarantee removal of bias.  
 
I based my adjusted analyses on CMH test and proportional odds logistic 
regression analyses. This approach to data analyses were applied by Lees et al in 
the SAINT trial271 and have been tested and shown to give reliable estimates on 
other datasets.269 These also add to the power of the study.401  The CMH test is 
limited by sample size, and if data on covariates are missing, it may not be able 
to stratify beyond a limit. For example, in chapter 7, fifty-nine per cent of 
records lacked coding for the variable “antithrombotic” (i.e. antiplatelet and 
anticoagulants) (N=3432). If the analyses were to be done within each stratum of 
the baseline stroke severity level, there would occur further diminution of the 
available data per stratum. Hence, an adjusted analysis for several covariates 
would be difficult within the stratum. In chapter 3, prior use of antiplatelet and 
anticoagulants was not used for adjusted analyses along with other co-variates 
that had differed at baseline, because, by including antithrombotic in the 
analyses, the effective size of dataset reduced from 4620 to 1930 for the non-
elderly and from 1152 to 454 for the elderly. In chapter 4, adjusted analyses 
were possible for all variables that differed at baseline: the effective sample 
size reduced from 26028 patients to 22148 patients for the non-elderly age group 
and from 3472 to 2593 patients for the elderly age group. Adjustment by 
regression analysis relies on assumptions that there is a linear relationship 
between the covariates measured at baseline and outcomes at a later time 
point; and these can be expressed by regression equation. However, the 
assumption that the relationship is linear between the baseline stroke severity 
and outcomes may not always be true.280,402  
 
Despite these limitations, and pending randomised data, evidence presented in 
this thesis may be found useful by stroke physicians to guide therapy in their 
patients. International Stroke Trial (IST-3) has been enrolling patients in 0-6 hour 
time window for about a decade and will report subgroup analyses on some of 
the patients that are currently excluded from European drug label (like the 
elderly). Subgroup analysis of an open label trial spanning a period of >10 years 
will require careful scrutiny. These will be selected patients who may have been 
treated by centres that may have had doubts about their capability to deliver 
    
 
 
alteplase safely or about treatment efficacy. Owing to dismal prospects of 
conducting large randomised trials that specifically test a hypothesis of 
outcomes in the specific subgroups of patients for which data are currently 
lacking (e.g. concomitant diabetes and previous stroke), data like those that are 
presented in this thesis may have relevance to the routine clinical practice. 
Clinicians should individualise the stroke therapy based on their clinical 
judgement.  
 
In the future, I intend to expand this work by examining outcomes in remaining 
exclusion subgroups. In order to do this, I have initiated collaborations with 
colleagues at various centres. Working together, I will undertake systematic 
reviews and meta-analysis of data. Also, where sufficient data are available, I 
will compare outcomes between thrombolysed and non-thrombolysed groups for 
improvement in patients’ outcomes. Whereas in this thesis, I employed adjusted 
analyses technique, adjusting for age and baseline stroke severity, for any 
further work, I may also consider matching procedures like propensity scores, 
the Mahalanobis method or Kent’s method when dealing with non-random data 
like these.280 
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Appendix 
SAS 9.2 Codes for statistical analyses 
A PROC FREQ function was employed to run CMH test. In SAS 9.2 software, 
analyses employing a code “proc freq; tables A*B*C*D / cmh; run;” was 
undertaken. Here, the analysis examines association of C with D when adjusted 
by stratification for covariates A and B. 
A  PROC LOGISTIC function was used to fit the proportional odds model.  
 
SITS and VISTA steering committee members 
 
SITS steering committee members comprised A Davalos, Department of 
Neurosciences Hospital Universitari Germans Trias, Universitat Autònoma de 
Barcelona Ctra Canyet s/n 08916 Badalona, Barcelona, Spain, G. Ford, 
Department of Clinical Pharmacology, New Castle University, Level 6 Leazes 
Wing Royal Victoria Infirmary, Newcastle NE1 4LP; M. Grond, Department of 
Neurology, Kreisklinikum Siegen, Siegen, Germany, W. Hacke, Neurologische 
Klinik, Universität Heidelberg ,Im Neuenheimer Feld 400 , 69120 Heidelberg; M. 
Hennerici, Department of Neurology University Hospital Mannheim University of 
Heidelberg 68167 Mannheim; M. Kaste Department of Neurology, Helsinki 
University Central Hospital, University of Helsinki, Finland; V. Larrue, Dept of 
Neurology, Toulouse University Hospital, Toulouse, K.R. Lees, Institutes of 
Cardiovascular and Medical Sciences, University of Glasgow, UK; R.O. Roine, 
Turku University Central Hospital, Turku, Finland, D. Toni, Dept of Neurological 
Sciences, University 'La Sapienza', Rome,Italy; N. Wahlgren (Chair), Department 
of Neurology, Karolinska University Hospital, Stockholm, Sweden. VISTA Steering 
Committee members comprised K.R. Lees (Chair), MD, Institutes of 
Cardiovascular and Medical Sciences, University of Glasgow, UK; L. Claesson,  
    
 
 
AstraZeneca LLP,  Södertälje, Sweden; E. Bluhmki, PhD, Boehringer Ingelheim, 
Biberach, Germany; B. Gregson, Dept. of Neurosurgery, Newcastle University, 
Newcastle General Hospital, UK; G. Donnan, MD, Neurology, University of 
Melbourne, Australia; H. C. Diener, MD-PhD, Department of Neurology, 
University Duisburg-Essen, Hufelandstrasse, Essen, Germany; J. Grotta, MD, 
Department of Neurology, University of Texas, Houston Medical School, USA; J. 
Marler, MD, Food and Drug Administration , USA; P. Teal, MD, Professor of 
Stroke Neurology, University of British Columbia, Vancouver.; M.G. Hennerici  
MD-PhD, Department of Neurology, University of Heidelberg, Germany; N.G. 
Wahlgren, MD PhD, Karolinska Hospital, Stockholm, Sweden; P. Lyden, MD 
Cedars-Sinai Medical Center, Los Angeles, USA; P.W. Bath, MD Institute of 
Neuroscience, University of Nottingham, UK; R. Sacco, MD Miller School of 
Medicine, University of Miami, USA; S.M Davis, MD Department of Neurology, 
Royal Melbourne Hospital, University of Melbourne, Australia; W. Hacke, MD PhD 
Department of Neurology, University of Heidelberg, Germany; S. Warach, MD 
National Institute of Neurological Disorders and Stroke, USA; M. Fisher, MD, 
Dept of Neurology, University of Massachusetts Medical School, USA; M. 
Hommel, MD Joseph Fourier University, Grenoble, France; M. Kaste, MD 
Department of Neurology, Helsinki University Central Hospital, University of 
Helsinki, Finland; K. Muir, MD, Division of Clinical Neurosciences, University of 
Glasgow, Glasgow, UK; A. Shuaib, MD, Director, Stroke Program, University of 
Alberta, Canada; C. Weimar, MD Department of Neurology, University Hospital 
Essen, University of Duisburg-Essen, Essen, Germany; A. Alexandrov, MD 
University of Alabama Hospital, Birmingham, AL, USA. Once the approval was 
obtained, request for data was made to the VISTA co-ordinator, Dr Myzoon Ali 
and the SITS-ISTR co-ordinator, Dr Niaz Ahmed.  
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